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In 2012, almost one third of all deaths in the Netherlands was related to 
cardiovascular diseases (CVDs), such as coronary artery disease (CAD), 
peripheral artery disease and cerebrovascular disease (www.cbs.nl: health and 
welfare, key figures primary causes of death). Atherosclerosis, a chronic, lipid-
driven disease of the arterial wall is the main cause of CVD.1-5 It is now widely 
acknowledged that atherosclerosis is an inflammatory disease, starting at early 
adolescence, at which both innate and adaptive immune responses play 
essential roles in its initiation and progression. How different immune cells 
contribute to the atherosclerotic process is extensively reviewed by Hansson et 
al.6 and Weber et al.7. In the first part of this introduction, we will focus on the 
vital role of diverse T-cell subtypes in atherosclerosis and evaluate T-cell 
immunosuppression as a potential therapeutic modality for atherosclerosis. 
Radiation exposure has been identified as an independent risk factor 
promoting atherosclerosis, in addition to established factors such as genetic 
predisposition, hypertension, age, obesity, type 2 diabetes, smoking and stress. 
Radiotherapy of the thorax or head and neck region, including parts of the 
heart and major arteries, is commonly used in the primary treatment of 
several cancers with good long-term prognosis, such as breast cancer or 
Hodgkin’s lymphoma. Unfortunately, survivors of these cancers are at risk to 
develop long-term treatment-related severe complications, including 
secondary cancers and normal tissue damage.8 CVDs, such as congestive heart 
failure, are among the most serious and life-threatening late adverse effects 
encountered by the growing number of cancer survivors who received 
therapeutic doses of thoracic radiotherapy. In the second part of this 
introduction, the most important epidemiological studies providing evidence 
of a strong correlation between radiation dose to the thorax or head and neck 
region and increased risk of developing CVD will be summarized. In addition, 
experimental data considering micro- and macrovascular damage, as well as 
direct cardiac damage, as major underlying pathologies of late morbidity and 
mortality after radiotherapy will be reviewed. Macrophages will be considered 
as key players in radiation-induced atherosclerosis. 
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Atherosclerotic plaque development 
Large arteries such as coronary, carotid and iliac arteries are susceptible to 
atherosclerotic plaque formation, especially at bifurcations due to 
hemodynamic factors like low shear stress and disturbed laminar flow.9-12 This 
leads to endothelial cell (EC) damage or dysfunction that results in increased 
permeability and, in the presence of hypercholesterolemia, subendothelial 
accumulation of lipoproteins. Activated ECs subsequently express chemokines 
(such as chemokine (C-C motif) ligands 2 (CCL2) and 5 (CCL5)) and adhesion 
molecules (such as E- and P-selectin and intercellular adhesion molecule-1 
(ICAM-1)), which promote the initial contact between circulating leukocytes 
and the endothelium. EC-derived monocyte chemoattractant protein-1 (MCP-1 
or CCL2) further promotes transmigration of monocytes into the intima via CC-
chemokine receptors type 2 (CCR2) and 5 (CCR5) and CX3CR1.5, 13 In response 
to pro-inflammatory cytokines, such as macrophage-colony stimulating factor 
(M-CSF), interleukin (IL)-1, tumor necrosis factor α (TNFα), interferon-γ (IFN-γ) 
and growth factors, these monocytes differentiate into macrophages which 
ingest the accumulated modified lipids (mainly oxidized low-density 
lipoprotein (oxLDL)) via upregulated scavenger receptors (such as CD36, SR-A), 
and progress into foam cells.14-17 This will lead to intimal thickening and the 
formation of a fatty streak.  
Once the atherosclerotic process is initiated, activated macrophages and 
lipid-loaded foam cells secrete inflammatory cytokines, reactive oxygen 
species (ROS), chemokines and growth factors. This will trigger further 
leukocyte recruitment and activation, as well as smooth muscle cell (SMC) 
proliferation and migration, leading to a stable, collagen-rich advanced lesion 
containing a necrotic core, modified lipids and a thick fibrous cap.3, 15 Extra-
cellular matrix (ECM) degradation due to the action of matrix 
metalloproteinases (MMPs) and the ongoing cell death caused by sustained 
inflammation will eventually weaken the fibrous cap.7, 18 Exposure of the pro-
thrombotic content of the plaque to the blood during plaque rupture will 
result in occlusive thrombus formation, leading to acute fatal cardiovascular 
events such as a myocardial infarction or a stroke.19 The ruptured lesion may 
also heal, resulting in a stenotic vessel.20 
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T-cell subtypes in atherosclerosis 
Naive T-cells in lymph nodes can differentiate into different types of effector T-
helper (Th) cells such as Th1, Th2 and Th17 or regulatory T-cells (Tregs), each 
with their specific cytokine secretion profile. T-cell polarization depends on the 
antigen-presenting cell (APC) released cytokine profiles, on antigen 
presentation by major histocompatibility complexes (MHC) to the T-cell 
receptor (TCR), on the expression and cross-interaction of co-stimulatory 
molecules and on the nature and intensity of the antigenic stimulus itself. The 
effector T-cells are primed to migrate to inflamed sites, such as vascular 
lesions, where atherosclerosis-related antigens are presented to the T-cells by 
macrophages or dendritic cells, thus generating adaptive immune responses.  
Different T-cell subsets have been characterized and CD4+ T-cells are the 
dominant T-cells found in atherosclerotic lesions compared to CD8+ cytotoxic 
T-cells.21 Th1-cells are regarded as pro-inflammatory and induce cellular 
immunity by producing IFN-γ and TNFα, while Th2-cells secrete anti-
inflammatory IL-5, IL-13, IL-10 and IL-4 and mediate humoral immune 
responses by supporting antigen-specific antibody production by B-cells.22 Th1-
cells are the most abundant T-cell subtype in atherosclerosis and are regarded 
as being pro-atherosclerotic, partly because of the pro-inflammatory and 
collagen-degrading effects of IFN-γ.6, 23-25 Furthermore, patients with CAD have 
been shown to exhibit increased Th1-activation.26, 27 Specific deficiencies in 
transcription factor T-bet (T-box transcription factor TBX21), IFN-γ or its 
receptor in atherosclerosis-prone mouse models reduced lesion development 
and enhanced plaque stability by increased collagen deposition28, 29, whereas 
exogenous administration of IFN-γ itself or specific cytokines activating T-bet 
(IL-12, IL-18) accelerated disease progression.30-33 In addition, Elhage et al. 
demonstrated a marked reduction in plaque development and diminished Th1-
cell activity in atherosclerosis-prone apolipoprotein E (ApoE)-/- mice deficient in 
IL-18.34  
On the contrary, the role of Th2-responses in atherosclerosis is not 
explicit and seems to depend on the location and stage of lesion development 
as well as on the experimental model. Th2-responses were originally thought to 
be atheroprotective by counteracting pro-atherogenic Th1-differentiation and 
responses. Nevertheless, dual and opposite effects of Th2-cytokines have been 
reported. IL-5 has a protective role through anti-oxLDL IgM antibody 
CH1 General introduction.pdf   10 17-11-2013   12:43:28
general introduction 
 
11 
production35 and IL-13 improves plaque stability by reducing plaque 
inflammation and inducing fibrosis36. IL-10 also exerts an atheroprotective 
function as its deficiency in ApoE-/- mice resulted in increased levels of 
atherosclerosis, thrombosis and rupture-prone plaques37. However, deficiency 
of IL-4 showed no substantial effect38 or even led to reduced site-specific 
plaque formation in hypercholesterolemic mice, indicating a pro-atherogenic 
effect.39, 40  
Although Th17-cell accumulation recently has been observed in human41, 
42 and murine43, 44 atherosclerosis, the exact role of Th17-cells producing IL-17, 
IL-22 and IL-23 also remains controversial and poorly understood, as both   
pro-41, 43, 45-50 and anti-atherogenic51, 52 effects have been reported.  
An additional subset, Treg, has been implicated in atherosclerosis as 
being atheroprotective by direct effects on T-cells or through effects on 
APCs.53-61 Natural Tregs develop in the thymus and are characterized by CD4, 
CD25 and forkhead box p3 (Foxp3) expression. These Tregs are important to 
maintain self-tolerance and prevent autoimmunity through the inhibition of 
lymphocytes, while so-called ‘induced Tregs’ in the periphery were seen to 
suppress the activation of effector T-cells and inhibit atherogenesis by 
secreting among others anti-inflammatory cytokines (transforming growth 
factor β (TGFβ) and IL-10).62-67 Adoptive transfer of Tregs attenuated 
atherosclerotic lesion development in ApoE-/- mice, pointing to a possible 
therapeutic use.61, 68 
 
T-cell differentiation and NFAT 
The choice of T-cell differentiation into effector T-cell subsets is critically 
regulated by nuclear factor of activated T-cells (NFAT) (Figure 1). NFAT 
transcription factors are expressed in T-cells, B-cells, NK-cells and mast cells, as 
well as in cardiomyocytes, SMCs, ECs and macrophages.69 NFATC1, C2 and C3 
family members play a key role in T-cell activation and are tightly regulated by 
calcium-calcineurin signaling.70 Upon engagement of the TCR and co-
stimulatory receptors (such as CD28) that are coupled to the calcium-signaling 
pathway, calcineurin, a calmodulin-dependent calcium-activated phosphatase, 
docks on the regulatory domain of NFAT and subsequently dephosphorylates 
multiple phosphorylated serine residues. This will lead to the exposure of the 
nuclear localization signal and the translocation of NFAT to the nucleus of 
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activated T-cells. There NFAT proteins cooperate with signal transducer and 
activator of transcription (STAT) proteins and other transcriptional partners 
(such as activator protein 1 (AP1)) activated by costimulatory signals to induce 
the expression of T-cell lineage-specific transcription factors T-bet (Th1), GATA-
binding protein 3 (GATA3) (Th2), retinoid-related orphan receptor γT (RorγT) 
(Th17) and Foxp3 (Treg). In turn, these transcription factors and other partners, 
including NFAT, enhance the expression of a specific set of cytokines to 
maintain and commit to T-cell differentiation. Therefore, NFAT protein 
isoforms have selective roles in Th1/Th2/Th17-cell differentiation71, as well as in 
the development and immunosuppressive function of Tregs.72-74 The loss of 
NFATC2 (and NFATC3) diminishes Th1-cell differentiation with reduced IFN-γ 
production, while expression of Th2-cytokines is markedly increased.75-79  
Furthermore, mice expressing hyperactive NFATC2 exhibit enhanced IL-17 
production.80 These results indicate that NFATC2 can promote Th1- and Th1781-
cell differentiation and negatively regulates Th2-immune responses. In 
contrast, NFATC1-deficient T-cells show impaired production of Th2-responses, 
suggesting that NFATC1 is required for Th2-cell differentiation.82, 83  
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Figure 1. Role of NFAT transcription factors in Th1- and Th2-cell differentiation. In response to IL-
12 receptor (IL-12R) engagement, NFAT proteins cooperate with STAT4 to induce the expression 
of IFN-γ. Signaling through the IFN-γ receptor (IFN-γR) induces STAT1 activation and expression 
of the Th1-lineage specific transcription factor T-bet. Subsequently, NFAT proteins cooperate 
with T-bet to maintain and commit to Th1-cell differentiation through the induction of IFN-γ. The 
committed Th1-cells are then reactivated by the TCR pathway and the positive-feedback loop of 
the IFNγ-STAT1 signaling pathway. In Th2-cells, IL-4 signaling induced by c-MAF (cellular homolog 
of the v-MAF oncoprotein) and NFAT proteins causes the activation of STAT6, which promotes 
GATA3 expression. GATA3 together with NFAT and other costimulatory transcription factors 
drives IL-4 transcription and commits to Th2-cell differentiation. NFAT proteins might also 
cooperate with STAT factors to induce the expression of T-bet and GATA3. Data from mice 
lacking specific NFAT proteins indicate that NFATC2 is required for Th1-cell differentiation and 
negatively regulates Th2-cell differentiation, whereas NFATC1 promotes Th2-cell differentiation. 
Adapted from Macian.70  
 
 
 
 
 
Committed Th1-cell 
Committed Th2-cell 
C2 C2
C1C1
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Epidemiological studies on radiotherapy and risk of CVD 
Evidence of a long-term increased incidence of CVD after high therapeutic 
doses of thoracic irradiation can be extracted from many epidemiological 
studies on survivors of Hodgkin’s lymphoma84-92, breast93-99 and head and neck 
cancer100, 101.  
 In comparison to the general population and patients not receiving 
radiotherapy, survivors of Hodgkin’s lymphoma show strongly elevated risk (2 
to >7-fold greater) of cardiac death (mainly due to congestive heart failure and 
valve disease), depending on the method of radiotherapy (older techniques 
include whole heart and aortic arch in the irradiation field), use of 
anthracycline chemotherapy (enhanced risk) and follow-up time (increased risk 
with time). For instance, significantly increased standardized incidence ratios 
of various heart diseases (myocardial infarction 2.4 (95% confidence interval 
(CI) 1.1-5.2), angina 4.9 (2.0-12.0), valve disease 7.0 (2.6-18.5), congestive 
heart failure 7.4 (1.8-30.0)) were observed in patients treated for Hodgkin’s 
lymphoma before the age of 41 years, who normally would be at low risk, even 
after a follow-up of more than 20 years.102  
 Furthermore, excess morbidity and mortality from heart disease is also a 
well-described late effect of post-operative radiotherapy observed from 
several randomized trials of women with breast cancer. The benefit of 
radiotherapy in reducing cancer-related deaths was offset by an increased 
relative risk (RR) of cardiac death.103, 104 The RR was proportional to the 
estimated mean cardiac dose, increasing with 3.1-7.4% per Gray (Gy).105, 106 
Moreover, the RR of cardiac mortality in irradiated breast cancer patients was 
higher for left-side- (mean cardiac dose of 12 Gy, RR 1.44) vs. right-side-treated 
patients (mean cardiac dose of 5 Gy, RR 1.18) and increased with time from 
irradiation. Data from a recent study, including 35,000 women treated with 
radiotherapy for breast cancer and a follow-up of 30 years, provided further 
evidence of increased incidence ratios of heart diseases (acute myocardial 
infarction 1.22 (95% CI 1.06-1.42), pericarditis 1.61 (1.06-2.43), angina 1.25 
(1.05-1.49) and valvular heart disease 1.54 (1.11-2.13)) in women irradiated for 
left-sided breast cancer (estimated mean total heart dose of 6.3 Gy compared 
to 2.7 Gy for right-sided tumors).107  
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 In addition, radiotherapy treatment (total fractionated doses of 60-70 
Gy) of head and neck cancer patients, during which the carotid arteries are 
fully located in the irradiation field, has also been shown to be an independent 
risk factor for death from stroke at more than 10 years after the treatment.101  
 Data from studies on human tissue revealing the possible underlying 
pathogenesis of radiation-induced CVDs are scarce.108 An induction or 
acceleration of atherosclerosis in major arteries located in the irradiation field 
is considered to play a fundamental role. Indeed, intima-media thickening 
(IMT), an early sign of atherosclerosis109, 110, and an increased luminal 
narrowing have already been observed within a few years after receiving high 
radiation doses, resulting in carotid artery stenosis and consequently ischemic 
cerebrovascular diseases.111-113 Muzaffar and colleagues estimated that the 
rate of progression of IMT was 21 times that expected in the general 
population.114  
 
Experimental studies on radiation-induced vascular damage and 
atherosclerosis 
Radiation is a potent inducer of inflammatory and thrombotic changes in ECs. 
Experimental studies have shown that irradiation (≥2 Gy) of the endothelium 
induced endothelial dysfunction associated with increased expression of 
various inflammatory cytokines (IL-6 and IL-8)115 and adhesion molecules (E- 
and P-selectin116-118, ICAM-1116, 117, 119-125), as well as loss of thromboresistance 
(increased expression of von Willebrand Factor (vWF) and thromboxane 
(TXA2), and decreased production of prostacyclin, thrombomodulin (TM) and 
ADPase)126-130. In the microcirculation, radiation can cause EC detachment or 
apoptosis131, 132, leading to exposure of the pro-thrombotic subendothelial 
matrix and SMCs with subsequent microthrombi formation and tissue 
ischemia.  
 Recent studies using hypercholesterolemic animals receiving local 
irradiation to large arteries, mimicking the clinical situation for certain cancer 
patients, demonstrated that the process of radiation-induced atherosclerosis 
development was different from age-related atherosclerosis. Single as well as 
fractionated doses of radiation not only initiated and accelerated the process 
of atherosclerosis, but also predisposed to the formation of highly 
inflammatory, macrophage-rich, thrombotic plaques, more likely to rupture 
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and to cause a fatal myocardial infarction or stroke.133-136 This was shown by 
studies of Stewart et al. in which young atherosclerosis-prone ApoE-/- mice 
received radiation (single dose of 14 Gy134 or fractionated doses of 20*2Gy133) 
to the neck region (Figure 2), including both carotid arteries, and were 
followed-up for up to 34 weeks. In contrast, irradiation of C57BL/6J wild-type 
mice on a normal chow did not result in signs of (early) atherosclerosis, 
suggesting that radiation-induced inflammatory responses are acting in 
concert with the effects of hypercholesterolemia to determine disease 
severity.  
 
 
Figure 2. Irradiation field and dose distribution to the arterial tree. Reproduced with permission 
of Stewart et al.134  
 
 These experimental data indicate that the increased long-term risk for 
cardiovascular events after local high therapeutic doses is in part determined 
by radiation-induced atherosclerosis. Moreover, total body irradiation has to 
be considered in the risk for CVD. While no systemic changes in inflammatory 
markers or increased cholesterol levels have been reported after local 
irradiation of the neck region134, total body exposure increases circulating 
inflammatory markers (C-reactive protein (CRP), IL-6, TNFα)137, cholesterol138, 
139 and blood pressure140. Furthermore, whole-body radiation dose was 
recently associated with renal failure.141 These systemic effects can impact 
atherosclerosis and cardiac mortality.142 Follow-up studies of atomic-bomb 
survivors provide strong evidence of increased risk for heart diseases after 
total body exposures of <2.5 Gy.143 
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Macrophages and tissue damage 
Cells of the innate immune system, such as monocytes/macrophages and 
dendritic cells, play a central role in inflammation and tissue damage, and 
mediate the direct response to pathogens by recognizing pathogen-associated 
molecular patterns (PAMPs) via Toll-like receptors (TLRs).144 
Monocytes/macrophages are the most prominent cells of the innate 
immune system. It is known that the target for the biological effects of 
radiation is larger than the directly irradiated cells.145 Cells exposed to ionizing 
radiation induce genomic instability in unirradiated descendants or release 
signals that can induce damage in neighboring non-targeted cells, known as 
bystander effects. ROS146, 147, IL-8148, TGFβ149-151 and TNFα152 are among others 
proposed as bystander messengers. Radiation-induced cytotoxic effects 
include reduced clonogenic survival153, genomic instability154-156 manifested by 
increased sister chromatid exchange157, chromosomal aberrations158, 
formation of micronuclei and apoptosis159-161, and altered gene expression and 
level of RNA transcripts162-164. Clastogenic factors that can cause damage to 
chromosomes in unirradiated cells have been shown in the blood of 
radiotherapy patients, Chernobyl liquidators and atomic bomb survivors.165-168 
Lorimore et al. recently showed that bone-marrow derived macrophages 
(BMDM) from irradiated CBA/Ca mice, susceptible to radiation-induced acute 
myeloid leukemia, were able to cause chromosomal instability in the clonal 
descendants of non-irradiated stem cells as a consequence of pro-
inflammatory cytokine signaling.169 Thus, macrophages can contribute to non-
targeted and delayed radiation effects. In atherosclerotic plaques, both direct 
and indirect macrophage responses following radiation exposure should be 
considered in radiation-induced vascular damage.  
In age-related atherosclerosis (i.e. non-radiation-induced), macrophages 
clear the accumulated lipids and play an essential role in the development and 
progression of lesions.7 In the absence of macrophages, hypercholesterolemia 
was not sufficient to drive the process of atherosclerosis.170, 171 Blood 
monocytes continuously adhere to and transmigrate through the EC layer to 
differentiate into tissue macrophages, contributing to chronic inflammation in 
atherosclerosis.172  
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Once differentiated, macrophages retain the ability to efficiently respond 
to specific micro-environmental stimuli and subsequently polarize into two 
main phenotypic states, classically-activated M1 macrophages and 
alternatively-activated M2 macrophages.173-181 M1 macrophages are classified 
as being pro-inflammatory. Their activation is dependent on pro-inflammatory 
Th1-cytokines, such as IFN-γ and TNFα, and TLR activation by exogenous stimuli 
such as microbial lipopolysaccharides (LPS) or endogenous stimuli such as 
oxLDL. M1 macrophages are responsible for promoting inflammation by 
producing high levels of pro-inflammatory cytokines, including IL-1β, IL-6, IL-
12, IL-23 and TNFα, supporting Th1- and Th17-differentiation and expansion, as 
well as reactive nitrogen and oxygen species. Inducible nitric oxide synthase 
(iNOS) is an enzyme that allows M1 macrophages to metabolize arginine into 
nitric oxide (NO) for microbial killing.  
Conversely, M2 macrophages are responsible for the resolution of 
inflammation and support Treg and Th2-associated effector functions. M2 
macrophages are further subdivided based on their stimuli and secretome; 
M2a macrophages are referred to as ‘wound-healing macrophages’ mediating 
tissue repair, while M2b and M2c are known as ‘regulatory macrophages’. IL-4 
and IL-13, most likely produced by mast cells, granulocytes and Th2-cells within 
the atherosclerotic plaque, stimulate arginase 1 (Arg1) activity in M2a 
macrophages, allowing them to convert arginine to ornithine, a precursor of 
polyamines and collagen. Thereby M2a macrophages contribute to the 
production of ECM, indicating homeostatic repair and remodeling functions of 
macrophages beyond defense. Secretion of fibronectin and insulin-like growth 
factor, enhancing ECM deposition, is also supported by IL-4 and IL-13 
stimulation. M2b and M2c macrophages predominantly secrete anti-
inflammatory mediators, notably IL-10 that restricts the production of pro-
inflammatory mediators by surrounding cells, including M1 macrophages. 
These potent immunosuppressors are generated by immune complexes (M2b) 
or prostaglandins, adenine nucleotides, glucocorticoids, apoptotic cells and 
even IL-10 itself (M2c).  
Commonly used markers to identify M1 and M2 macrophages are listed 
in Table 1. Although general properties of macrophages are conserved 
between mice and human, there are no human homologs of particular markers 
(e.g. Ym1, FIZZ1 and Arg1).182-185 Therefore, it remains crucial to expand our 
CH1 General introduction.pdf   18 17-11-2013   12:43:29
general introduction 
 
19 
understanding of the interspecies differences in macrophage marker 
expression to take the next step in translational atherosclerosis research. 
 
Table 1. Selection of M1 and M2 macrophage-specific markers. 
M1-macrophages M2-macrophages
Transcription factors NFκB p65, STAT1, IRF1 NFκB p50, PPAR-γ, LXRα, STAT6 (M2a)
STAT3 (M2b/c)
Intracellular enzymes iNOS, Arg2 Arg1, TGM2
Secrete IL-6, IL-8, IL-12, IL-1β, IL-23, TNFα, MCP-1 IL-10, DCIR, Ym1, FIZZ1, IGF1, TGFβ
CXCL9, 10, 11 CCL17, 24
Cell surface MARCO MR  
NFκB= nuclear factor κB, STAT= signal transducers and activators of transcription, IRF1= interferon 
regulatory factor 1, PPAR-γ= peroxisome proliferator-activated receptor-γ, LXRα= liver X receptor α, iNOS= 
inducible nitric oxide synthase, Arg= arginase, TGM2= transglutaminase 2, IL= interleukin, TNFα= tumor 
necrosis factor α, MCP-1= monocyte chemotatic protein-1, DCIR= dendritic cell immuno receptor, Ym1= 
chitinase-like lectin, FIZZ1= found in inflammatory zone 1, IGF1= insulin-like growth factor 1, TGFβ= 
transforming growth factor β,  CXCL= CX chemokine ligands, CCL= CC chemokine ligands, MARCO= 
macrophage receptor with collagenous structure, MR= mannose receptor (CD206). 
 
Macrophages are the major cellular components of an atherosclerotic 
lesion and the M1/M2 balance can impact plaque progression and stability by 
determining cholesterol homeostasis and the level of efferocytosis (i.e. 
clearing of apoptotic cells by phagocytosis) and necrosis, as well as by 
producing pro- and anti-inflammatory mediators, chemokines and tissue-
degrading MMPs.186 Macrophages expressing markers of M1 or M2 activation 
have been demonstrated in human and experimental atherosclerotic lesions187-
189 and recently additional macrophage subsets have been identified 
(Mox/Mha190-192 and M4 macrophages193, 194). 
 As described above, radiation predisposed to the formation of 
macrophage-rich plaques in hypercholesterolemic animals133-136, but the effect 
of high therapeutic doses on macrophage polarization has not been 
characterized. Of note, Monceau et al. recently found increased M1 
macrophages and IL-6 in the heart of ApoE-/- mice after local low- (0.2 Gy) and 
intermediate- (2 Gy) radiation doses.195 
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Experimental studies on radiation-induced cardiac damage 
Radiotherapy of the thorax, including part of the heart, is commonly used in 
the primary treatment of several cancers with good long-term prognosis. 
Cardiomyocytes are well-differentiated cells and relatively radio-resistant.89, 196 
Indirect myocyte damage caused by both radiation-induced inflammation and 
macrovascular injury leading to accelerated coronary atherosclerosis, and 
microvascular EC damage resulting in a reduction of myocardial capillary 
density, are therefore believed to be the major underlying causes of 
myocardial degeneration and heart failure occurring decades after 
irradiation.196-198 Experimental studies using rabbits and rats receiving a single 
cardiac dose of 15 to 20 Gy indicated that radiation damage to the 
microvasculature of the heart was the earliest morphological change observed 
after irradiation.197-201 This is supported by clinical studies showing myocardial 
perfusion changes at 6 months after irradiation using functional imaging in 
asymptomatic breast cancer patients.202, 203 Furthermore, left-sided breast 
cancer patients receiving radiotherapy suffered perfusion defects within the 
part of the left ventricle exposed to high-dose irradiation that persisted for 
years after the treatment.204, 205 Radiation-induced capillary endothelial 
dysfunction, indicated by a focal loss of the endothelial marker enzyme 
alkaline phosphatase (ALP) and increased deposition of vWF, results in 
thrombus formation, obstruction of the microvessels and a progressive 
reduction in the number of capillaries. This will eventually lead to focal 
ischemia, myocardial cell death and replacement of cardiac tissue by 
interstitial fibrosis.126, 198, 201, 206-209  
 Studies by Schultz-Hector et al. showed that rats receiving local heart 
irradiation of ≥15 Gy suffered premature death. Histological analysis of heart 
tissue revealed extensive focal myocardial damage. Clinical manifestations 
reported months to several years after high-dose heart irradiation include 
acute pericarditis (i.e. inflammation of the pericardium associated with 
protein-rich exudate), cardiomyopathy, pericardial and myocardial fibrosis, 
valvular disorders, conduction abnormalities, CAD and sudden death.89, 105, 196, 
201, 210-218 Diffuse myocardial fibrosis can lead to cardiac rhythm disturbances by 
impairing myocardial relaxation.215 Adverse cardiac remodeling in irradiated rat 
hearts correlated with mast cell hyperplasia, suggesting that mast cells 
mediate collagen deposition after radiotherapy.219 In addition, radiation can 
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induce senescent changes in fibroblasts220, 221, leading to excessive collagen 
production222 mediated by increased TGFβ levels and downstream Smad 
protein signaling195, 223-225. Hilbers et al. reported an association between 
TGFβ1 single nucleotide polymorphism and CVD risk in long-term breast cancer 
survivors.226     
 Radiation-induced valvular abnormalities present late after therapeutic 
radiation as thickening, fibrosis and calcification of the cusp and/or leaflets of 
valves, leading to functional impairment.88, 210 
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Thesis hypothesis 
Calcineurin-NFAT signaling, responsible for the transcriptional activation of 
cytokine genes, has emerged as an attractive target in the regulation of 
immune responses. Inhibitors of calcineurin, such as cyclosporin A (CsA) and 
FK506 (tacrolimus)227, have been extensively used as immunosuppressive 
agents after organ transplantation. Nevertheless, calcineurin can regulate 
various downstream targets besides NFAT, and high dose and long-term use of 
these drugs in transplant recipients increased the risk for severe complications 
such as infections228 and CVDs229 (due to hyperlipidemia and hypertension). 
Experimental studies investigating the effect of anti-inflammatory CsA and 
FK506 treatment on atherosclerosis showed conflicting results, with either 
increased230-232 or decreased plaque development233, 234. However, different 
doses were given. We therefore hypothesize that the dosage of 
immunosuppressive drugs is critical in NFAT-regulated inflammatory responses 
and atherosclerosis.  
A major drawback of the clinical use of calcineurin inhibitors, such as 
FK506 or CsA, is that these drugs also affect numerous other downstream 
effectors of calcineurin besides NFAT (like protein kinase C activation or NFκB 
activity), thereby creating adverse side-effects and toxicity such as nephro- and 
neurotoxicity, hypertension and hyperlipidemia.229, 235-246 We propose that 
specifically blocking the NFATC2 pathway (mediating Th1 pro-atherogenic 
immune responses and regulating Treg development and immunosuppressive 
function) will circumvent the regulation of undesired targets while still 
protecting against atherosclerotic plaque development and progression. 
  The influence of irradiation on pre-existing lesions is unknown. As 
previous studies from our group demonstrated that radiation exposure to 
major arteries accelerated the development of atherosclerotic plaques in 
ApoE-/- mice and predisposed to an inflammatory, pro-thrombotic plaque 
phenotype133, 134, we suggest that radiation of pre-existing lesions will 
accelerate the atherosclerotic process by skewing towards a more 
inflammatory plaque phenotype. 
 Recent epidemiological and experimental evidence shows that thoracic 
radiotherapy increases the long-term risk for cardiovascular morbidity and 
mortality. Although microvascular damage and the development of coronary 
lesions are suggested to play crucial roles, the pathogenesis of radiation-
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induced cardiotoxicity has not been studied in detail. We hypothesize that 
cardiac irradiation will lead to increased myocardial damage with time and 
dose by stimulating coronary atherosclerosis and/or by causing progressive 
damage to the capillary network. 
 
Thesis outline 
There is a clear discrepancy between the possible protective effect of 
immunosuppressive drugs against atherosclerosis and adverse side effects 
after long-term use. However, variation in dosage of the drug might explain 
this discrepancy. In a previous experimental study from our laboratory, low-
dose FK506 was able to inhibit the progression of atherosclerosis, without 
affecting systemic immunological parameters. We therefore expect low-dose 
FK506 treatment to be the most suitable for long-term therapy. In chapter 2, 
we further explored low- and high-dose FK506 treatment on collar-induced 
carotid atherosclerosis and relevant inflammatory mediators to fully 
comprehend dose-dependent mechanisms of FK506 and associated side-
effects. 
 NFATC2, activated by calcium-calcineurin signaling, is a crucial 
transcriptional regulator of inflammatory genes during immune responses, 
such as pro-inflammatory IL-2, IFN-γ and TNFα. Therefore it is an attractive 
target for treatment of Th1-driven atherosclerosis and prevention of unwanted 
side-effects associated with calcineurin inhibitors. In chapter 3, we studied the 
effect of NFATC2 hematopoietic and whole-body depletion in low-density 
lipoprotein receptor (LDLr)-/- mice.  
 As the majority of cancer patients involve the elderly, radiotherapy will 
generally be applied in patients suffering from moderate to advanced 
atherosclerosis. From a clinical point of view, it is therefore crucial to focus on 
the effect of radiotherapy on pre-existing atherosclerotic lesions. For that 
reason, we irradiated atherosclerotic ApoE-/- mice to the neck region to mimic 
the clinical situation for aged cancer patients (chapter 4). To elucidate the 
mechanisms responsible for inflammatory responses and potential ongoing 
damage in atherosclerotic plaques long-term after the initial radiation insult, in 
vitro studies were performed, focusing on the effect of irradiation on 
macrophage polarization and function. 
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 We further explored the contribution of macro- and microvascular 
damage in the pathogenesis of radiation-induced heart disease. The main 
objective was to evaluate the dose and time dependence of structural and 
functional cardiovascular damage after heart irradiation in wild-type C57BL/6J 
(chapter 5) and hypercholesterolemic ApoE-/- mice (chapter 6). We showed 
that radiation-induced pro-inflammatory responses and loss or damage of ECs 
are most likely the driving forces for cardiac microvascular defects and 
enhanced atherosclerosis development in coronary arteries. 
 Finally, in chapter 7 major findings of this thesis and future implications 
are discussed.  
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Abstract 
 
Previous studies showed both pro- and anti-atherogenic effects of 
immunosuppressant drug FK506 on atherosclerosis. As these divergent/ 
paradoxical results of FK506 may at least in part be attributable to differences 
in FK506 dosing, we have, in the current study, assessed dose-dependent 
effects of FK506 on atherosclerotic lesion formation as well as on inflammatory 
parameters relevant to atherosclerosis. Unlike low-dose FK506, high-dose 
FK506 did not protect against atherosclerosis in ApoE-/- mice. The high dose 
induced hypercholesterolemia, whereas the low dose did not. Both low- and 
high-dose FK506 treatment significantly reduced systemic CD3+ and CD4+CD25+ 
T-cell populations, and showed similar suppression of Foxp3+ regulatory T-cell 
populations. Increased IL-4+ CD4+ T-cells and decreased IgG-MDA-LDL antibody 
titers pointed to a selective, albeit modest Th2 skewing in the high-dose 
treatment group, despite the advanced stage of atherosclerosis. Low 
concentrations of FK506, however, skewed bone marrow-derived macrophage 
polarization towards a M2-macrophage phenotype, whereas the high 
concentration did not. A low-dose FK506 treatment regime protected against 
atherosclerosis by suppressing T-cell activation and favoring (M2) macrophage 
polarization. Although a high-dose FK506 treatment effected a similar T-cell 
suppressive effect, with an even more pronounced shift towards Th2-type 
immune responses, this did not translate in atheroprotection due to the 
hypercholesterolemia and absent M2 skewing. 
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Introduction 
 
A potent immunosuppressive drug, FK506 (tacrolimus) is widely used in 
patients following transplantation. At a molecular level, FK506 binds to the 
cytosolic FK506 binding protein (FKBP) 12-member of the FKBP family.1 In T-
lymphocytes, FK506 interacts with FKBP12 to form a FK506-FKBP12 complex.2 
This complex blocks calcineurin, a Ca2+-calmodulin-regulated protein 
phosphatase. As a consequence, calcineurin fails to dephosphorylate amongst 
others cytosolic nuclear factor of activated T-cells (NFAT), thereby inhibiting its 
translocation to the nucleus. NFAT is one of the most important transcriptional 
factors involved in the activation of cytokine genes such as interleukin (IL)-2. In 
addition, NFAT partners with the transcription factor AP-1 (Fos-Jun) in the 
nucleus of ‘effector’ T-cells. As a consequence, FK506 will inhibit both NFAT 
and NFAT-AP1 function in transactivating cytokine genes, genes that regulate 
T-cell proliferation and other genes that orchestrate an active immune 
response.3 Less is known about the role of calcineurin and NFAT in innate 
immune responses. Calcineurin inhibitors have been shown to induce a state 
of reduced responsiveness in dendritic cells and macrophages.4 Atherosclerosis 
is a chronic inflammatory disease in which NFAT responsive cytokines such as 
IL-2 are deemed to play a prominent role. In a previous study, we showed that 
FK506 at a low dose of 0.05 mg/kg/day beneficially affected the progression of 
murine atherosclerosis, reducing plaque area and increasing cell density and 
collagen content.5 Intriguingly and in contrast to our findings, Matsumoto et al. 
reported that FK506 treatment deteriorated atherosclerosis in cholesterol-fed 
rabbits.6 In their study, a relatively high dose of FK506 was applied. 
Conceivably dose-specific effects of FK506 on cell subsets relevant to 
atherosclerosis7 may explain these paradoxical findings. For clinical practice, it 
is important to comprehend the mechanisms underlying these potentially 
dose-dependent effects of FK506 on atherosclerosis, in particular as in organ 
transplant recipients a high-dose regime was seen to be associated with 
substantial side-effects.8, 9 Therefore, in this study, we investigated effects of 
low- and high-dose FK506 treatment on atherosclerosis and atherosclerosis-
related immunomodulation in apolipoprotein E (ApoE)-/- mice. 
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As our data pointed to dose-dependent immunoregulatory effects of 
FK506, in vivo and in vitro experiments were designed to address this in more 
detail. Firstly, we studied whether in vivo low-/high-dose FK506 treatment 
differentially affected T-cell patterns and activity in spleen, lymph node and 
peripheral blood. Secondly, as a further measure of the effects of FK506 on T-
helper (Th) cell skewing, splenic gene expression of T-cell transcription factors 
such as Foxp3, T-bet, RorγT and GATA-3 were analyzed by real-time 
polymerase chain reaction (PCR). Finally, the effect of ex vivo and in vitro 
treatment of low-/high-dose FK506 on cytokine secretion by T-cells and 
macrophage polarization were investigated. 
 
 
Materials and methods 
 
In vivo studies 
 
Mouse model of collar-induced atherosclerosis 
Animal experiments were approved by the regulatory authority of the 
University of Maastricht and were performed in compliance with the Dutch 
government guidelines. Male ApoE-/- mice (14 weeks old, C57BL/6J 
background) were fed a Western-type diet throughout the experiment. Carotid 
atherosclerotic lesions were induced by silastic tubing (collar) around the 
carotid artery, as described by von der Thüsen et al.10. To assess the effect of 
FK506 on lesion initiation, one week after collar-placement, osmotic 
minipumps (Alzet type 2004, Alzet, Cupertino, CA, USA) containing FK506 
(Fujisawa GmbH, München, Germany) were placed subcutaneously to achieve 
a pumping rate of either 0.05 mg/kg/day or 1 mg/kg/day. Mice without 
treatment served as controls. Mice were sacrificed four weeks after pump 
placement. 
 
Assessment of serum cholesterol levels and anti-ox-LDL antibody levels 
Serum cholesterol levels were determined with the CHOD-PAP method (Roche 
Diagnostics, Burgess Hill, UK). Anti-oxidized low-density lipoprotein (oxLDL) 
antibody levels were determined by ELISA as described previously11. In brief, 
serum IgM and IgG isotypes of oxLDL antibodies were determined by coating 
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MaxiSorp 96-well plates (Nunc, Roskilde, Denmark) overnight with 100 μg 
native LDL or malondialdehyde- (MDA) oxLDL. Mouse plasma was added in 
duplicate at a 1:20 dilution for IgG antibody levels and a 1:50 dilution for IgM 
antibody overnight at 4°C. Plates were then incubated with either alkaline 
phosphatase-labeled anti-mouse IgG or IgM (1:4000, Jackson Immuno-
Research Laboratory, West Grove, PA, USA). Plates were read at 405 nm in an 
ELISA reader. Anti-oxLDL antibody levels were calculated by subtracting the 
mean absorbance of native LDL from that of oxLDL. 
 
Tissue harvesting and analysis 
Cross-sections from the right common carotid artery after in situ perfusion-
fixation were processed for morphometric analysis as described previously12. 
(Immuno)histochemical stainings were performed to detect macrophages 
(anti-MAC3 antibody), collagen (picrosirius red) and CD3+ T-cells (anti-CD3 
antibody) as described previously12. 
 
Fluorescence-activated cell sorting (FACS)-analysis 
To assess systemic CD3+, CD4+, CD4+CD25+ and CD8+ cell numbers, spleen and 
lymph node cells were isolated and single-cell suspensions were made. 
Erythrocytes in peripheral blood and spleen were removed by hypotonic lysis 
with NH4Cl. Cells were incubated first with anti-CD16/32 (eBioscience, San 
Diego, CA, USA) to block Fc binding and subsequently incubated with anti-CD3-
FITC, anti-CD8-Pacific blue, anti-CD25-APC (eBioscience) and anti-CD4-PerCp 
(BD- Pharmingen, San Diego, CA, USA). Foxp3-positive cells were detected with 
PE anti-mouse/rat Foxp3 Staining Set, according to the manufacturer’s 
instructions (eBioscience). Cells were analyzed using FACS Canto II (BD) flow 
cytometer. 
As a measure of Th1/Th2 skewing, expression of intracellular cytokine 
levels in splenic T-cells was assessed. Hereto, splenocytes from mice treated in 
vivo for four weeks with low- and high-dose of FK506, were stimulated for 2 
hours (h) with 50 ng/ml PMA (Sigma, St Louis, MO, USA) and 1 μg/ml 
ionomycin (Sigma). Cell suspensions were then incubated with 1 μl/ml of 
Golgistop (1:1000 dilution, BD- Pharmingen) for 4 h. Cells were washed and 
incubated with anti-CD16/32 (eBioscience) to block Fc binding. After fixation 
and permeabilisation, intracellular cytokines were stained with anti-IL-4-PE 
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(BD) and anti-interferon(IFN)-γ-PECy7 (BD). The IFN-γ- and IL-4-producing CD4+ 
T-cells were analyzed with FACS Canto II (BD) flow cytometer. 
 
Quantitative PCR (qPCR) 
RNA was extracted from the spleen lysate with Nucleospin RNA II kit 
(MACHEREY-NAGEL, Düren, Germany). cDNA was generated with iSCript™ 
cDNA synthesis kit (BIO-RAD, Hercules, CA). Real-time PCR was performed with 
a Taqman IQ™ SYBR Green Super Mix (BIO-RAD). Primer sequences for Foxp3, 
T-bet, RorγT, GATA3, cyclophilin and 18S are shown in Supplemental Table I on 
page 61. Gene expression was normalized to the average expression of 
cyclophilin and 18S. 
 
 
Ex vivo and in vitro studies 
 
Effect of FK506 treatment on CD4+ T-cells 
Mice were treated using identical protocols as described above. CD4+ T-cells 
were isolated from splenocytes of FK506-treated or untreated mice using the 
Negative Isolation Kit (Dynal, Biotech ASA, Oslo, Norway). The purity of CD4+ T-
cells was 87 ± 5% as evaluated by FACS (data not shown). 
CD4+ T-cells were incubated with PMA (4 ng/ml) and ionomycin (500 nM) 
for 48 h. IL-4, IL-10 and IFN-γ in supernatants were assayed by ELISA according 
to the manufacturer’s instructions (BD). 
 
Effects of FK506 on Jurkat T-cells – cytokine secretion profiles and NFAT/IκB 
luciferase reporter assays 
Jurkat T-cells were pretreated with FK506 at a dose of 0, 20, and 2000 ng/ml 
for 1 h. Cells were then stimulated with PMA (8 ng/ml) and ionomycin (1000 
nM) for 48 h. IFN-γ and IL-10 in supernatant were assayed by ELISA according 
to the manufacturer’s instructions (Sanquin, Amsterdam, The Netherlands).  
Jurkat T-cells were transfected with 1.8 μg pIκB-luciferase reporter 
plasmid (kindly provided by Dr. M. de Winther, Maastricht University, The 
Netherlands) or 1.8 μg pNFAT-luciferase reporter plasmid (kindly provided by 
Dr. L. de Windt, Maastricht University, The Netherlands) using Amaxa reagent 
V. After 24 h, cells were pretreated with 0, 20 and 2000 ng/ml FK506 in 
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medium for 2 h followed by stimulation with 25 ng/ml PMA and 1 μM 
ionomycin for 18 h. Cells were lysed and luciferase-activity was measured with 
a luminometer. 
 
Effect of FK506 treatment on bone marrow-derived macrophages (BMDM) 
BMDM were isolated from the femur and tibia of ApoE-/- mice. Cells were 
cultured in standard RPMI culture medium containing L-glutamine, HEPES, 10% 
fetal calf serum, 100 IU/ml penicillin/streptomycin, and 15% L929 cell 
conditioned medium. Macrophage polarization was induced by culturing 
BMDM for 16 h at a density of 1x106 cells/ml in the aforementioned medium 
supplemented with 10 ng/ml lipopolysaccharides (LPS) to induce M1 
polarization or 20 ng/ml IL-4 to induce M2 polarization in the presence of 
FK506 at a concentration of 0, 20 and 2000 ng/ml. After 16 h, cells were 
harvested, RNA was isolated and cDNA was generated using iSCriptTM cDNA 
synthesis kit (BIO-RAD). Real-time PCR was performed with a Taqman IQTM 
SYBR Green Super Mix (BIO-RAD). Primer sequences for specific M1 markers 
(nitric oxide synthase 2 (Nos2), IL-18), and M2 markers (Arginase-1, mannose 
receptor (MR) and IL-10) are shown in Supplemental Table I on page 61. Gene 
expression was normalized to the expression of cyclophilin. 
 
Statistical analysis 
All results were expressed as mean ± standard error of the mean (SEM). 
Differences between values were considered significant at p≤ 0.05 using Mann-
Whitney U test. 
 
 
Results 
 
Low-dose FK506 inhibits collar-induced atherosclerosis whereas high-dose 
did not 
Mice weight was not affected by low-/high-dose FK506 treatment (data not 
shown). Concentrations of FK506 in blood were essentially similar as described 
in our previous study5. Total serum cholesterol level was significantly elevated 
in mice that received high-dose FK506 in vivo treatment compared to control 
and low-dose treatment group. In contrast, low-dose FK506 in vivo treatment 
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did not significantly alter serum cholesterol level compared to controls (Figure 
1A). 
FK506 treatment did not affect kidney morphology. Focal 
microaneurysm was present in glomeruli at similar frequency in the low-/high- 
dose group. There was no histological evidence of tubular toxicity. Acute 
(indicated by isometric vacuolization and thrombotic mesangiopathy) or 
chronic kidney toxicity (indicated by arteriolar hyalinosis and tubularinterstitial 
fibrosis atrophy) were not observed. 
In keeping with our earlier study5, plaque size in low-dose FK506-treated 
mice was significantly lower (72.1%, p=0.05) compared to controls (Figure 1B). 
Remarkably, plaque sizes of control and high-dose-treated mice were 
essentially similar (Figure 1B). Representative micrographs of HE-stained cross-
sections are shown in Figure 1D-F. There was no significant difference in 
macrophage content between the control, low- and high-dose group 
(Supplemental Figure IA on page 62). Lipid/necrotic core content in the low-
dose group tended to be decreased compared with control group (p=0.075), an 
effect that was not observed after high-dose treatment (Figure 1C). In 
addition, both low- and high-dose treatment did not affect collagen content 
(Supplemental Figure IB on page 62). Furthermore, FK506 treatment did not 
affect the lesion CD3+ leukocyte content (Supplemental Figure IC on page 62). 
In the adventitia, however, high- but not low-dose FK506 reduced the number 
of infiltrating CD3+ leukocytes (Supplemental Figure ID on page 62). However, 
despite the apparent reduction in inflammatory status of the plaque after 
high-dose FK506 treatment, this did translate in an altered atherogenic 
response as plaque size was comparable to that of the control group. 
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Figure 1. Effect of low- (0.05 mg/kg/day) and high-dose (1 mg/kg/day) FK506 in vivo on serum 
cholesterol level (A, n=5–6 per group), intima volume (B), and lipid/necrotic core content (C), 
and representative HE-stained cross-sections of control (D, n=10), low-dose (E, n=9) and high-
dose (F, n=10) FK506-treated mice, respectively. **p<0.01. 
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Both low- and high-dose FK506 treatment suppressed peripheral immune 
activity 
To examine whether FK506 influenced lesion development indirectly by 
altering peripheral immune activity, single-cell suspensions of spleen, lymph 
nodes and blood were analyzed to determine the number of T-cells by FACS 
(Figure 2). The CD3+ T-cell % out of total living cells in spleen, lymph node and 
blood was significantly reduced after low- and high-dose FK506 treatment 
(Figure 2A). The relative abundance of CD4+ cells within the CD3+ population in 
lymph node was significantly reduced after high-dose FK506 treatment, 
whereas low dose did not alter the CD4+ cell content (Figure 2B). Overall, high- 
but not low-dose FK506 decreased the lymph node CD4+ to CD8+ ratio (Figure 
2D). Activated T-cell numbers (CD4+CD25+) in spleen, lymph node and blood 
were reduced to a similar extent with low- and high-dose treatment as 
compared to controls (Figure 2E). Finally, low- and high-dose treatment 
resulted in a comparable, albeit moderate suppression of spleen Foxp3+ 
regulatory T-cell population (Figure 2F). 
 
 
 
Figure 2. Flow-cytometric analysis of the effect of low- (0.05 mg/kg/day) and high-dose (1 
mg/kg/day) FK506-treatment (n=6 per group) on % CD3+ T-cells of total living cells (A), % CD4+ of 
CD3+ T-cells (B), % CD8+ of CD3+ T-cells (C), CD4+ to CD8+ ratio (D), CD4+CD25+ T-cells of total 
cells (E), % Foxp3+ of CD3+ T-cells (F). *p< 0.05. 
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To further investigate the effects of FK506 treatment on critical T-cell 
differentiation factors, gene-expression of Foxp3, T-bet, RorγT and GATA-3 in 
spleens of in vivo treated animals was analyzed (Supplemental Figure II on 
page 62). Foxp3 and RorγT gene expression was not affected by FK506 
treatment, whereas both the low- and high-dose led to a profound decrease in 
T-bet and GATA-3 expression, compatible with the observed systemic 
reduction of CD3+ and CD4+CD25+ T-cell populations. Thus, both low- and high-
dose FK506 treatment led to a systemic suppression of T-cell numbers and 
activation. 
 
High-dose FK506 treatment decreased IgG antibodies to MDA-oxLDL 
As the aforementioned reduction in CD4/CD8 ratio might reflect a shift in 
humoral immune response, we investigated whether FK506 treatment 
affected anti-oxLDL antibody titers, anti-MDA-LDL IgG and IgM titers in serum. 
As shown in Figure 3, low- and high-dose FK506 did not affect anti-MDA-LDL 
IgM levels. Anti-MDA-IgG levels, however, were sharply decreased in the high-
dose group only. 
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Figure 3. Analysis of the antibody titers (IgM and IgG) to oxLDL in ApoE-/- mice treated in vivo 
for four weeks with low- (0.05 mg/kg/day) and high-dose (1 mg/kg/day) FK506. The net 
absorbance was calculated by subtracting the mean absorbance of native LDL from that of 
MDA-oxLDL. n=5–6 mice per group, *p< 0.05, **p<0.01. 
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High-dose FK506 treatment induced a Th2 skewing, whereas the low-dose did 
not affect Th1-Th2 parameters 
Giving the important role of calcineurin-signaling in T-cell responses, the effect 
of FK506 treatment on T-cell function and cytokine secretion profiles was 
further investigated in in vivo and in vitro experiments.  
Assessment of the percentage of IL-4-positive T-cells by FACS showed 
that in vivo low-dose FK506 treatment did not affect Th-cell skewing to Th2 (IL-
4) or Th1 (IFN-γ) (Figure 4); high-dose treatment did not alter intracellular IFN-
γ+ CD4+ cell numbers but did increase IL-4+ CD4+ cell numbers, suggestive of a 
Th2 skewing. 
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Figure 4. Presence of IL-4+ and IFN-γ+ CD4+ splenocytes in ApoE-/- mice treated in vivo for four 
weeks with low- (0.05 mg/kg/day) and high-dose (1 mg/kg/day) FK506. n=5–6 mice per group, 
**p<0.01. 
 
Cytokine secretion patterns of isolated CD4+ cells from in vivo treated 
animals were analyzed to further assess the potential effects of FK506 on Th1-
Th2 skewing. As shown in Supplemental Figure IIIA-C on page 63, neither low- 
nor high-dose in vivo FK506 treatment affected secretion of Th2 cytokines (IL-4 
and IL-10) or the Th1 cytokine IFN-γ. 
In the next experiment, Jurkat T-cells were used to verify the lack of 
effect of FK506 in CD4+ T-cells. IL-10 and IFN-γ secretion were significantly 
suppressed by both 20 and 2000 ng/ml FK506 (Supplemental Figure IIID-E on 
page 63), suggesting that the human Jurkat T-cells are more responsive to 
FK506, regardless of the dose. The effect of FK506 on transcriptional activation 
of downstream calcineurin-responsive transcription factors was addressed in a 
luciferase-reporter assay. NFAT activity was almost completely inhibited 
independent of the FK506 concentration, confirming the observed strong 
inhibition of IFN-γ and IL-10 secretion by FK506 in Jurkat T-cells. IκB activity, on 
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the other hand was unaffected by FK506, even at concentrations of 2000 
ng/ml, suggesting that FK506 does not interfere with nuclear factor κB (NFκB) 
signaling in Jurkat cells (data not shown). These data are in close agreement 
with our earlier study5, in which FK506 inhibited the activity of NFAT but not 
NFκB in RAW264.7 macrophages and vascular smooth muscle cells (vSMCs). 
 
Low-dose FK506 induced M2 macrophage skewing in vitro 
As the data on analysis of T-cell function did not reveal major dose-dependent 
differences in FK506 response, we focused on effects on function and 
phenotype of BMDM. Baseline expression of M2 macrophage markers such as 
arginase-1, IL-10 and MR, and M1 macrophage markers such as IL-18 and Nos2 
were measured in BMDM isolated from ApoE-/- mice, treated in vitro with low- 
(20 ng/ml) and high-concentration (2000 ng/ml) FK506. Compared to control 
and low-FK506 concentration, high-FK506 concentration significantly reduced 
gene expression of M2 macrophage markers arginase-1 and IL-10 (Figure 5A). 
In keeping, the high concentration of FK506 almost ablated M2 macrophage 
MR expression as compared to the low concentration (Figure 5A). The low 
concentration, on the other hand, significantly elevated M2 macrophage 
marker MR (Figure 5A). Both low- and high-FK506 concentrations did not 
significantly alter M1 macrophage marker (Nos2 and IL-18) expression (Figure 
5A). Therefore, low-FK506 concentration skewed basal macrophage 
polarization towards an M2 macrophage phenotype, whereas high-FK506 
concentration reversed this effect. In addition, the capacity of BMDM to 
polarize in response to IL-4 (M2) or LPS (M1) stimuli in vitro was investigated. 
Again, the low-concentration FK506 significantly suppressed M1 macrophage 
marker IL-18 (Figure 5B) and enhanced that of the M2 marker arginase-1 
(Figure 5C), indicating a pronounced M2 macrophage skewing upon low-FK506 
concentration. The high concentration, however, downregulated both M1 (IL-
18; Figure 5B) and M2 (MR; Figure 5C) macrophage marker expression in LPS- 
and IL-4-primed macrophages respectively. 
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Figure 5: Effect of FK506 in vitro treatment on M1 (Nos2, IL-18) and M2 (arginase-1, mannose 
receptor (MR) and IL-10) macrophage marker expression of non-stimulated (A), LPS-stimulated 
(B) and IL-4-stimulated (C) BMDM. BMDM from ApoE-/- mice were isolated and cultured in the 
absence or presence of LPS/IL-4 for 16 h and FK506 at a concentration of 0, 20 and 2000 ng/ml. 
BMDM cell lysates were analyzed for M1 and M2 marker gene expression relative to cyclophilin 
expression. n=6 per group, *p< 0.05, **p<0.01. 
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Discussion 
 
Inflammation plays an important role in atherosclerosis formation, rendering 
immunosuppressive therapy an attractive therapeutic modality in the 
treatment of this disease. Though the immunosuppressive drug FK506 is 
widely used in clinical transplantation, diverse side-effects of this drug in 
clinical dosage limit its utility in other applications such as the promising 
treatment of (auto)immune diseases and atherosclerosis.13 We have in this 
study investigated the dose-dependent effect of FK506 on collar-induced 
carotid atherogenesis in ApoE-/- mice. This is an extension of our previous 
study5 in which only the low-dose regime was applied in the treatment of 
atherosclerosis. Consistent with our previous study, low dose of FK506 
markedly reduced atherosclerosis. High-dose treatment on the other hand did 
not protect against atherosclerosis at all. Plaque macrophage and collagen 
content were not influenced by FK506 treatment regardless of the dose. CD3+-
leukocyte content in the adventitia was, however, markedly inhibited by the 
high-dose treatment. FK506 increased total serum cholesterol levels, resulting 
in significantly increased cholesterol levels in the high-dose group only. FACS 
analysis showed that both low- and high-dose FK506 treatment significantly 
reduced systemic CD3+ and CD4+CD25+ T-cell populations. Assessment of Th- 
cell differentiation (based on intracellular cytokine expression) and anti IgG 
MDA-LDL antibody titers pointed to a selective, albeit modest Th2 skewing in 
the high-dose treatment group only, despite the fact that atherosclerosis was 
more pronounced in the high-dose treatment group. 
As the data on analysis of T-cell function did not reveal major dose-
dependent differences in FK506 response, we focused on effects on 
macrophage function, as calcineurin-signaling pathways are also important in 
innate immune responses.4 Low-dose FK506 skewed basal as well as LPS-
primed polarization of BMDM towards a M2-macrophage phenotype, whereas 
high dose did not. These data suggest that the low-dose FK506 treatment 
regime protected against atherosclerosis partly due to a favorable (M2) 
macrophage polarization, whereas this protective effect did not occur at the 
high dose. In addition, the increase in cholesterol levels may have conduced to 
a lack of effect of high-dose FK506 treatment, despite a compensatory switch 
towards a Th2 response that was observed in the high-dose group only. 
CH2 FK506 paper new.pdf   15 17-11-2013   15:11:28
chapter two 
 
58 
The use of calcineurin inhibitors, such as FK506 and cyclosporine A (CsA), 
in transplant recipients has been associated with the development of 
hypercholesterolemia.14, 15 In our study, the high-dose FK506 treatment 
induced a (mild) hypercholesterolemia whereas the low dose did not. From a 
clinical point of view, this would make the low dose amendable to long-term 
treatment of chronic inflammatory disorders such as atherosclerosis. Besides 
FK506, other immunosuppressive drugs, for instance mycophenolate mofetil 
(MMF), sirolimus, CsA and their concomitant anti-inflammatory effects have 
been studied in atherosclerotic animal models.16 MMF and sirolimus showed a 
consistent atheroprotective potential. Regarding CsA and FK506, results in 
animal studies are rather contradictory, probably due to specific animal 
models used and large differences in dosages.16 As shown, the dosage could 
very well be of vital importance as many of the side-effects of FK506 and CsA 
reported in patients occur at high dose and long-term regimes. Indeed our 
animal study indicated that only low dose suppressed atherosclerosis, whereas 
high dose did not. 
Given the recent data on the interaction between NFAT and regulatory 
T-cell activity17, we investigated whether NFAT can act as regulator of the 
Th1/Th2 balance. NFAT proteins are expressed in most cells of the immune 
system and play a pivotal role in the transcriptional activation of cytokine 
genes and other genes critical for the immune response. In the current study, 
several independent sets of experiments showed that both the low- and high-
dose FK506 led to a repression of systemic T-cell numbers and activation. This 
was mirrored by a suppression of the expression of important T-cell 
transcription factors T-bet and GATA-3. It is thought that the fate of CD4+ Th-
cell differentiation is at least in part governed by T-bet (Th1), GATA-3 (Th2) and 
RorγT (Th17), respectively.18 Low- and high-dose FK506 had comparable 
suppressive effects on T-bet and GATA3, while leaving RorγT expression 
unaltered. Although low- and high-dose FK506 treatment did not affect in vitro 
secretion of Th2 cytokines, such as IL-4 and IL-10, or the Th1 cytokine IFN-γ in 
isolated CD4+ cells from in vivo treated mice, FK506 markedly reduced IFN-γ 
and IL-10 release by human Jurkat T-cells. This reduction, however, was 
equally potent after both low- and high-concentration FK506. While the in vitro 
studies did not point to dose-dependent effects of FK506 on Th1-Th2 
differentiation, spleen cells showed a modest enrichment in IL-4+ Th2 cells after 
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high-dose FK506. In addition, high- but not the low-dose treatment reduced 
the CD4/CD8 ratio, suggestive of a decreased humoral immune response.19 In 
support of this finding, anti-MDA-IgG titers were decreased in the high-dose 
group only. It has been suggested that IgM anti-oxLDL antibodies may have a 
protective role, whereas IgG anti-oxLDL displays a more pathogenic role in 
atherosclerosis.11, 20 Taken together, high-dose FK506 induced hyper-
cholesterolemia and a selective, albeit modest Th2 skewing, concomitant with 
decreased humoral response. A similar Th2 response during hyper-
cholesterolemia has been described in a study by Zhou et al.21, where ApoE-/- 
mice on a high-fat diet also showed modulation of the T-cell response towards 
Th2. 
Low-dose treatment of FK506 appeared to induce a subtle shift towards 
an atheroprotective immune response, especially in the myeloid lineage. 
Although the role of calcineurin in T-cell function is well established, less is 
known on its role in innate immune cells. Jennings et al.4 recently showed that 
FK506 treatment of macrophages and dendritic cells induced a state of 
reduced LPS responsiveness in vitro and conferred protection to LPS toxicity in 
vivo in mice. This tolerance to LPS may well be associated with a M2-
macrophage phenotype, as Sly et al.22 recently reviewed that SHIP-/- mice did 
not display LPS-induced tolerance, most likely due to a M2-macrophage 
skewing. In the present study, a low-, but not a high-concentration FK506 
induced a M2 polarization, which is generally considered anti-inflammatory 
and anti-atherogenic.23 Indeed, Khallou-Laschet et al.24 recently showed that 
lesion development in ApoE-/- mice was associated with a progressive M2 to 
M1 switch of plaque macrophages. Conceivably, the detainment of the M2 
phenotype by low-dose FK506 might have at least partly contributed to the 
pronounced atheroprotective effects seen in this study. 
In summary, low- and high-dose FK506 differently affected 
atherogenesis. Our findings indicate that a low-dose FK506 treatment regime 
protects against atherosclerosis by suppressing T-cell activation and favoring 
(M2) macrophage polarization. While high-dose FK506 treatment effected a 
similar T-cell suppressive effect, with an even more pronounced shift towards 
Th2-type immune responses, this did not translate in atheroprotection due to 
the hypercholesterolemia and absent M2 skewing. The fact that low- but not 
high-dose FK506 treatment reduced plaque development and induced M2 
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macrophage polarization suggests that it can be particularly effective for long-
term therapy of chronic inflammatory disorders such as atherosclerosis. 
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Supplemental data 
 
Supplemental Table I. Primer sequences. 
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Supplemental Figure I. The effect of low- (0.05 mg/kg/day) and high-dose (1 mg/kg/day) FK506 
treatment on macrophage- (A), collagen- (B) and CD3+ leukocyte- (C and D) content. 
Macrophage content was expressed as MAC3-positive cell numbers relative to total number of 
plaque cells (A). Collagen content is expressed as area stained by picrosirius red relative to the 
plaque area (B). T-cell content was expressed as CD3-positive cell numbers relative to total 
number of plaque cells (C) or adventitial cells (D). n=8-10 mice per group, *p< 0.05.  
 
 
 
Supplemental Figure II. qPCR of Foxp3, Tbet, GATA3 and RorγT mRNA expression relative to the 
average expression of 18S and cyclophilin in spleen of ApoE-/- mice treated in vivo for 4 weeks 
with low- (0.05 mg/kg/day) and high-dose (1 mg/kg/day) of FK506. n=5-10 mice per 
group,**p<0.01. 
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Supplemental Figure III. Effects of FK506 treatment on cytokine secretion. Panel A-C show IL-10 
(A), IL-4 (B) and IFN-γ (C) secretion by spleen CD4+ T-cells isolated from ApoE-/- mice treated with 
low- (0.05 mg/kg/day) and high-dose (1 mg/kg/day) of FK506 (n=4 mice per group). Panel D and 
E show the effect of FK506 in vitro treatment on IFN-γ (D) and IL-10 (E) secreted by PMA- and 
ionomycin-stimulated Jurkat T-cells that were pretreated with FK506 of 0, 20, and 2000 ng/ml 
for 1 hour (n=6 per group). *p<0.05, **p<0.01. 
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Abstract 
 
Objective Nuclear Factor of Activated T-cells C2 (NFATC2) is a crucial 
transcriptional regulator of numerous inflammatory genes during immune 
responses. The recently reported role of NFATC2 in regulatory T-cell function 
and Thelper1-cell differentiation, as well as the finding that the NFAT signaling 
inhibitor FK506 diminished atherosclerosis, suggestive of a pro-atherogenic 
role of NFATC2, led us to investigate the effect of NFATC2 deficiency on 
atherosclerosis. 
Approach and Results The effect of NFATC2 deficiency on atherosclerosis and 
T-cell phenotype and function was investigated in LDLr-/- mice with either 
whole body or hematopoietic NFATC2 deficiency. Contrary to our expectations, 
both murine models showed significantly increased advanced atherosclerotic 
lesion burden in the aortic arch, and sharply increased plaque CD3+ T-cell 
content. NFATC2-deficient splenic T-cells displayed Th2-biased T-cell responses 
in vivo, enhanced CD3 expression and CD3-induced mitogenic response, which 
was not attributable to a change in regulatory T-cell function. Importantly, 
flow-cytometric analysis of T-cell subsets revealed a clear shift from naïve 
towards migratory CD44highCD62Llow effector/memory T-cells in NFATC2-/-
//LDLr-/- as well as hematopoietic NFATC2-deficient LDLr-/- mice. Moreover, 
NFATC2-/- T-cells showed impaired spleen grafting and preferential homing to 
the atherosclerotic plaque.  
Conclusions Collectively, NFATC2 knockout and hematopoietic depletion 
resulted in an augmented rather than compromised T-cell response, which 
underlies the aggravated atherogenic response. 
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Introduction 
 
The transcription factor Nuclear Factor of Activated T-cells (NFAT) is essential 
for an adequate immune response.1, 2 It is expressed in a variety of immune 
cells such as T- and B-lymphocytes, natural killer cells, monocytes and other 
myeloid cells.2-4 The NFAT family encompasses five well-characterized 
members with NFATC1 and NFATC2 as major isoforms relevant to T-cell 
activation.5, 6 NFAT function is tightly regulated by calcineurin, a calmodulin-
dependent calcium-activated phosphatase.7 Upon dephosphorylation NFAT 
translocates to the nucleus to induce the expression of several cytokine genes, 
such as interleukins IL-2, IL-3, IL-4, IL-5, interferon-γ (IFN-γ), tumor necrosis 
factor α (TNFα), granulocyte macrophage colony-stimulating factor (GM-CSF), 
and TNF family members, such as CD40L, CTLA-4, and FasL (reviewed in ref.8). 
However, NFAT-family members C1 and C2 were also reported to regulate T-
helper (Th) and regulatory T-cell (Treg) differentiation1, 9-11, and mice deficient 
in NFATC2 showed modest splenomegaly with hyperproliferation of T- and B-
lymphocytes and an augmented allergic phenotype characterized by 
eosinophilia in vivo and in vitro.12-15 Despite the pleiotropic activity of NFAT, 
intervention in NFAT signaling by immunosuppressive drugs such as FK506 
(tacrolimus) and cyclosporine A (CsA) is widely regarded as an effective 
therapeutic strategy in a number of chronic inflammatory and autoimmune 
disorders as well as in transplant rejection.16-19  
Several lines of evidence indicate that NFAT is implicated in chronic 
inflammatory processes that underlie atherosclerosis. Firstly, low-dose 
treatment with FK506 inhibited the initiation and progression of collar-induced 
atherosclerosis in apolipoprotein E (ApoE)-/- mice.20, 21 Secondly, NFATC2 was 
recently reported to control Treg development and suppressive function11, 22, 23 
and NFATC2 deficiency led to Th2-biased T-cell responses9, 12, 24, 25, both 
processes that were previously shown to attenuate atherosclerosis.26 
However, no data are available on the role of NFATC2 in atherosclerosis. Here, 
we showed that NFATC2 knockout and hematopoietic depletion led to Th2-
skewed immune responses and, contrary to our expectations, deteriorated 
atherosclerosis. NFATC2-deficient T-cells showed an enhanced mitogenic 
response to CD3 stimulation and displayed an effector/memory T-cell 
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phenotype more prone to migrate to the atherosclerotic plaque, which may 
have contributed to the exacerbation of atherosclerosis. 
 
 
Materials and methods 
 
Animal experimental design 
Female low density lipoprotein receptor-knockout (LDLr-/-) mice on a C57BL/6J 
background (6-8 weeks old) were obtained from Jackson (Bar Harbor, USA). 
The generation of NFATC2-/- mice has been described previously.13 NFATC2 and 
LDLr double-knockout (DKO) mice were generated by intercrossing LDLr-/- mice 
three times with NFATC2-/- mice on a C57BL/6J background. Age- and gender-
matched 14 LDLr-/- and 15 NFATC2-/-//LDLr-/- mice were placed on a high-
cholesterol diet containing 0.25% cholesterol (Special Diets Services, Witham, 
Essex, UK) for 8 weeks. 
In addition to NFATC2-/-//LDLr-/- mice, NFATC2-/--bone-marrow 
transplanted (BMT) mice were generated. One day before the BMT, LDLr-/--
recipient mice were exposed to a single dose of 9 Gray (Gy) of total body 
irradiation (Roentgen source, Philips MU15F/225). Bone marrow was harvested 
by flushing femurs and tibias of either LDLr-/- or NFATC2-/- donor mice with 
phosphate-buffered saline (PBS). Single-cell suspensions were prepared by 
passing the cells through a 19-gauge needle, followed by a 25 gauge-needle. 
Age- and gender-matched 9 irradiated LDLr-/--recipient mice received 5 x 106 
LDLr-/--bone-marrow cells each and 10 irradiated LDLr-/--recipients received 5 x 
106 NFATC2-/--bone-marrow cells by intravenous injection into the tail vein. 
BMT-recipient mice were housed in sterilized filter-top cages and fed a 
sterilized normal-chow diet and sterile drinking water containing neomycin 
(100 mg/L) and polymyxin B (60.000 U/L). Four weeks after the BMT, antibiotic 
treatment was discontinued and the diet was switched to a high-cholesterol 
diet containing 0.25% cholesterol (Special Diets Services, Witham, Essex, UK) 
for another 23 weeks to induce atherosclerosis.  
All animal experiments were approved by the regulatory authority of the 
University of Maastricht and were performed in compliance with the Dutch 
government guidelines. 
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Determination of chimerism 
Chimerism in transplanted mice was determined as described previously.27 
Genomic DNA was isolated from the blood of recipient LDLr-/- mice, at 27 
weeks after the BMT, using the Illustra blood genomic prep Mini spin kit (GE 
Healthcare, Amersham, England). The standard curve was composed of DNA 
from LDLr–/– and LDLrWT blood mixed at different ratios. Chimerism was 
determined by quantifying the amount of LDLrWT DNA in samples from 40μl 
peripheral blood by quantitative real-time PCR (qPCR). Samples were assayed 
in duplicate using the Taqman IQ TM SYBR Green Super Mix (BIO-RAD, Hercules, 
CA). Chimerism was calculated as the percentage of LDLrWT DNA in the blood 
samples. An average of 96.8% of the white blood cells was of donor origin, 
establishing successful engraftment. The degree of chimerism was identical in 
NFATC2-/-- and LDLr-/--BMT mice (97.1%±0.3 vs 96.5%±0.5). 
 
Plasma cholesterol 
Serum cholesterol levels of NFATC2-/-//LDLr-/-, NFATC2-/--chimeric and control 
mice were determined with the CHOD-PAP method (Roche Diagnostics). 
 
Histological analysis of atherosclerosis 
To study the development of atherosclerosis, sections of the aortic arch were 
prepared and analyzed as described previously.28 Briefly, the arterial system 
was perfused with PBS containing 0.1mg/ml nitroprusside (Sigma, St Louis, 
MO). The aortic arch, including its main branch points, was excised and fixed 
with 1% paraformaldehyde. Approximately 40 serial cross-sections (4 µm thick) 
from the longitudinally embedded aortic arch were cut. Every fifth paraffin 
section was stained with hematoxylin and eosin (H&E) for the analysis of 
plaque number and area. Plaque area was measured on 4 of these sections per 
aortic arch, selected to cover the central part of each lesion. Lesions containing 
only foam cells were categorized as initial, whereas advanced lesions were 
determined by the presence of necrotic core and/or fibrous cap. The relative 
collagen content in atherosclerotic lesions that was stained positive for Sirius 
red was determined under a microscope coupled to a computerized 
morphometry system (Quantimet 570, Leica Qwin V3, Leica, Rijswijk, The 
Netherlands). Morphometric analysis was performed by one blinded 
investigator (K.G., intra-observer variability was < 10%). 
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Immunohistochemical stainings  
Sections were stained with the following antibodies: Rabbit anti-mouse/human 
CD3 (1:200, Dako, Glostrup, Denmark) to detect T-cells, MAC3 rat monoclonal 
antibody (1:30, BD Biosciences Pharmingen, San Diego, CA) to detect 
macrophages, CD45 (1:5000, BD Biosciences Pharmingen, San Diego, CA) to 
detect leukocytes, and cleaved caspase-3 (1:100, Cell Signaling, Boston, MA) to 
detect apoptotic cells. To determine the relative amounts of T-cells, 
macrophages, leukocytes and caspase-3-positive cells, the number of 
respectively CD3-, MAC3-, CD45- and cleaved caspase-3-positive cells in the 
lesions were divided by the corresponding lesion area. All measurements were 
conducted by one investigator (K.G., intra-observer variability was < 10%). 
 
Fluorescence-activated cell sorting (FACS) 
Spleens, blood and lymph nodes were isolated and single-cell suspensions 
were created (spleens and lymph nodes were pushed through a 70 µm 
strainer) for FACS analysis using BD FACS CANTO II. All samples were collected 
in PBS and stored on ice during staining and analysis. Erythrocytes in peripheral 
blood and spleen were removed by hypotonic lysis with NH4Cl. First, cells were 
incubated with anti-CD16/32 (eBioscience, San Diego, CA) in FACS buffer (0.5% 
bovine serum albumin (BSA) and 1mM EDTA in PBS) for 30 minutes to block Fc-
receptor binding and secondly stained with anti-CD3, anti-CD8, anti-CD4, anti-
CD25 (eBioscience, San Diego, CA) and anti-CD45R/B220 (BD-Biosciences 
Pharmingen, San Diego, CA). Leukocytes were furthermore incubated with 
anti-CD62L (eBioscience, San Diego, CA) and anti-CD44 (BD-Biosciences 
Pharmingen, San Diego, CA) to identify naïve T-cells (defined as 
CD44lowCD62Lhigh) and effector/memory T-cells (defined as CD44highCD62Llow). 
Cells were fixed and made permeable, according to the manufacturer’s 
instructions (eBioscience, San Diego, CA), for anti-Foxp3, anti-Tbet, anti-
GATA3, anti-RorγT, anti-IFN-γ, (eBioscience, San Diego, CA), anti-IL-4 (BD-
Biosciences Pharmingen, San Diego, CA) and anti-IL-17 (Becton & Dickinson, 
Franklin Lakes, US) intracellular stainings. 
 Flow cytometric analysis of IFN-γ, IL-4 and IL-17 was performed after 5 
hours in vitro incubation (Golgistop (1µl/ml, BD 554724) was added after 1 
hour incubation) with phorbol 12-myristate 13-acetate (PMA, 50ng/ml, Sigma 
p1585, St Louis, MO) and ionomycin (1µg/ml, Sigma I0634, St Louis, MO) of 
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splenocytes resuspended in medium (RPMI medium supplemented with 25 
mM HEPES buffer, 2 mM L-glutamine, 1% penicillin/streptomycin (Gibco) and 
10% fetal  calf serum (FCS)). Splenocytes were seeded in 24-well plates at a 
density of 1x106 cells/ml. 
 
Preparation of lysates and western immunoblotting  
T-cells were sorted from the spleen of NFATC2-/-//LDLr-/- and LDLr-/- mice, and 
lysed in 1x protein loading buffer. Lysates were subsequently boiled for 5 
minutes and separated by electrophoresis (SDS-PAGE). Proteins were 
transferred to polyvinylidene fluoride (PVDF) membranes and incubated for 1h 
at room temperature with blocking solution (5% (w/v) milk + 0.1% Tween20 in 
PBS (PBST)). To detect NFAT dephosphorylation, the membranes were first 
incubated for 1h with anti-NFAT1 (NFATC2) antibody (1:000, NEBlab), anti-
NFAT2 (NFATC1) antibody (1:1000, Abcam) and anti-NFATC3 antibody (1:1000, 
Santa Cruz) in 5% (w/v) milk/PBST, followed by 1h incubation with secondary 
donkey anti-rabbit and sheep-anti mouse horse radish peroxidase- (HRP) 
conjugated (1:2000, GE Health) in 5% (w/v) milk/PBST. Next, membranes were 
extensively washed in PBST and PBS and proteins were visualized by ECL-plus 
detection system according to the manufacturer’s instructions (GE Life 
Sciences). 
 
T-cell proliferation and regulatory T-cell function assay 
Cell-proliferation experiment and Treg function assay were performed as 
described before.29 Cells were purified and pooled from 3 mice per group at 
the time of sacrifice. CD4+CD25– cells (0.5x105 cells) were cultured alone or in 
co-culture with CD4+CD25+ cells at diverse concentrations (0.5x105, 0.25x105, 
0.12x105, 0.06x105), in flat-bottomed 96-well microplates (total volume 200 
µl/well). Cells were stimulated with purified soluble CD3-specific antibody (1 
µg/ml, Pharmingen) in the presence of antigen-presenting cells (0.1x105 cells) 
purified on CD11c-coated magnetic beads (Miltenyi Biotech). Cells were 
cultured at 37°C for 72 hours, pulsed with 1 µCi of [3H] thymidine (Amersham) 
and incubated for another 18 hours. Thymidine incorporation was assessed 
using a TopCount NXT scintillation counter (Perkin Elmer).  
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RNA isolation and real-time PCR 
RNA was extracted from spleen lysates with Nucleospin RNA II kit (MACHEREY-
NAGEL, Duren, Germany). cDNA was generated using iSCript TM cDNA synthesis 
kit (BIO-RAD, Hercules, CA). qPCR was done with a Taqman IQ TM SYBR Green 
Super Mix (BIO-RAD, Hercules, CA). Primer sequences of Tbet, IFN-γ, GATA3, IL-
4, Foxp3, Cblb, Egr2, 18S and cyclophilin are shown in Supplemental Table I on 
page 88. An average expression of 18S and cyclophilin was considered as 
reference value for total RNA expression. 
 
In vivo trafficking experiments 
Wild-type (WT) and NFATC2-/- mice received an intravenous injection of 90µg 
of lipopolysaccharides (LPS). Two hours after LPS injection, splenocytes from 
WT and NFATC2-/- mice were isolated and labeled with 2 µM CFSE (Invitrogen) 
in PBS at 37°C for 15 minutes. Labeled cells were incubated in RPMI medium at 
37°C for 30 minutes to ensure that by-products had passively diffused into the 
medium. After washing with PBS containing 0.1% BSA, 3x107 of labeled cells in 
0.2ml of PBS were injected intravenously into ApoE-/--recipient mice (37-40 
weeks old, 4 received labeled splenocytes from WT mice and 5 received 
labeled splenocytes from NFATC2-/- mice). Forty two hours after the injection, 
mice were sacrificed and perfused with PBS. Spleen and aortic arch were 
harvested to identify the number of CFSE-positive cells that migrated to the 
spleen and atherosclerotic lesions. The percentage of CFSE-labeled splenocytes 
in the spleen was determined by FACS. 
Perfused aortic arches were placed in Tissue-Tek O.C.T. embedding 
medium (Miles Inc), snap-frozen at -160°C in liquid nitrogen-cooled isopentane 
(Baxter Scientific). Twenty cross-sections (4 µm thick) from the longitudinally 
embedded fresh-frozen aortic arches were cut. Four sections with a distance of 
20 µm each were selected to analyze CFSE+ cells in the lesions. Nuclei were 
counterstained using Mounting Medium with DAPI (VECTOR). Overlay images 
were acquired using fluorescence microscopy (Leica DM 5000B) with the filter 
system I3 to detect CFSE+ cells, and SGR to detect DAPI. Lesional CFSE+-cell 
content was calculated from the total number of CSFE+ cells divided by that of 
all cells in the lesion. Analysis was performed by one blinded investigator (L.B., 
intra-observer variability was < 10%). 
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Statistics 
Statistical analyses were performed using a nonparametric Mann–Whitney U 
test. The number of CFSE+ cells in the lesion in the in vivo homing experiment 
was compared with independent sample T test. Data are expressed as mean ± 
SEM. Probability values of < 0.05 were considered significant. 
 
 
Results 
 
Serum cholesterol levels 
Western-type diet feeding for 8 weeks led, as expected, to increased plasma 
total cholesterol levels in LDLr-/- and NFATC2-/-//LDLr-/- mice; however, 
cholesterol levels did not differ between LDLr-/- and NFATC2-/-//LDLr-/- mice 
both at the start of the experiment and at sacrifice (Supplemental Figure I on 
page 88). Likewise, plasma cholesterol levels were comparable in LDLr-/- mice 
transplanted with LDLr-/-- and NFATC2-/--bone marrow at sacrifice 
(Supplemental Figure I on page 88). 
 
Increased atherosclerotic plaque area and T-cell content in NFATC2-/- and 
hematopoietic-depleted mice 
While the number of initial or advanced lesions in the aortic arch of LDLr-/- and 
NFATC2-/-//LDLr-/- mice did not differ (data not shown), the average plaque size 
of advanced lesions was significantly increased in NFATC2-/-//LDLr-/- mice 
compared to LDLr-/- mice (Figure 1A). Analysis of plaque composition revealed 
significantly increased relative CD3+ T-cell content in NFATC2-/-//LDLr-/- mice 
compared to LDLr-/- controls (Figure 1B).  
Hematopoietic deficiency of NFATC2 resulted in similarly enhanced 
advanced lesion area (Figure 1C), suggesting that hematopoietic NFATC2 
depletion was responsible for the aggravated disease progression. Again, we 
did not observe any differences in the average initial lesion size between both 
groups (data not shown), indicating that NFATC2 deficiency predominantly 
impacts advanced plaque development. Similar to the whole body knockouts, 
NFATC2 deficiency in the hematopoietic-lineage resulted in a dramatic 
increase in lesional CD3+ T-cell content (Figure 1D). Relative CD45+-leukocyte 
and MAC3+-macrophage numbers, collagen content, lipid core size as well as 
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percentage cleaved caspase-3-positive cells did not differ between both groups 
of transplanted mice (Supplemental Figure II on page 89). Interestingly, the 
degree of calcification, characterized by plaque mineralization and the 
presence of intraplaque chondrocytes, was dramatically increased in NFATC2-
transplanted mice, compared with control mice (Figure 1E), which was not 
observed in NFATC2-/-//LDLr-/- mice (data not shown).  
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Figure 1. NFATC2-/- (top panels) and hematopoietic-depleted mice (bottom panels) showed 
increased advanced lesion size and T-cell content in the aortic arch. A, Area (µm2) of advanced 
lesions measured in the aortic arch of LDLr-/- and NFATC2-/-//LDLr-/- mice and representative 
photographs of H&E-stained aortic arches containing atherosclerotic plaques (arrows). B, 
Quantification of CD3+ T-cells, relative to plaque area, of lesions in the aortic arch of LDLr-/- and 
NFATC2-/-//LDLr-/- mice, and representative photographs of anti-CD3 T-cell staining (arrows). 
Insets show lower magnification. Similar area measurement (C) and relative CD3+ T-cell content 
analysis (D) of plaques in the aortic arch of LDLr-/-- and NFATC2-/--BMT mice. E, The percentage of 
calcification, characterized by mineralization and the presence of chondrocytes (relative to non-
calcified area), in plaques of NFATC2-/--BMT mice compared with LDLr-/--BMT mice. H&E-stained 
advanced plaque of NFATC2-/--BMT mouse showing calcified cartilage (arrow). Bars represent 
mean ± SEM; * P<0.05, *** P<0.001. 
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NFATC2-/- led to a Th2 T-cell response 
Intracellular flow-cytometric staining of the lineage-specific transcription 
factors Tbet and GATA3, critical for Th1- and Th2-differentiation respectively, 
were performed and showed a significant increase in GATA3 expression and no 
difference in Tbet expression in CD4+ T-cells in spleens of NFATC2-/-//LDLr-/- 
mice compared with control LDLr-/- mice (Figure 2A). In keeping, 
PMA/ionomycin-induced cytokine IFN-γ expression in CD4+ and CD8+ T-cells in 
vitro was significantly decreased in NFATC2-/-//LDLr-/- mice (Figure 2B-C), while 
that of IL-4 was undetectably low in both genotypes (data not shown). No 
differences were observed in the intracellular expression of transcription 
factor RorγT and cytokine IL-17 between NFATC2-/-//LDLr-/- and LDLr-/- mice, 
reflective of an unaltered Th17 response (data not shown). The Th1 to Th2 
shifted immune response in NFATC2-/- mice could be confirmed in vivo as 
judged by the markedly increased GATA3 and IL-4 gene expression in spleen of 
NFATC2-/-//LDLr-/- mice (Figure 2D). Tbet and IFN-γ expression was not 
significantly altered between NFATC2-/-//LDLr-/- and LDLr-/- mice (data not 
shown). 
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Figure 2. Th2 differentiation in spleen of NFATC2
-/- mice. A, Flow cytometric analysis of Tbet and 
GATA3, transcription factors responsible for a Th1 and Th2 response respectively, in splenic CD4
+ 
T-cells of LDLr-/- and NFATC2-/-//LDLr-/- mice. B, Flow-cytometric analysis of IFN-γ level after in 
vitro stimulation with PMA/ionomycin of CD4+ and CD8+ splenocytes. C, Representative FACS 
plots of intracellular staining of transcription factors Tbet and GATA3, and cytokines IFN-γ and IL-
4 of CD4+ and CD8+ T-cells. D, GATA3 and IL-4 gene expression (relative to the average 
expression level of house-keeping genes) in spleen of NFATC2-/-//LDLr-/- mice compared to LDLr-/- 
mice. Bars represent mean ± SEM; * P<0.05, *** P<0.001. 
 
NFATC2 deficiency enhanced T-cell mitogenic response to anti-CD3 treatment 
The remarkable increase in plaque T-cell content prompted further 
investigation of T-cell phenotype and function. Therefore, single-cell 
suspensions of blood, spleen and lymph nodes of NFATC2-/- mice were 
analyzed for lymphocyte subsets by FACS. Relative CD3+ T-cell numbers were 
significantly elevated in spleen, but decreased in lymph nodes of NFATC2-/-
//LDLr-/- mice compared to LDLr-/- mice (Figure 3A). T-cells in blood, spleen and 
lymph nodes showed no changes in CD4+ to CD8+ ratio (data not shown). 
However, CD4+CD25- T-cell numbers were significantly increased in spleen and 
lymph nodes of NFATC2-/-//LDLr-/- mice (Figure 3B). Of note, no differences 
were observed in number of monocytes, granulocytes or natural killer cells 
between NFATC2-/-//LDLr-/- and LDLr-/- mice (data not shown).  
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Relative CD3+ T-cell numbers in spleen and blood of NFATC2-/--BMT mice 
were not altered compared with LDLr-/--transplanted mice (Figure 3C). 
Circulating T-cells in NFATC2-/--BMT mice displayed a sharply reduced CD4+ to 
CD8+ ratio (Figure 3D). Relative CD4+, CD8+, CD4+CD25+ and CD4+CD25- of CD3+ 
T-cell contents in spleen of NFATC2-/--BMT mice remained unaffected (data not 
shown). Interestingly, while blood and spleen CD3+ T-cell numbers were not 
altered in NFATC2-/--transplanted mice (Figure 3C), CD3+ expression (mean 
fluorescent intensity) was markedly enhanced (Figure 3E). In keeping with this 
notion, the mitogenic response of CD4+CD25- T-cells to anti-CD3 antibody 
treatment in vitro, as measured by incorporation of [3H] thymidine, was 
enhanced by a significant 24% in NFATC2-/- T-cells (Figure 3F) pointing to an 
increased responsiveness of NFATC2-/- T-lymphocytes to anti-CD3 activation. 
 
Unchanged Treg-suppressive function 
The CD4+CD25+ T-cell subset, which was significantly expanded in NFATC2-/--
BMT mice (Figure 3D), was enriched in CD4+CD25+Foxp3+ Tregs (blood) and 
CD4+CD25+Foxp3- activated T-cells (spleen) (Figure 4A). CD4+CD25+Foxp3+ 
Tregs were also overrepresented in spleen and lymph nodes of NFATC2-/-
//LDLr-/- mice (Figure 4B). In agreement with the observed Treg expansion, 
gene expression of Foxp3, a critical transcription factor in Treg differentiation 
and function30, 31, was seen to be upregulated in spleen of NFATC2-/-//LDLr-/- 
mice (Figure 4C). Considering the observed enhanced CD4+CD25- T-cell 
responsiveness to CD3 stimulation (Figure 3F) and the increased Treg numbers, 
we investigated the suppressive capacity of Tregs. However, NFATC2-/-- and 
LDLr-/--BMT mice showed equal Treg function (Figure 4D).  
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Figure 3. NFATC2-/- (top panels) and hematopoietic deficiency (middle panels) altered T-
lymphocyte pattern and enhanced mitogenic response to anti-CD3 treatment (bottom panels). 
A, Flow-cytometric analysis of the percentage CD3+ T-cells of total cells measured in circulation, 
spleen and lymph nodes (LN) of LDLr-/- and NFATC2-/-//LDLr-/- mice. B, The relative number of 
CD4+CD25- T-cells in blood, spleen and LN of LDLr-/- and NFATC2-/-//LDLr-/- mice. C, Percentage 
CD3+ T-cells in blood and spleen of NFATC2-/--BMT mice compared with LDLr-/--BMT mice. D, 
Flow cytometric analysis of CD4+, CD8+, CD4+CD25+ and CD4+CD25- T-cell populations in blood of 
LDLr-/--BMT and NFATC2-/--BMT mice. E, CD3 mean fluorescent intensity (MFI) of CD3+ T-cells in 
blood and spleen of LDLr-/-- and NFATC2-/--BMT mice. F, Assessment of the proliferation of 
purified CD4+CD25- T-cells ([3H] thymidine incorporation) after stimulation with anti-CD3 in the 
presence of purified WT CD11c+ dendritic cells (counts per minute, CPM). Bars represent mean ± 
SEM; * P< 0.05, ** P<0.01, *** P<0.001. 
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Figure 4. NFATC2 deficiency increased Treg numbers without changing Treg function. Flow-
cytometric analysis of the effect of hematopoietic NFATC2 depletion (A) and NFATC2-/- (B) on 
CD4+CD25+Foxp3+ and Foxp3- T-cells in blood, spleen and lymph nodes (LN). C, Foxp3 gene 
expression level (relative to the average expression level of house-keeping genes) in spleen of 
LDLr-/- and NFATC2-/-//LDLr-/- mice. D, Difference in regulatory T-cell function in suppressing T-
cell proliferation. Inhibition of proliferation of CD4+CD25- T-cells after coculture with CD4+CD25+ 
Treg cells. Bars represent mean ± SEM; * P< 0.05, ** P<0.01. 
 
Hematopoietic depletion and NFATC2-/- resulted in enhanced 
effector/memory T-cell phenotype 
Another feature of altered T-cell function in NFATC2-/-//LDLr-/- mice was the 
decreased ratio of naïve T-cells, defined as CD4+CD44lowCD62Lhigh T-cells, to 
effector/memory (CD4+CD44highCD62Llow) T-cells in blood, spleen and lymph 
nodes (Figure 5A-B). Of note, the CD8+ T-cell population showed a comparable 
pattern with minor decreases and increases, respectively, in naïve and memory 
T-cell counts in blood, spleen and lymph nodes of NFATC2-/-//LDLr-/- mice (data 
not shown).  
Analysis of hematopoietic depletion of NFATC2 confirmed these findings, 
in that naïve (CD4+CD44lowCD62Lhigh) T-cells were significantly reduced (8.7%) in 
blood of NFATC2-/--transplanted mice, while the effector/memory 
CD4+CD44highCD62Llow T-cell subset was expanded by 42.3% (Figure 5C). This 
ratio shift towards effector/memory T-cells was also apparent in the CD8+ T-
cell population in blood and spleen (data not shown). Not only the CD4+ T-cell 
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population as a whole but also the CD4+CD25+ T-cell subset showed a 
significantly shifted ratio of naïve to effector/memory T-cells in blood and 
spleen of NFATC2-/--BMT mice (Figure 5D). Interestingly, not only fewer T-cells 
were CD62L+, also the mean CD62L expression of CD4+-, CD8+- and CD4+CD25+-
CD62Lhigh T-cells was substantially reduced (Figure 5E). Furthermore, Western 
blot data showed no difference in the level of dephosphorylated NFATC1 
between LDLr-/- and NFATC2-/-//LDLr-/- splenocytes (data not shown), excluding 
the possibility of overcompensation. In addition, no significant alteration in 
expression of anergy-associated genes (Cblb and Egr2) was found (data not 
shown). 
 
NFATC2 deficiency reduced spleen engraftment, but enhanced homing of 
splenocytes to atherosclerotic lesions 
Given the marked and consistent skewing towards a migratory 
effector/memory T-cell phenotype in NFATC2 deficiency, we examined 
whether this shift accounted for the higher T-cell content in NFATC2-/--
atherosclerotic lesions. Therefore, CSFE+ splenocytes isolated from NFATC2-/- 
and WT mice were injected into ApoE-/- recipients with established 
atherosclerotic lesions. Forty two hours after injection, CFSE+ cells could be 
detected in recipient spleens as measured by FACS. In agreement with our 
hypothesis, recovery of NFATC2-/- CFSE+ cells in spleen was dramatically 
reduced compared to that of WT CFSE+ splenocytes (Figure 6A). In contrast, 
the percentage of CFSE+ cells of total cells in plaque was 2.7 fold higher in 
recipients that had received NFATC2-/- CFSE+ splenocytes than in recipients 
receiving WT CFSE+ splenocytes (Figure 6B). Thus, NFATC2 deficiency is 
associated with enhanced migration capacity of splenocytes to atherosclerotic 
lesions, while splenic grafting was reduced.  
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Figure 5. NFATC2-/- (top panels) and hematopoietic depletion (lower panels) enhanced 
effector/memory T-cell phenotype. A, Flow-cytometric analysis of the percentage of naïve CD4+ 
T-cells, defined as CD44lowCD62Lhigh and effector/memory (Eff/Mem) T-cells, defined as 
CD44highCD62Llow in blood, spleen and lymph nodes (LN) of NFATC2-/-//LDLr-/- mice compared 
with controls. B, FACS plots of splenocytes stained with anti-CD44 and anti-CD62L on gated CD4+ 
cells. The percentage of naïve and effector/memory CD4+ (C) and CD4+CD25+ (D) T-cells in blood 
and spleen of LDLr-/-- and NFATC2-/--BMT mice. E, Flow-cytometric analysis of the effect of 
NFATC2-hematopoietic deficiency on CD62L mean fluorescent intensity (MFI) of CD4+CD62Lhigh, 
CD8+CD62Lhigh and CD4+CD25+CD62Lhigh T-cell subsets in blood and spleen. Bars represent mean 
± SEM; * P< 0.05, ** P<0.01. 
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Figure 6. NFATC2 deficiency enhanced homing of splenocytes to atherosclerotic lesions. Flow 
cytometric analysis of CFSE+ splenocytes relative to total cell number, isolated from either donor 
NFATC2-/- or WT mice, in spleen (A, B) and atherosclerotic aortic arch lesions (C) of recipient 
ApoE-/- mice.  Bars represent mean ± SEM; * P< 0.05, *** P< 0.001. 
 
 
Discussion 
 
A critical regulator of immune responses, NFAT, contributes to a variety of 
inflammatory and autoimmune disorders. The recent finding that NFAT 
activation was indispensable for Treg function11, 22, 23 and that NFATC2 
deficiency led to Th2-biased immune responses12, 24, 25, and the prominent role 
of T-cells in atherosclerosis26, suggested a role of this transcription factor in 
this disease as well. Indeed, we have previously shown that inhibition of 
calcineurin/NFAT signaling by low-dose FK506 inhibited the initiation and 
progression of collar-induced atherosclerosis.20, 21 This led us to investigate the 
role of a major mediator in NFAT signaling in T-cells, NFATC2, in 
atherosclerosis.  
Contrary to our expectations, NFATC2-/- and hematopoietic depletion led 
to dramatically increased lesional CD3+ T-cell content and exacerbated the 
atherogenic response, and in particular advanced lesion development. As 
expected, NFATC2-/-//LDLr-/- mice showed an increase in Th2-reponse in spleen, 
as witnessed by the upregulated transcription factor GATA3 and cytokine IL-4, 
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as well as downregulated Th1-cytokine (IFN-γ) expression, an effect that is 
generally deemed atheroprotective. This is concordant with previous reports 
that NFATC2-deficient mice exhibited a Th2-dominated pro-allergic 
phenotype.12-15 The nuclear balance between NFAT-family members and 
costimulatory transcription factors was deemed instrumental in coordinated 
transcriptional regulation of Th-immune programs. While plaque T-cells are 
thought to display a pro-atherogenic Th1 phenotype32, our study showed that 
NFATC2 aggravated the atherogenic response due to or despite an overt 
splenic Th2 polarization of T-cell responses. In support of the former, both 
ApoE-/-//IL-4-/- mice33 and LDLr-/- mice reconstituted with IL-4-deficient bone 
marrow34 showed a marked decrease in atherosclerosis, illustrating the 
dichotomous activity of Th2 cytokines in atherosclerosis.  
A consistent feature of NFATC2 deficiency was the observed enrichment 
in CD4+CD25+Foxp3+ Treg subset. Interestingly, NFATC2 has been shown to 
directly interact with Foxp3 after T-cell receptor (TCR) activation35 as part of 
the transcriptional program required for Foxp3 promoter transactivation, and 
for proper Treg function11. In fact, the balance between initiation of an 
inflammatory T(effector)-cell versus Treg response depended critically on the 
nuclear concentration of NFAT to interact with Foxp3 or activator protein 1 
(AP1).36 To illustrate this notion, pharmacological inhibition of NFAT 
dephosphorylation with CsA in CD4+CD25- T-cells favored Treg activity.22 In this 
study, however, while CD4+CD25+Foxp3+ Treg numbers were augmented in 
NFATC2-/-, we found that their intrinsic suppressive activity was unaltered. 
Thus, the stronger proliferative response of NFATC2-/- responder T-cells to in 
vitro CD3 activation was not attributable to compromised Treg function with 
NFATC2 deficiency, but might be associated with the enhanced CD3 expression 
on T-lymphocytes in these mice reflecting a lower threshold for TCR activation. 
This is in keeping with the previously suggested involvement of NFATC2 in the 
modulation of TCR responsiveness, as T-cells from NFATC2 and C3-DKO mice 
showed increased proliferation in response to CD3 stimulation, even without 
CD28 costimulation.37 Thus in the absence of NFATC2 the threshold is lowered, 
resulting in increased proliferation and activation, and attenuated 
responsiveness to Treg-mediated suppression. As Treg function remained 
intact in NFATC2-deficiency, Treg function in itself appeared not exclusively 
dependent on NFATC2-transcriptional activity. In normolipidemic mice the 
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CD4+CD25+ T-cell subset largely comprises Foxp3+ Tregs38, but this does not 
necessarily hold for high-fat fed LDLr-/- recipients. The CD4+CD25+CD44high T-cell 
subset encompasses Foxp3- effector T-cells as well as self-antigen specific 
Foxp3+ memory Tregs, which were recently reported to constitute a first line of 
tolerogenic control to self antigens.39 Therefore, the Foxp3- effector subset 
skewed T-cell differentiation seen in NFATC2 deficiency, paralleled by a 
concomitant increase in memory Treg, may possibly represent a compensatory 
response to control T-cell activity.  
Another intriguing observation in this study was that NFATC2 deficiency 
resulted in enhanced effector/memory T-cell numbers characterized by 
CD44highCD62low and reduced levels of the CD44lowCD62Lhigh naïve T-cell 
phenotype in CD4+ and CD4+CD25+ T-cells. This observation fits well with the 
earlier reported effector/memory phenotype displayed by peripheral T-cells 
from NFATC2/C3 compound knockout mice, featuring elevated CD44 
expression.40 NFATC2 indeed is expressed and operational in memory CD4+ T-
cells where it is, amongst others, required for IL-2 production.41 Enhanced 
NFATC1/C2 transcriptional activity was considered instrumental in the rapid 
response of memory CD4+ T-cells to antigen stimulation by inducing cell 
migration and cytokine expression and release.41 Our study thus adds to these 
findings, identifying NFATC2 as key suppressor of CD44highCD62Llow 
effector/memory T-cell differentiation. 
CD44 expression is important for effector/memory T-cell extravasation 
at inflammatory sites42, whereas CD62L is responsible for homing of naïve T-
cells to and retention in lymph nodes.43 Central memory T-cells, unlike naïve T-
cells, were able to migrate to inflammatory sites and subsequently responded 
rapidly to antigens by secreting large amounts of effector cytokines such as IL-
4, IL-5 and IFN-γ, whereas naïve T-cells mainly traffic to lymph nodes.44-47 Our 
in vivo trafficking studies showed that NFATC2-/- splenocytes preferentially 
home to the atherosclerotic lesion compared with WT splenocytes and the 
associated impairment of spleen grafting points in that direction. The 
increased plaque homing capacity and plaque CD3+ T-cell content in NFATC2 
deficiency may thus be explained by the profoundly shifted balance between 
naïve and effector/memory T-cells, the predominant subset in chronically 
inflamed tissue.48 
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How exactly NFATC2 deficiency tunes effector/memory function remains 
elusive. As reported, T-cells lacking NFATC2 were resistant to anergy induction 
and showed drastically reduced expression of anergy-associated genes, such as 
Cblb, Egr2, Egr3, Grail and Caspase 3.49, 50 One might speculate that the failure 
to undergo T-cell anergy could have contributed to the observed expansion of 
the effector/memory T-cell subset and to the proliferative response in  
NFATC2-/- mice, as anergy renders the TCR uncoupled from down-stream 
signaling pathways preventing proliferation and cytokine expression in 
response to subsequent antigen encounter. However, we did not observe any 
major changes in anergy-associated gene expression. 
In conclusion, although NFAT-family members are critical activators of 
immune responses and NFATC2 deficiency in mice resulted in a Th2-biased T-
cell response, deficiency in NFATC2 in atherosclerosis-prone LDLr-/- mice 
aggravated rather than ameliorated atherosclerosis. NFATC2-deficient T-cells 
displayed an augmented proliferative response to CD3 stimulation and an 
effector/memory phenotype, and showed robust accumulation in 
atherosclerotic lesions, which could well have contributed to the surprising, 
aggravated atherogenic response in NFATC2 deficiency. 
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Supplemental data 
 
Supplemental Table I. Forward and reverse primer sequences of genes tested by qPCR. 
 Forward primer (5’-3’) Reverse primer (5’-3’) 
Tbet GGGAACCGCTTATATGTCCA GGGCTGGTACTTGTGGAGAG 
IFN-γ TGGCTGTTTCTGGCTGTTACTG GCTCTGCAGGATTTTCATGTCA 
GATA3 CAGCTGCCAGATAGCATGAA GCAGGCATTGCAAAGGTAGT 
 IL-4 ACGTCCTCACAGCAACGAAGA AATATGCGAAGCACCTTGGAA 
 Foxp3 CCAGTCTGGAATGGGTGTCC CTGCTTGGCAGTGCTTGAGA 
 Cblb  ACAGGCTGGCGAGTGTTC  GAGCCTGGCGATGTGACT 
 Egr2  CTACCCGGTGGAAGACCTC  AATGTTGATCATGCCATCTCC 
 Cyclophilin CAAATGCTGGACCAAACACAA TTCACCTTCCCAAAGACCACAT 
 18S GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
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Supplemental Figure I. No difference in total cholesterol between control and NFATC2-/- or -BMT 
mice. Differences in total cholesterol levels at the start of the experiment and time of sacrifice of 
LDLr-/- and NFATC2-/-//LDLr-/- mice, and LDLr-/-- and NFATC2-/--BMT mice. Bars represent mean ± 
SEM; *** P<0.001. ND means not determined. 
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Supplemental Figure II. Influence of hematopoietic NFATC2 deficiency on plaque composition. 
Leukocyte content (CD45+ staining, A) and macrophage content (MAC3+ staining, B) relative to 
advanced lesion area were not significantly different between NFATC2-/--BMT and LDLr-/--BMT 
mice. C, Percentage collagen content in advanced plaques, measured by Sirius red staining, and 
(D) number of cells positive for cleaved caspase-3 relative to advanced lesion area, as well as (E) 
the percentage lipid core area. Bars represent mean ± SEM. 
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Abstract 
 
Background and purpose: Recent studies have shown an increased incidence 
of localized atherosclerosis and subsequent cardiovascular events in cancer 
patients treated with thoracic radiotherapy. We previously demonstrated that 
irradiation accelerated the development of atherosclerosis and predisposed to 
an inflammatory plaque phenotype in young hypercholesterolemic ApoE-/- 
mice. However, as older cancer patients already have early or advanced stages 
of atherosclerosis at the time of radiotherapy, we investigated the effects of 
irradiation on the progression of existing atherosclerotic lesions in vivo.  
Material and methods: ApoE-/- mice (28 weeks old) received local irradiation 
with 14 Gy or 0 Gy (sham-treated) at the aortic arch and were examined after 
4 and 12 weeks for atherosclerotic lesions, plaque size and phenotype. 
Moreover, we investigated the impact of irradiation on macrophage 
phenotype (pro- or anti-inflammatory) and function (efferocytotic capacity, i.e. 
clearance of apoptotic cells) in vitro.  
Results: Irradiation of existing lesions in the aortic arch resulted in smaller, 
macrophage-rich plaques with intraplaque hemorrhage and increased 
apoptosis. In keeping with the latter, in vitro studies revealed augmented 
polarization towards pro-inflammatory macrophages after irradiation and 
reduced efferocytosis by anti-inflammatory macrophages. In addition, 
considerably more lesions in irradiated mice were enriched in pro-
inflammatory macrophages.  
Conclusions: Irradiation of existing atherosclerotic lesions led to smaller but 
more inflamed plaques, with increased numbers of apoptotic cells, most likely 
due to a shift towards pro-inflammatory macrophages in the plaque. 
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Introduction 
 
Cardiovascular disease (CVD) and cancer are the two leading causes of 
morbidity and mortality in industrialized societies.1 Although the number of 
patients diagnosed with cancer grows continuously, screening and treatment 
have improved, leading to increased survival rates. At least half of all long-term 
cancer survivors will have received radiotherapy. As a consequence, new 
challenges are emerging due to the development of secondary illnesses caused 
by radiotherapy. Survivors of Hodgkin’s Lymphoma or breast cancer have 
higher risk of stroke and coronary heart disease.2-7 This is partly due to vascular 
damage and sustained inflammation leading to atherothrombosis, decades 
after receiving thoracic radiotherapy. Most radiotherapy treatments for breast 
cancer deliver more than 40 Gy in total to the tumor bed. Although only a 
small part of the heart is usually exposed to this high dose, additional research 
dissecting the underlying causes of radiation-induced CVD is crucial for 
developing specific intervention therapies.  
One of the main causes of cardiovascular morbidity and mortality is 
atherosclerosis; it is a chronic lipid-driven inflammatory disorder of the arterial 
wall that can give rise to acute atherothrombotic events due to plaque erosion 
or rupture.8 Whereas wild-type mice have very low cholesterol levels and are 
resistant to atherosclerosis, hypercholesterolemic apolipoprotein E-knockout 
(ApoE-/-) mice have elevated levels of total cholesterol and low-density 
lipoproteins (LDL) and develop atherosclerotic lesions spontaneously with age. 
As we have shown previously, local irradiation of the carotid arteries with a 
single dose of 14 Gy accelerated the progression of atherosclerosis in young 
ApoE-/- mice and predisposed to macrophage-rich, thrombotic plaques, with 
less collagen, all features of a rupture-prone plaque.9, 10 Clinically relevant 
fractionated schedules of 20 x 2 Gy to the carotid artery resulted in a similar 
plaque phenotype in ApoE-/- mice compared to a single-dose treatment (14 
Gy).9 Furthermore, local cardiac irradiation of ApoE-/- mice induced an 
inflammatory response and microvascular damage, and enhanced 
atherosclerosis development in coronary arteries.11 
In the absence of monocytes/macrophages, hypercholesterolemia is not 
sufficient to drive the pathologic process of atherosclerosis, indicating that 
macrophages exert essential functions during atherogenesis.12 They are the 
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major cellular components of an atherosclerotic lesion and can impact plaque 
progression and stability by producing inflammatory mediators, regulating 
cholesterol metabolism, recruiting vascular smooth muscle cells (vSMCs), 
inducing lipid necrotic core formation, and producing matrix 
metalloproteinases (MMPs) and reactive oxygen species (ROS).13, 14 
Macrophages have remarkable plasticity that allows them to efficiently 
respond to different micro-environmental signals and to change their 
phenotype. Their physiology can also be markedly altered by both innate and 
adaptive immune responses.15, 16 In the last few years, it has become accepted 
that macrophages can reversibly polarize into two main phenotypes, 
classically- (M1 phenotype) and alternatively-activated (M2 phenotype) 
macrophages, responsible for promoting and resolving inflammation 
respectively.17-20 Classically-activated macrophages are generated by pro-
atherogenic stimuli and support a T-helper (Th)1-immune response, by 
producing pro-inflammatory cytokines as well as ROS and nitrogen 
intermediates through inducible nitric oxide synthase (iNOS) expression. In 
contrast, alternatively-activated macrophages are induced by Th2-related 
cytokines and secrete anti-inflammatory cytokines and upregulate scavenger 
receptors and arginase-1. M1- and M2-macrophage subsets have been 
identified in multiple pathological settings21, 22, including experimental and 
human atherosclerotic lesions.23-25 Due to the very heterogeneous plaque 
micro-environment, new plaque-specific macrophage phenotypes, such as 
Mox and M4 macrophages, were recently discovered.26-28  
In developed countries, almost all individuals have subclinical 
atherosclerotic lesions even at young age, and although cancer may affect 
people of all ages, the risk for the more common varieties of cancer increases 
with age. Moreover, Mitchel et al. have recently stressed the importance of 
atherosclerotic disease stage in determining the effect of radiation exposure 
on the progression of atherosclerosis.29 Therefore, we here investigated the 
effect of local radiotherapy on pre-existing atherosclerotic lesions in the aortic 
arch of aged ApoE-/- mice. 
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Material and Methods 
 
Mice and irradiation procedure 
At an age of 28 weeks and an average body weight of 33.2 gram ± 1.1, ApoE-/- 
mice on a C57BL/6J background were randomly allocated to receive irradiation 
or sham-treatment. The mice were housed in filter-top cages and provided ad 
libitum with standardized mouse chow containing 3.7% fat (RM1 (E) SQC, SDS 
London, UK) and with drinking water. A total of 46 mice were included in the 
quantitative analysis of atherosclerotic lesions, 22 mice were sacrificed 4 
weeks after treatment (10 mice were used as control, 12 mice received 
irradiation) and 24 mice were sacrificed 12 weeks after treatment (control and 
irradiated groups contained each 12 mice).  
Mice were locally irradiated with a single dose of 14 Gy(1) (250-kV X-rays 
at 12 mA, filtered with 0.6 mm copper) to the neck region encompassing 
carotid arteries, aortic arch and base of the heart, as described before10, or 
received sham-treatment (0 Gy). During irradiation or sham-treatment, mice 
were immobilized in perspex jigs with the non-target areas shielded with lead.  
Experiments were in agreement with the national regulations for animal 
experiments and the local animal welfare committee approved all 
experimental protocols.  
 
Tissue preparation 
Immediately after sacrifice the arterial system was perfused with 0.1 mg/ml 
sodium-nitroprusside in phosphate-buffered saline (PBS), followed by 1% 
paraformaldehyde. The cervical, thoracic and abdominal arterial tree was 
excised and fixed for 24 hours in 1% paraformaldehyde before transfer to 70% 
ethanol. The aortic arch was embedded in paraffin and 4 µm longitudinal, 
serial sections were cut and numbered sequentially. 
 
 
                                                 
(1) Assuming an α/β ratio of 2-3 Gy for late vascular damage, a single dose of 14 Gy is 
approximately equivalent to 48-56 Gy in 2 Gy fractions, according to the Linear 
Quadratic formula:  
EQD2 = D (d+(α/β)/2+(α/β)) 
EQD2 = equivalent dose in 2 Gy fractions; D = total dose; d = dose per fraction 
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Morphometric analysis of plaque 
Every fifth section of the aortic arch was stained with hematoxylin and eosin 
(H&E) and examined for the presence of atherosclerotic plaques, as described 
previously10. These plaques were categorized as initial lesions (macrophage-
rich without a thick fibrous cap) or advanced lesions (well-defined necrotic 
core or thick fibrous cap) based on the criteria by Virmani et al.30 The mean 
number of initial and advanced lesions in the brachiocephalic artery was 
determined 4 and 12 weeks after 0 Gy or 14 Gy. 
Morphometric parameters were analyzed using a microscope coupled to 
a computerized morphometry system (Leica Qwin V3, Leica, The Netherlands). 
All measurements were done by one investigator (KG), without prior 
knowledge of the treatment group. The intra-observer variation was less than 
10%. Plaque and necrotic areas (expressed as percentage of individual plaque 
area) were measured on four selected sections that cover the central part of 
the brachiocephalic artery lesion (present in 90% of the mice) and the average 
of these measurements was determined. 
The collagen content, based on a Sirius Red staining, was analyzed on 
two selected sections that cover the central part of the advanced 
brachiocephalic artery lesion. The relative collagen content was calculated by 
dividing the area of collagen by the individual plaque area. The average 
collagen content was determined per lesion. 
Evaluation of thrombotic characteristics of plaques in the aortic arch was 
performed on one of the central sections and scored semi-quantitatively. 
Sections were examined for the presence of fibrin deposits (Martius-Scarlet-
Blue Trichrome staining) and erythrocyte- (H&E staining) or iron (Fe)-
containing macrophages (Perl’s staining), as an indication of previous 
intraplaque hemorrhage.  
 
Immunohistochemistry 
One central section per brachiocephalic artery lesion was stained with MAC3-
antibody (1:30, Becton & Dickinson, USA), cleaved caspase-3-antibody (1:100, 
Cell Signaling, USA) and CD45-antibody (1:5000, Becton & Dickinson, USA) to 
detect macrophages, apoptotic cells and leukocytes, respectively. Results were 
expressed as number of antibody-positive cells relative to the average plaque 
area and group means were calculated. Furthermore, a staining with rabbit-
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anti-mouse iNOS (1:20, Abcam, UK) and rabbit-anti-mouse arginase-1 (1:500, 
kindly provided by Paul van Dijk, department of Anatomy and Embryology, 
Maastricht University, The Netherlands) was performed to semi-quantitatively 
score the presence of respectively M1 (pro-inflammatory) and M2 (anti-
inflammatory) macrophages in the plaque (grading no presence, presence or 
high presence).  
 
Macrophage culture and irradiation 
Both tibias and femurs were removed from ApoE-/- mice. The bone marrow 
was harvested by flushing the bones with PBS using a 25G needle. After 
collecting, the cells were centrifuged for 5 minutes at 4°C, 1100 rpm. Cell 
pellets were resuspended in cell culture medium (RPMI + 25MM HEPES buffer 
+ L-glutamine, with 1% penicillin/streptavidin and 10% filtered fetal calf 
serum), containing 15% fresh LCM. LCM, a conditioned medium from L929 cells 
(fibroblast cell line), contains macrophage-colony stimulating factor (M-CSF) 
and differentiates the bone marrow cells into macrophages attaching to the 
plate, while other cell types do not survive. After 3 and 6 days at 37°C, medium 
was refreshed and on day 7 macrophages were collected from the plate by 
adding lidocaine dissolved in PBS containing EDTA (0.2%) for 1-2 minutes at 
37°C. Cell number was counted using a Burker Chamber. Depending on the 
type of experiment, cells were diluted to the desired concentration to be 
seeded in culture plates. 
To test the effect of irradiation on M1- and M2-macrophage polarization 
and function, cells were seeded in a 24 (RNA isolation and efferocytosis assay) 
or 48 well cell-culture plate (apoptosis assay). The following conditions were 
investigated: 0 Gy, 0.5 Gy (low-dose) and 5 Gy (high-dose) irradiation of either 
M0 (unstimulated), M1 (18 hours lipopolysaccharides (LPS) stimulation, 0.01 
µg/ml, Sigma), or M2 (18 hours interleukin (IL)-4 stimulation, 20 ng/ml, 
Peprotech via Bioconnect) macrophages using X-radiation (Philips MU15F/225, 
RNL, Maastricht, The Netherlands).  
 
Apoptosis assay 
Macrophages were plated in a 48 well cell-culture cluster plate at a 
concentration of 1.5 x105 cells per well, skewed towards a M0, M1 or M2 
phenotype, and irradiated as described above. Immediately after irradiation, 
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macrophages were labeled with Annexin A5-Alexa fluor (Invitrogen, 1:20 
diluted in binding buffer, incubated at 37°C for 15 minutes). Bright field and 
fluorescent photos were taken with a 40x objective (5 photos per well) and the 
number of apoptotic cells was determined by overlaying both photos. Results 
were expressed as the ratio of fluorescent (apoptotic) to total cells.  
 
Efferocytosis assay 
Macrophages were seeded in a 24 well cell-culture plate (3.5 x105 cells per 
well) and labeled with cell tracker Red (Invitrogen, 1:500, 30 min in serum free 
RPMI medium). Apoptotic macrophages, stained with Calcein-AM (Invitrogen, 
1:1000, 60 min) and induced by 7-ketocholesterol (7KC, Sigma, 1:500, 24hrs), 
were added to the labeled macrophages (1x106 apoptotic cells per well) and 
incubated for 45 minutes. After incubation, non-bound cells were washed and 
cells were dissociated from the wells with lidocaine as described above, 
centrifuged (5 min, 4°C, 1100 rpm) and resuspended in fluorescence-activated 
cell sorting (FACS) buffer (0.5% BSA and 1mM EDTA in PBS) for analysis using 
FACS Canto II. Results were expressed as the percentage of double positive 
events (macrophages containing apoptotic cells). 
 
Gene expression profiling  
Gene expression profiles were determined by quantitative real-time 
polymerase chain reaction (qPCR) of 5x105 cells per well. RNA was isolated 
according to the manufacturer’s protocol (RNA isolation kit of Bioké, 
Nucleospin® RNA II, Macherey-Nagel, Germany) and stored at -80°C. RNA was 
converted into stable cDNA by reverse transcriptase PCR (RT-PCR) using 
iSCriptTM cDNA synthesis kit (BIO-RAD, CA) to a desired concentration of 25 
ng/µl. cDNA (10 ng) was used for amplification and products were probed with 
Taqman IQTM SYBR Green Super Mix (BIO-RAD, CA). Specific genes of interest 
(Supplemental Table I on page 111) were analyzed with Biorad CFX manager. 
An average housekeeping gene expression of 18S and cyclophilin was 
considered as reference value for total RNA expression. 
 
Statistics 
Groups were compared using a non-parametric Mann-Whitney U-test. Data of 
semi-quantitative assessment of plaque phenotype were compared using 
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Fisher’s exact test. Group differences were considered statistically significant 
at P < 0.05. 
 
 
Results 
 
Evaluation of systemic effects 
There was no significant difference in body weight between the irradiated and 
sham-treated mice at the start of treatment or time of sacrifice. After 12 
weeks follow-up the sham-treated mice gained weight, whereas the irradiated 
mice did not (Supplemental Table II on page 112). No mice had to be 
prematurely sacrificed due to health problems. 
 
Plaque size and phenotype after in vivo irradiation  
Lesions in the brachiocephalic artery were categorized as initial or advanced. 
Four weeks after sham-treatment, 37.5% of lesions were classed as initial, 
while by 12 weeks all lesions had progressed to the advanced stage (Figure 1A-
B). This shift from initial to advanced plaque phenotype was confirmed by a 
significant increase in relative collagen content from 20.8% at 4 weeks to 
44.2% at 12 weeks follow-up (P<0.05, data not shown). Four weeks after 14 Gy 
irradiation, 90.9% of lesions were classified as advanced (P<0.001, Figure 1A), 
suggesting that irradiation had accelerated the disease progression. On the 
other hand, irradiation significantly decreased advanced (Figure 1C) and total 
plaque area (Figure 1D) after 12 weeks follow-up, compared to unirradiated 
controls. The relative lipid core areas of irradiated and control lesions were not 
different at 4 and 12 weeks follow-up (means of 26.7% ± 4.0 and 24% ± 4.5 at 
12 weeks after 0 and 14 Gy respectively, data not shown). 
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Figure 1. Morphometric analysis of existing lesions in the brachiocephalic artery after 4 and 12 
weeks follow-up (FU). (A) Bar graphs showing percentage initial and advanced lesions of total 
lesions after 0 Gy and 14 Gy irradiation. (B) Representative photographs (10 x objective) of H&E 
staining of an advanced lesion 12 weeks after 0 and 14 Gy. (C) The mean advanced and (D) total 
(initial and advanced) plaque areas. Error bars are SEM and * indicates significant differences 
between irradiated (14 Gy) and unirradiated (0 Gy) mice (P<0.05 by Mann-Whitney test). 
 
The number of erythrocyte- or Fe-containing macrophages (indicative of 
previous hemorrhage) was higher in lesions 12 weeks after irradiation than in 
control lesions (Supplemental Table III on page 112), without an increase in 
fibrin deposits.  
In unirradiated lesions the macrophage content and number of apoptotic 
cells decreased with time (Figure 2A-B). In the irradiated lesions, however, 
macrophage content progressively increased with time and the number of 
apoptotic cells, characterized histological as macrophage foam cells confirmed 
by MAC3-immunostaining on adjacent sections (Figure 2C), remained high 
(Figure 2A-B). At 12 weeks after treatment, both the macrophage and 
apoptotic cell content of irradiated lesions were significantly higher than 
control lesions (Figure 2A-B). The increased apoptotic rate in lesions of 
irradiated mice may have contributed to the observed decrease in advanced 
plaque area (Figure 1C). There were no significant differences in lesional CD45+ 
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leukocyte content between treatment groups at 4 to 12 weeks follow-up (data 
not shown). 
 
4 weeks FU 12 weeks FU
0
50
100
150
200
*
B
* 0 Gy
14 Gy
C
as
pa
se
-3
-p
os
 c
el
ls
 /
pl
aq
ue
 a
re
a 
(m
m
2 )
4 weeks FU 12 weeks FU
0
500
1000
1500
2000
A
** *
M
AC
3-
po
s 
ce
lls
 /
pl
aq
ue
 a
re
a 
(m
m
2 )
C
 
Figure 2. (A) Mean MAC3- and (B) cleaved caspase-3-positive cells relative to total plaque area 4 
and 12 weeks after (sham-)irradiation of the brachiocephalic artery. Error bars show SEM. * 
P<0.05 by Mann-Whitney test. (C) Representative photographs (20 x objective) of MAC3 (top, 
red) and cleaved caspase-3 (bottom, brown) immunostaining of an irradiated lesion at 12 weeks 
follow-up (FU). 
 
Effects of irradiation on macrophages 
Addition of the positive control 7KC resulted in 29.7% apoptosis in M0 
macrophages (Supplemental Figure IA on page 113). After sham-treatment (0 
Gy), the unstimulated macrophages (M0) contained 4.6% apoptotic cells. 
Stimulation with LPS (M1) or IL-4 (M2) both increased apoptosis (13.7% and 
12.1% respectively). Low- and high-dose irradiation induced similar levels of 
apoptosis in the M0 macrophages (10.9% and 12.3%, respectively), whereas 
irradiation did not induce apoptosis in M1 or M2 macrophages. Taken 
together, these data indicate that in vitro macrophage skewing induced a 
similar level of apoptosis as irradiation, and that irradiation of skewed M1 or 
M2 macrophages did not further increase apoptosis.  
The influence of irradiation on phagocytic capacity was determined in 
M0 (unstimulated), M1 (LPS stimulated) and M2 (IL-4 stimulated) 
macrophages. Phagocytic capacity of M0 macrophages was not influenced by 
irradiation (Supplemental Figure IB on page 113). However, high-dose 
irradiation significantly decreased the ability of M2 macrophages to take up 
apoptotic cells (Supplemental Figure IB-C on page 113). The baseline 
phagocytic capacity of M1 macrophages was lower than M0 macrophages, and 
was stimulated by low- and high-dose irradiation. 
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Macrophage phenotype after irradiation 
Irradiated or sham-treated macrophages were stimulated in vitro with either 
LPS or IL-4 to polarize towards a pro- (M1) or an anti-inflammatory (M2) 
phenotype. Differential cytokine production is a key feature of polarized 
macrophages and many specific markers of M1 and M2 macrophages have 
been described.31 As expected, IL-4-primed macrophages showed no 
expression of the M1-specific marker iNOS (Figure 3A) and LPS-stimulated 
macrophages showed undetectable expression of the M2-specific marker 
arginase-1 (Figure 4A). This indicates that macrophages were fully polarized 
into M1 or M2 macrophages. 
Gene expression levels of iNOS, IFN-γ, TNF-α and interleukins IL-6, IL-12β 
and IL-18 were higher after polarization with LPS (Figure 3A-F). The expression 
of all of these M1-related genes was dose-dependently augmented after 
irradiation with 0.5 Gy and 5 Gy (not significant for iNOS and IFN-γ), compared 
to unirradiated control macrophages (Figure 3A-F). 
Polarization of anti-inflammatory M2 macrophages with IL-4 resulted in 
specific upregulation of arginase-1, IL-10, insulin-like growth factor 1 (IGF1), 
chitinase-like lectin (YM1) and scavenger receptors such as mannose receptor 
(MaRc) and dendritic cell immune receptor (DCIR) (Figure 4A-F). High-dose 
irradiation (5 Gy) was seen to further increase expression levels of all of these 
M2-related genes, while low doses of 0.5 Gy did not (Figure 4A-F).  
Considerably more lesions in irradiated mice were enriched in M1 
macrophages at 12 weeks follow-up (9/11 brachiocephalic artery lesions 
showed high expression of iNOS versus 4/11 for the controls) (Figure 5A). In 
keeping, M2 macrophages were less prominent in irradiated brachiocephalic 
artery lesions (8/9 showed no expression of arginase-1 versus 6/12 for the 
controls). 
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Figure 3. Gene expression levels (relative to housekeeping genes) of specific M1 markers after 
irradiation and stimulation of in vitro ApoE-/- bone-marrow derived macrophages (n=8 
wells/condition). Error bars are SEM and * indicates significant differences (P<0.05 by Mann-
Whitney test). 
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Figure 4. Gene expression levels (relative to housekeeping genes) of specific M2 markers after 
irradiation and stimulation of in vitro ApoE-/- bone-marrow derived macrophages (n=8 
wells/condition). Error bars are SEM and * indicates significant differences (P<0.05 by Mann-
Whitney test). 
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Figure 5. Percentage of brachiocephalic artery lesions showing high expression of M1 or M2 
macrophages 12 weeks after 0 or 14 Gy. (A) Percentage of lesions showing high presence of 
iNOS- or arginase-1- (arg) positive macrophages. (B) Representative photographs (20x objective) 
of iNOS-immunostaining (red, arrows) of unirradiated and irradiated lesions at 12 weeks follow-
up. 
 
 
Discussion 
 
To emulate most closely the clinical situation for elderly cancer patients with a 
cardiovascular burden receiving radiotherapy, we exposed aged ApoE-/- mice 
with pre-existing atherosclerotic lesions to local thoracic irradiation. We found 
that irradiation of existing lesions accelerated advanced atherosclerosis 
development and predisposed to an inflammatory, macrophage-rich plaque 
phenotype prone to hemorrhage. These findings are consistent with previous 
studies of plaque development after single dose or fractionated irradiation.9, 10, 
32-34 Such a shift in phenotype could render the plaques more vulnerable to 
rupture, thereby contributing to the higher risk for CVD after radiotherapy. Of 
note, an association between plaque hemorrhage and macrophage presence 
has been reported.35  
Rapid recognition, uptake and degradation of apoptotic macrophages by 
phagocytes, prevents secondary necrosis and triggers an anti-inflammatory 
response mediated by IL-10, transforming growth factor β (TGFβ) and other 
cytokines.36 The process of efferocytosis, one of the main functions of anti-
inflammatory M2 macrophages20, 36, is therefore crucial in the resolution of 
inflammation and plaque stability.37, 38 There can be many underlying reasons 
for impaired efferocytosis, including improper presentation of apoptotic 
ligands, failure to secrete recruitment signals or a defect at the level of the 
phagocyte itself. In case of mice lacking the engulfment receptor MerTK, a 
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defect in macrophage efferocytosis was observed, which resulted in an 
increase in plaque apoptotic cellular debris, inflammation and necrosis thereby 
accelerating the progression of atherosclerosis.39, 40  
In advanced atherosclerotic plaques, macrophages outnumber all other 
phagocytes.41 Therefore, a defect in apoptotic cell clearance is most likely 
attributable to macrophage loss or dysfunction. Our study showed that in vitro 
irradiation of M2 macrophages reduced its phagocytic function. This could 
contribute to the increased presence of lesional apoptotic cells, which was not 
compensated by an increased phagocytic capacity of M1 macrophages as 
observed after in vitro irradiation. The increased number of apoptotic cells 
results in a more inflammatory plaque phenotype as new leukocytes are 
recruited.  
One of the hallmarks of macrophages is their ability to maintain 
plasticity, meaning that alteration of micro-environmental signals could change 
their phenotype and subsequent function, and shifts the balance between M1 
and M2 populations. Such adaptive responses may well be decisive for the 
course of atherosclerotic plaque development and progression.42 Illustratively, 
Hirata et al. showed a positive correlation between the expression of M1-
derived pro-inflammatory cytokines and the severity of coronary artery 
disease.43 It was proposed that M2 macrophages predominate in initial lesions, 
with a switch to M1 macrophages in advanced lesions, due to changes in the 
cytokine milieu.23, 44 In vivo radiation exposure of an existing plaque could lead 
to a chronic hyperinflammatory plaque micro-environment by inducing 
oxidative damage and cell death45, thereby indirectly favoring a switch in 
macrophage polarization. Indeed, we observed more macrophages with a pro-
inflammatory M1 phenotype after plaque irradiation. In addition, increased 
gene expression of specific M1 and M2 markers after macrophage irradiation 
in vitro suggests a possible direct effect of irradiation on the inflammatory 
status of plaque macrophages. The radiation-induced imbalance in M1 and M2 
macrophages in the plaque can contribute to the accumulation of apoptotic 
cells, rendering the plaque more unstable. Future studies should investigate 
how irradiation can directly alter macrophage inflammatory status and 
function in the plaque, and can augment the polarization-effects of specific 
stimuli, in order to identify specific targets for early preventive measures in 
radiation-induced inflammatory atherosclerosis.   
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In conclusion, we highlighted the importance of investigating the effect 
of irradiation on pre-existing atherosclerotic lesions as an underlying 
pathogenic cause of increased long-term risk for CVD. We show that irradiation 
results in an increased presence of lesional macrophages, specifically pro-
inflammatory M1 macrophages, and an accumulation of apoptotic cells. 
Further understanding of the underlying effects of irradiation will help to 
identify interventional strategies to prevent or ameliorate the accelerated 
development and progression of radiation-induced atherosclerosis. 
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Supplemental data 
 
Supplemental Table I. Forward and reverse primer sequences of genes tested by qPCR. 
 Forward primer (5’-3’) Reverse primer (5’-3’) 
M1-markers
iNOS CCTGGTACGGGCATTGCT GCTCATGCGGCCTCCTTT 
TNF-α CATCTTCTCAAAATTCGAGTGACAA TGGGAGTAGACAAGGTACAACCC 
IFN-γ ATCTGGAGGAACTGGCAAAA TTCAAGACTTCAAAGAGTCTGAGGTA 
IL-12β CGCAGCAAAGCAAGATGTGT TGGAGACACCAGCAAAACGA 
IL-6 ACAAGTCGGAGGCTTAATTACACAT TTGCCATTGCACAACTCTTTTC 
IL-18 ACAACTTTGGCCGACTTCAC GGGTTCACTGGCACTTTGAT 
M2-markers
arginase-1 ATGGAAGAGACCTTCAGCTAC GCTGTCTTCCCAAGAGTTGGG 
MaRc GCAAATGGAGCCGTCTGTGC CTCGTGGATCTCCGTGACAC 
DCIR CCTGGTGATTCTATGCTGTGGT GTCAGAAGAGAGCCTTGTTCCTTC 
IL-10 TGCTCCTAGAGCTGCGGACT CTTGATTTCTGGGCCATGCT 
YM1 TGGCCCACCAGGAAAGTACA CAGTGGCTCCTTCATTCAGAAA 
IGF-1 TTCAGTTCGTGTGTGGACCGAG TCCACAATGCCTGTCTGAGGTG 
 
 
Cyclophilin CAAATGCTGGACCAAACACAA TTCACCTTCCCAAAGACCACAT 
18S GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
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Supplemental Table II. Changes in mouse weight in gram (g) between the start of treatment and 
the time of sacrifice.  
  Weight (g) at treatment Weight (g) at sacrifice Finale weight
(% of initial weight)
4 weeks FU
0 Gy 33.1 ± 0.8 33.0 ± 0.8 99.7 ± 1.1
14 Gy 33.1 ± 0.8 33.0 ± 0.7 99.8 ± 1.0
12 weeks FU
0 Gy 32.7 ± 2.1 33.9 ± 0.7 104.6 ± 2.4
14 Gy 33.9 ± 0.7 32.8 ± 0.5   99.0 ± 0.9*  
Values are group means ± SEM. * indicates significant change (P<0.05) in body weight during 
follow-up between unirradiated (0 Gy) and irradiated (14 Gy) mice. 
 
 
Supplemental Table III. Semi-quantitative assessment of aortic arch lesions containing specific 
thrombotic characteristics at 4 and 12 weeks follow-up (FU). Due to bad quality of the tissue 
during staining procedure, 1 and 2 aortic arches could not be analyzed 4 weeks after respectively 
14 Gy and 0 Gy.   
Ery-/Fe-macrophages Fibrin deposits
4 weeks FU
0 Gy  2/8 4/8
14 Gy 3/11 9/11
12 weeks FU
0 Gy  2/12 8/12
14 Gy  7/12* 6/12
 
* indicates significant difference between irradiated (14 Gy) and control (0 Gy) mice, P<0.05 by 
Fisher’s Exact test. 
 
CH4 existing plaque paper.pdf   18 18-11-2013   11:59:09
effect of irradiation on existing atherosclerotic lesions 
 
113 
0
10
20
30
40
*
M0 M1 M2 7KC
*
*
*
A
%
 A
po
pt
os
is
0
20
40
60
80
100
*
0Gy
0.5Gy
5Gy
M0 M1 M2
*
*
B
%
 P
ha
go
cy
to
si
s
C 0 Gy 5 Gy
 
Supplemental Figure I. (A) Percentage of apoptosis of ApoE-/- bone-marrow derived 
macrophages (n=5 wells/condition), with 7-ketocholesterol (7KC) as a control inducer, and (B) 
percentage uptake of apoptotic macrophages (% phagocytosis) by unstimulated (M0) and 
polarized ApoE-/- bone-marrow derived macrophages (M1, M2) after low- and high-dose 
irradiation (n=5 wells/condition). Error bars are SEM and * indicates significant differences 
(P<0.05 by Mann-Whitney test). (C) Representative FACS plots of Cell Tracker Red-labeled M2 
macrophages (red), Calcein-AM-labeled apoptotic cells (green) and double positive cells (purple) 
after 0 and 5 Gy. 
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Abstract 
 
Background: Radiotherapy of thoracic and chest wall tumors increases the 
long-term risk of cardiotoxicity, but the underlying mechanisms are unclear. 
Methods: Single doses of 2, 8 or 16 Gy were delivered to the hearts of mice 
and damage was evaluated at 20, 40 and 60 weeks, relative to age-matched 
controls. Single photon emission computed tomography (SPECT/CT) and 
ultrasound were used to measure cardiac geometry and function, which was 
related to histo-morphology and microvascular damage. 
Results: Gated SPECT/CT and ultrasound demonstrated decreases in end 
diastolic and systolic volumes, while the ejection fraction was increased at 20 
and 40 weeks after 2, 8 and 16 Gy. Cardiac blood volume was decreased at 20 
and 60 weeks after irradiation. Histological examination revealed inflammatory 
changes at 20 and 40 weeks after 8 and 16 Gy. Microvascular density in the left 
ventricle was decreased at 40 and 60 weeks after 8 and 16 Gy, with functional 
damage to remaining microvasculature manifest as decreased alkaline 
phosphatase (2, 8 and 16 Gy), increased von Willebrand Factor and albumin 
leakage from vessels (8 and 16 Gy), and amyloidosis (16 Gy). 16 Gy lead to 
sudden death between 30 and 40 weeks in 38% of mice. 
Conclusions: Irradiation with 2 and 8 Gy induced modest changes in murine 
cardiac function within 20 weeks but this did not deteriorate further, despite 
progressive structural and microvascular damage. This indicates that heart 
function can compensate for significant structural damage, although higher 
doses, eventually lead to sudden death. 
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Introduction 
 
Radiation-induced heart disease (RIHD) can be a severe late side effect in 
cancer patients irradiated to their thorax.1 This has relevance for long-term 
survivors of cancer.2 Cancers with a good long-term prognosis that are treated 
with thoracic irradiation include childhood cancers, breast cancer and 
Hodgkin’s lymphoma. RIHD was first described in the 1960s, after mantle field 
radiotherapy for Hodgkin’s lymphoma.3 Since then treatment options and 
techniques, especially the development of 3D conformal radiation techniques, 
have improved and the relative 5-year survival rates for childhood cancer, 
including Hodgkin’s lymphoma, have increased from 30% in 1960 to 79% in 
2010.4 However, longer survival in Hodgkin’s lymphoma patients is associated 
with increased risks (relative to age-matched unirradiated populations) of late 
cardiac morbidity and mortality; from 2% after 5 years to 23% after 20 years.5 
Epidemiological studies also demonstrate increased risks for cardiac mortality 
and morbidity for breast cancer patients that received radiotherapy.2, 6 
Although the relative risk is lower than for Hodgkin’s lymphoma patients, the 
large number of women irradiated for breast cancer makes this a significant 
health problem. For both patient groups, the risk of RIHD becomes significant 
10 years after treatment and increases with time.6, 7 
RIHD includes a wide spectrum of cardiac pathologies, such as 
pericarditis, cardiomyopathy, valvular disorders, myocardial fibrosis, coronary 
artery disease, conduction abnormalities, and sudden death.8-10 In the early 
stages, before the onset of functional impairment, some experimental studies 
have shown evidence of inflammation in the myocardium, endothelial cell 
damage and decreased myocardial capillary density.11-13 Regional cardiac 
perfusion defects have also been identified in non-symptomatic breast cancer 
patients from 6 months after radiotherapy.14, 15 This suggests that early 
microvascular damage may precede severe cardiac functional impairment. 
The risk of RIHD is now well recognized but the underlying mechanisms 
of its initiation and progression, and the roles played by microvascular damage, 
fibrosis and atherosclerosis remain unclear. To shed light on the dose 
dependence of the severity and rate of progression of cardiovascular damage, 
mouse hearts were irradiated with doses of 2, 8 or 16 Gy and structural and 
functional changes were monitored after 20, 40 and 60 weeks. This is the first 
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study that characterizes in detail both the functional and structural cardiac 
damages after local heart irradiation in mice. 
 
 
Material and methods 
 
Mice and irradiation procedure 
Male C57BL/6J mice aged 8-12 weeks (from Charles River Laboratories, France) 
were randomly allocated to different treatment groups and housed in a 
temperature-controlled room with 12 h light-dark cycle. Standard mouse chow 
and water were provided ad libitum. During irradiation or sham-treatment (0 
Gy) unanaesthetized mice were held in a prone position, in restraining jigs with 
the thorax fixed using adjustable hinges. Single doses of 2, 8 or 16 Gy were 
given to the heart using 250 kV X-rays, operating at 12 mA and filtered with 0.6 
mm of copper. The dose rate was 0.94 Gy/min. The field size (10.6 x 15.0 mm) 
and the position was determined in pilot studies using soft X-rays (25 kV, 85 
mA) to visualize the hearts of mice of the same sex and weight. In order to 
ensure that the whole heart was irradiated in all mice, up to 30% of the lung 
volume was included in the field. The rest of the body was shielded with a 3 
mm thick lead plate. 
Separate cohorts of animals were irradiated for functional imaging and 
collecting of hearts for analyses at 20, 40 and 60 weeks after irradiation. Each 
dose and time point typically comprised 10-15 mice (n = 165 in total). Age-
matched controls (sham-irradiated with 0 Gy) were always included and these 
provide the appropriate comparison for irradiated groups at that time point. 
Experiments were in agreement with the Dutch law on animal 
experiments and welfare, and in line with the international Guide for the Care 
and Use of Laboratory Animals (Eighth edition). 
 
SPECT/CT 
Single photon emission computed tomography (SPECT) acquisitions were made 
with the dedicated small-animal NanoSPECT/CT (Bioscan Europe, Ltd., Paris, 
France). Animals were anesthetized with Hypnorm (Fentanyl 0.26 
mg/kg/Fluanisone 8.33 mg/kg, VetaPharma, Ltd., Leeds, UK) and Dormicum 
(Midazolam, 4.17 mg/kg, Roche, Woerden, The Netherlands) via 
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intraperitoneal (i.p.) injection (1:2:1 Hypnorm:H2O:Dormicum; 120 µl/mouse). 
They were then placed on the animal bed in the prone position and scanned in 
the tail-first direction. Human Serum Albumin (HSA) (Vasculosis, IBA Molecular, 
Gif-sur-Yvette, France) was labeled with 1-1.5 ml 99mTc-pertechnetate. The 
radiotracer (150 µl) was injected intravenously (i.v.), at a total activity of about 
50 MBq per mouse. X-ray topogram and SPECT acquisition were initiated 
directly after tracer administration. A total body scan was used to calculate the 
ratio between the total radioactivity (MBq) in the mouse and in the heart, and 
hence to calculate the blood volume of the heart chambers. 
 
Gated SPECT/CT 
Three-lead electrodes (3M red Dot 2282E, 3M, St. Paul, USA) were attached to 
both hind paws and right front paw of the mouse and connected to the 
integrated electrocardiography (ECG) monitor to measure heart rate (HR). 
ECG-gated data were recorded in 8 time-bins per cardiac cycle. The tracer 
tetrofosmin (Myoview, GE-healthcare, Hoevelaken, The Netherlands) was 
labeled with 99mTc-pertechnetate according to the manufacturer’s protocol. 
The radiotracer (150 µl) was injected i.v. with a total activity of about 65 MBq 
per mouse. Acquisitions were started 1 h after injection of the tracer. Once a 
stable HR was established, a short X-ray topogram was made to set the field of 
view (FOV) and to focus on the thorax to reduce scan time. After the FOV was 
set, gated SPECT acquisition was started using a quadruple-head gamma 
camera high precision gantry, equipped with 4 pyramid collimators and 9 
pinhole apertures (diameter 1.2 mm). The axial FOV was 16 mm. A 20% 
window centered on the 140 keV photoelectric peak of 99mTc was used to 
acquire 20 projections with uniform angular sampling over a 360° radius into a 
128 x 128 matrix. ECG-gated data were recorded in 8 time-bins per cardiac 
cycle, with an accepted frame time of 180 s. HiSPECT NG software 
(InVivoScope, Bioscan) was used to perform iterative reconstruction into 3D 
datasets. Quantitative analysis of the reconstructed datasets was performed 
on a clinical e.soft (syngo-based) workstation (Siemens Medical Solutions, 
Siemens AG, Erlangen, Germany), using algorithms to automatically 
reconstruct a count based 3D model of the dimensions of the left ventricular 
(LV) end diastolic and systolic volumes (EDV, ESV), as well as the thickness of 
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the LV wall in diastole and systole. The ejection fraction (EF) was calculated 
based on the difference between EDV and ESV divided by EDV.  
 
2D-Ultrasound 
Mice were lightly sedated with 2% isoflurane (Forane, Abbott, Hoofddorp, The 
Netherlands). Echocardiography images were acquired using a Vevo 770 
system (VisualSonics, Toronto, Canada). Images were obtained using a 30 MHz 
transducer with a focal depth range of 13 mm. Acquisitions were made in B-
mode in the long-axis view as well as in the short view, at the papillary muscle 
level, at a frame rate of about 90 MHz. Measurements of LV dimensions were 
obtained by visual determination in three respective cardiac cycles in long-axis 
mode. Calculations were based on the measurement of LV length and LV 
surface area during diastole and systole and the EF was calculated as described 
above. 
 
Tissue preparation 
On termination of the experiment, the heart was perfused via the aortic arch 
(retro-grade), under lethal sodium pentobarbital anesthesia (18 mg i.p. per 
mouse), with PBS (frozen sections) or PBS followed by 1% paraformaldehyde 
(paraffin sections). The heart was then quickly excised before freezing on dry 
ice or immersion in 1% paraformaldehyde. 
 
Histology 
Cross-sections were cut at the level of the mid-horizontal plane of the heart 
from fixed paraffin-embedded tissues (3 µm) or frozen tissues (7 µm). 
 
Paraffin sections 
Transverse sections were stained with hematoxylin and eosin (H&E) to 
measure the epicardial and myocardial thickness. To determine the extent of 
inflammation, sections were immuno-labeled with anti-CD45 antibody (1:5000, 
Becton&Dickinson, Franklin lakes, USA). Perls’ staining was performed to 
investigate the presence of iron-containing macrophages, indicative of 
previous hemorrhage. Based on a Sirius red staining, interstitial collagen was 
determined in the subendocardium and myocardium of the LV. Double staining 
for laminin (1:600) and collagen IV (1:2000, both kindly provided by Dr. J 
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Cleutjens, Maastricht University, The Netherlands) was used to measure the 
cross-sectional area of cardiomyocytes. To investigate vascular leakage, 
paraffin sections were stained for albumin (1:2500, Abcam, Cambridge, USA) 
and myocardial deposition was determined. A Congo red staining was used to 
detect amyloid deposits in the myocardium. Within one time group all sections 
were processed identically, at the same time with precisely the same 
incubation times for the primary and secondary antibody and 
diaminobenzidine (DAB) solution (Sigma, Zwijndrecht, The Netherlands). 
Therefore, all differences between the treatments are ultimately due to DAB 
identification of the relevant protein. 
Photographs of the LV wall (excluding the septum) were taken using a 5x 
objective (Leica DFC320) and 12 measurements per heart were performed to 
measure the epicardial and myocardial thickness. The number of CD45-positive 
cells per section was counted separately in the epicard and myocard to 
determine the extent of inflammation. Perls’ stained sections were examined 
for evidence of iron-containing macrophages and this was recorded as positive 
or negative for each section. Interstitial collagen was quantified in five 
randomly selected areas of the subendocardium and myocardium of the LV 
(40x objective) and results are expressed as percentage tissue positive for 
Sirius red relative to myocardial area. Photographs of laminin and collagen IV 
stained sections were taken using a 20x objective and approximately 200 
subendocardial myocytes were measured per heart. Cardiac amyloidosis was 
diagnosed by the apple-green birefringence of extracellular deposited amyloid 
fibrils, when stained with Congo red dye and viewed under polarized light. 
Morphometric parameters were analyzed using a computerized morphometry 
system (Leica Qwin V3, Leica, Rijswijk, The Netherlands). 
 
Frozen sections 
An anti-CD31 antibody (1:50, Becton&Dickinson) was used to visualize cardiac 
vasculature of the central part of the heart. To quantify the percentage of 
perfused microvessels, FITC-lectin (Fluorescein labeled Lycopersicon 
Esculentum (Tomato) Lectin (LEL, TL), Vector, Burlingame, USA) (100 µl) was 
injected i.v. 5 min before a lethal injection of sodium pentobarbital. Frozen 
sections were then stained for CD31 (1:50, Becton&Dickinson) using a 
fluorescent secondary antibody labeled with Alexa Fluor 594 (Invitrogen, 
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Breda, The Netherlands). To visualize tissue hypoxia, mice were injected i.v. 
with 10 nM of the hypoxic cell marker 2-nitroimidazole agent EF5 (a kind gift 
from Dr. C Koch, Department of Radiation Oncology, University of 
Pennsylvania, USA) 2 h prior to humane killing, and hearts were stained 
according to published protocols (www.hypoxia-imaging.org). To check the 
immunohistochemical procedure, tumor tissue was included as positive 
hypoxic control; this showed significant areas of EF5 positivity. 
To determine functional changes in the microvasculature a histochemical 
staining with Naphtol AS-MX/DMF and fast Blue BB salt was performed to 
detect endothelial cell alkaline phosphatase. Sections were also reacted with 
antibodies against von Willebrand Factor (vWF) (1:4000, Abcam) or 
thrombomodulin (TM) (1:200, American Diagnostica, Stamford, USA), as 
markers of thrombotic changes, and vascular cell adhesion molecule 1 (VCAM-
1) (1:200, Becton&Dickinson), as a marker for vascular inflammation. Within 
one time group all sections were processed identically, at the same time with 
precisely the same incubation times for the primary and secondary antibody 
and DAB solution. 
For quantification of microvessels, five random fields (40x objective) 
from transverse sections of the subendocardium were photographed with a 
CCD 2-Color Microscope system, including a Zeiss AxioCam color camera 
(Axiocam HRc, Zeiss, Göttingen, Germany) and a computerized morphometry 
system (Leica Qwin V3) was used to quantify the microvascular density (MVD). 
Vessels beneath a size of 1.5 or above 200 µm2 were automatically excluded 
from the measurements. Photographs of CD31/FITC-lectin were taken with a 
confocal microscope (Leica) and analyzed using Image J computer analysis 
program, to determine the percentage of microvessels that were perfused. 
Photographs of whole sections stained for ALP, vWF and TM were taken with 
an Aperio scanner (Scanscope-XT, Aperio technologies, Vista, USA) using 40x 
objective. Analyses of the percentage myocardium, excluding endocardium, 
positive for each marker were done with a computerized morphometry system 
(Leica Qwin V3). VCAM-1-stained sections were semi-quantitatively analyzed 
(without knowledge of treatment group) according to the criteria: no, mild or 
strong expression. 
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Statistics 
Data are expressed as mean ± SEM. Irradiated and control groups were 
compared using non-parametric Mann-Whitney U-tests or Fisher’s exact test 
(Table 2, Supplemental Table 1 and Figure 5). Group differences were 
considered statistically significant at p < 0.05. 
 
 
Results 
 
Mouse survival and weight 
There were very few unscheduled deaths after 2 and 8 Gy cardiac irradiation, 
although heart/body weight ratios of irradiated mice were 12-13% lower than 
in age-matched controls at 40 weeks and body weights were reduced by 6-13% 
at 60 weeks (Table 1). After 16 Gy, 38% of mice died or had to be humanely 
killed between 30 and 40 weeks. Because of these unscheduled deaths, all 
remaining animals in the 16 Gy group were killed at 40 weeks. 
 
Table 1. Body and organ weights of mice at sacrifice.
 
* Indicates significant differences between irradiated and age-matched control groups (p < 0.05; 
Mann-Whitney U-test). ND = not determined. 
 
Non-invasive cardiac imaging 
SPECT/CT and ultrasound were used to examine whether irradiation influenced 
cardiac function; these imaging experiments were performed in separate 
groups of mice. Static SPECT/CT images (99mTc-HSA) indicated a significant 
reduction (18-25%) in total cardiac blood volume at 20 weeks after 2, 8 and 16 
Gy compared to age-matched controls. There was no further reduction in 
mean cardiac blood volume for remaining mice tested at 40 weeks and no 
significant differences were observed between irradiated and control groups at 
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this time. By 60 weeks, cardiac blood volumes were again significantly lower 
after 2 and 8 Gy than in control animals (21-36%) (Figure 1A). 
Gated SPECT/CT images (99mTc-Myoview) showed radiation-induced 
decreases in EDV (10-25%) and ESV (16-39%) and increases in EF (6-20%) at 20 
weeks after 2, 8 and 16 Gy (Figure 1B). At 40 weeks, EDV and ESV were still 
similarly decreased, concomitant with a significant increase in EF (20%) after 8 
Gy (Figure 1B). 99mTc-Myoview gated SPECT/CT scans also showed increases in 
both anterior and posterior wall thickening (systole versus diastole) at 20 
weeks after 16 Gy and in the posterior wall at 40 weeks after 8 Gy (Figure 2). 
Ultrasound measurements showed similar decreases in EDV (20%) and 
ESV (33%) to those measured by gated SPECT, and an increase in EF (28%) at 
20 weeks after 16 Gy. However, at 40 weeks irradiated and control groups 
were not significantly different when measured by ultrasound (Supplemental 
Figure I on page 138).  
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Figure 1. Cardiac blood volume (A) or EDV, ESV and EF (B) at 20 weeks (●), 40 weeks (□) or 60 
weeks (▲) after irradiation or sham-treatment. Values represent mean ± SEM (9-18 mice in 
each irradiated group), *p < 0.05 compared to age-matched controls. 
 
 
Figure 2. Mean LV wall thickening at anterior (solid bars) and posterior (hatched bars) positions 
20 and 40 weeks after irradiation (mean ± SEM). Values represent mean ± SEM (9-18 mice in 
each irradiated group), *p < 0.05 compared to age-matched controls. 
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Inflammatory and fibrotic changes in irradiated hearts 
The epicardium and myocardium of irradiated and age-matched control mice 
were examined for evidence of inflammatory and fibrotic changes. At 20 
weeks, doses of 8 and 16 Gy resulted in increased epicardial thickness (Figure 
3A), associated with the presence of CD45-positive inflammatory cells (Figure 
3B) and iron-containing macrophages (Table 2), indicative of previous 
hemorrhage. At 40 weeks, epicardial thickening and increased numbers of 
CD45-positive inflammatory cells (per section) were found after 16 Gy (Figure 
3A and B). Doses of 2 and 8 Gy also resulted in epicardial thickening relative to 
age-matched controls, but not with respect to other control groups. Iron-
containing macrophages were still present at 40 weeks in the epicardium of all 
hearts after 8 and 16 Gy (Table 2). At 60 weeks, there was no evidence of 
increased epicardial thickening or inflammation after 2 or 8 Gy (Figure 3A and 
B) and the incidence of hearts with iron-containing macrophages was reduced 
compared to 40 weeks. 
The number of CD45-positive inflammatory cells (per section) in the 
myocardium increased significantly at 40 weeks after 16 Gy, but not at earlier 
times or lower doses (Figure 3C). Iron-containing macrophages were found in 
the myocardium of all these hearts, as well as at 20 weeks after 8 and 16 Gy 
(Table 2). The amount of interstitial collagen in the LV myocardium was 
significantly increased at 40 weeks after 8 and 16 Gy and 60 weeks after 2 and 
8 Gy, although this was never more than 2-5% of the tissue area (Figure 3D). 
Analysis of the mean size of individual myocytes showed transient increased 
size (indicative of swelling) at 20 weeks after 16 Gy, followed by reduced 
myocyte cell size in irradiated hearts at later times after all doses 
(Supplemental Figure II on page 139). 
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Figure 3. Inflammatory and fibrotic changes at 20 weeks (●), 40 weeks (□) or 60 weeks (▲) after 
irradiation or sham-treatment. Values represent mean ± SEM (with at least 4-7 mice in each 
irradiated group), *p < 0.05 compared to age-matched controls. (A) Epicardial thickness and H&E 
photographs illustrate extensive fibrous thickening after irradiation. (B) Quantification and 
photograph (16 Gy, 20 weeks) of CD45+ cells per section in the epicardium and (C) myocardium. 
(D) Percentage interstitial collagen content of irradiated heart sections, relative to age-matched 
controls. 
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Table 2. Perl’s staining at 20-60 weeks after irradiation demonstrates increased incidence of 
iron-containing macrophages in the epicardium and myocardium. 
* Indicates significant differences between irradiated and age-matched control groups   
(p < 0.05; Mann-Whitney U-test), ND = not determined. 
 
Microvascular density (MVD) and vascular function in irradiated hearts 
Doses of 2 and 8 Gy led to a transient increase (16-24%) in MVD at 20 weeks, 
relative to age-matched controls. At 40 weeks MVD was comparable between 
controls and 2 and 8 Gy, but there was a significant decrease after 16 Gy (26%). 
By 60 weeks MVD was significantly decreased after 8 Gy (23%), indicative of 
progressive loss of microvessels in a dose and time dependent way (Figure 4A). 
However, the loss of MVD did not lead to marked impairment of perfusion or 
tissue hypoxia. In 40-week age-matched controls, 87% of microvessels were 
functionally perfused (positive for CD31 and FITC-lectin), compared with 84% 
at 40 weeks after 16 Gy. There was a total absence of severe hypoxia in both 
control and irradiated hearts, since all sections were completely negative for 
EF5 staining, whereas positive control samples of mouse tumor sections 
(processed together with the heart sections) demonstrated clear areas of EF5 
staining. 
To further investigate functional changes in the microvasculature, the 
amount of endothelial cell ALP was quantified (Figure 4B). At 20 weeks after 
irradiation with 8 and 16 Gy, there was a significant decrease (30-44%) in 
percentage tissue stained for ALP, relative to age-matched controls. By 40 
weeks, the 2 Gy dose group also had significantly less ALP expression, 
CH5 BL6 heart paper.pdf   14 18-11-2013   12:40:37
cardiac function and structure after irradiation 
 
133 
indicative of further progression of endothelial damage in small blood vessel. 
At 60 weeks the ALP expression in irradiated groups (2 and 8 Gy) was 50% of 
the mean control value, but these differences were borderline significant 
compare to age-matched controls (p = 0.05).  
Analysis of the pro-thrombotic endothelial marker vWF showed 
significant increases at 20 weeks after 8 and 16 Gy and 40 weeks after 16 Gy 
(Figure 4C). By 60 weeks no differences between groups were observed. Semi-
quantitative analysis of VCAM-1 expression in endothelial cells showed 
significant increases at 20 weeks after 2 and 16 Gy and 40 weeks after 8 Gy 
(Supplemental Table I on page 138). There were no significant changes in the 
amount of thrombomodulin expression at 20 to 60 weeks after irradiation, 
relative to age-matched controls (data not shown). 
 
 
Figure 4. Microvascular alterations at 20 weeks (●), 40 weeks (□) or 60 weeks (▲) after 
irradiation or sham-treatment (Mean ± SEM with at least 4-7 mice in almost all groups). *p < 
0.05 compared to age-matched controls. (A) MVD per unit area expressed as percentage of age-
matched control values. (B) ALP positive tissue areas as % of age-matched unirradiated controls. 
(C) vWF positive tissue areas as % of age-matched controls. 
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To investigate whether these structural and functional changes in the 
microvasculature were associated with vascular leakage, albumin deposition in 
the myocardium was examined. At 40 weeks, half of the hearts irradiated with 
2 Gy and almost all hearts irradiated with 8 or 16 Gy showed albumin in the 
myocardium (Figure 5). Only one age-matched control heart showed mild 
albumin deposition in the myocardium. After 16 Gy, myocardial albumin was 
extensive in 5 of 11 hearts and all these animals also had diffuse amyloidosis, 
which was confirmed with a Congo red staining (Figure 5B and C). Of the 
remaining 6 animals from this group, 5 hearts showed mild albumin deposition 
and all these also had focal amyloidosis (Figure 5A). 
 
 
Figure 5. Evidence for blood vessel leakage after irradiation. (A) H&E staining showing amyloid 
deposition (arrows). (B) Amyloidosis was confirmed by Congo-Red staining and (C) yellow-green 
birefringence by polarizing microscopy at 40 weeks after 16 Gy. Incidence of hearts showing 
increased expression of plasma protein albumin outside blood vessels. *p < 0.05 compared to 
age-matched controls. # Hearts showing strong albumin protein deposition also had diffuse 
amyloidosis. ND = not determined. 
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Discussion 
 
This study demonstrated that irradiation affected cardiac structure and 
microvascular function in a dose- and time-dependent manner, with 
substantial damage after intermediate and high dose irradiation (8 and 16 Gy) 
and minor alterations after lower doses (2 Gy). Moreover, high doses induced 
changes at earlier time points and these effects progressed in time. 
The transient increase in MVD at 20 weeks after 2 and 8 Gy was 
presumably due to stimulated proliferation in response to damage, whereas 
proliferation after 16 Gy was counterbalanced by endothelial cell loss. The 
decreased MVD at 40-60 weeks after high doses confirms earlier studies in 
irradiated rat hearts.16 However, this did not lead to a marked loss of vascular 
perfusion and no severe hypoxia was detected. 
Despite the lack of hypoxia, progressive microvasculature damage was 
indicated by the vascular leakage, decreased amount of endothelial cell ALP 
and increased vWF in irradiated hearts. ALP is abundantly present in healthy 
cardiac microvasculature whereas loss of ALP is indicative of endothelial cell 
damage.16 ALP expression was significantly reduced at 20 weeks after doses of 
8 or 16 Gy and after 2, 8 or 16 Gy at 40 and 60 weeks. Increased deposition of 
vWF in irradiated rat hearts has been previously described as an indicator of 
thrombotic endothelial cell damage.17 In our studies, increases in vWF 
deposition were limited to hearts that received 8 or 16 Gy, with the largest 
increase at later times after the highest dose. Myocardial deposition of 
albumin (indicative of vascular leakage) was seen in almost all hearts examined 
at 40 weeks after 8 and 16 Gy, and this was strongly correlated with 
amyloidosis. All of the hearts exhibiting strong extracellular albumin deposition 
at 40 weeks after 16 Gy also had diffuse amyloidosis and those with mild 
albumin deposition had focal amyloidosis. Amyloidosis is caused by 
extracellular deposition of insoluble, abnormal fibrils, derived from 
aggregation of misfolded proteins. A prominent clinical feature of cardiac 
amyloidosis is heart failure.18 The presence of amyloidosis may therefore have 
contributed to the sudden death seen in 38% of mice between 30 and 40 
weeks after 16 Gy. 
Changes in cardiac function after irradiation were modest and non 
progressive, despite the progressive deterioration of microvascular structure 
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and function. This suggests that in mice the myocardium can compensate for 
structural degeneration to some extent. However, 16 Gy lead to sudden death 
at 30-40 weeks in a significant proportion of mice. It was only possible to 
autopsy a few of these mice so the exact cause of death remained unclear. The 
cardiac function at 20 weeks, for those mice that subsequently died, was 
comparable to mice which completed 40 weeks follow up after 16 Gy 
(Supplemental Figure III on page 139). There was also no indication of 
arrhythmia at 20 weeks in these mice. However, neither cardiac function nor 
histological analyses were done between 20 weeks and sudden death of these 
mice; therefore it remains possible that they subsequently developed 
conduction defects leading to arrhythmia and sudden cardiac death.19 We 
suspect that amyloidosis may be involved in the sudden deaths seen after 16 
Gy, since 4 of 7 mice that died immediately after their 40 week imaging 
procedure did have diffuse amyloidosis. These sudden deaths imply that 
compensatory mechanisms seen after low to intermediate doses (2 and 8 Gy), 
especially at earlier times, can not maintain cardiac function after high dose 
irradiation. 
There is some evidence from in vitro studies that cardiomyocytes can 
react to stress signals directly by initiating an inflammatory response.20 This 
response leads to the presence of macrophages, which can interact with 
cardiac myocytes and lead to decreased myocyte contractility, both in vitro 
and in vivo, resulting in a decrease in systolic and diastolic filling.21 We also 
observed this effect in our mouse model after irradiation. Decreased myocyte 
cell area and increased collagen deposition after irradiation may also have 
contributed to impaired myocardial contractility.22 Sarcoplasmic reticulum Ca2+ 
ATPase (SERCA) has been described as a compensatory mechanism in failing 
human myocardium, by maintaining relaxation and contraction of 
cardiomyocytes. However, this remains speculative and further investigations 
are necessary to understand compensatory mechanisms in the damaged 
heart.20 
In conclusion, these studies demonstrated decreases in both systolic and 
diastolic volumes and increased ejection fractions at 20-40 weeks after 
irradiation. The presence of inflammatory cells and iron-containing 
macrophages within the thickened epicardium suggests this could be due to 
constrictive pericarditis. This constrictive remodeling of the heart could also 
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lead to loss of normal blood filling and emptying during diastole and systole. 
However, the overall cardiac function remained within normal physiological 
limits, which suggests that compensatory mechanisms can initially maintain 
cardiac function after irradiation, despite deteriorating underlying morphology 
and vascular function. Ultimately, however, this compensatory mechanism 
fails, leading to sudden death. 
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Supplemental data 
 
Supplemental Table I. Incidence of hearts with VCAM-1 expression in the myocadium.  
 
* indicates significant differences between irradiated and age-matched control groups (p <0.05; 
Mann-Whitney U-test). ND = not determined. 
 
 
Supplemental Figure I. Ultrasound measurements (mean ± SEM) of EDV, ESV and EF for control 
and 16 Gy mice at 20 and 40 weeks. Numbers of mice indicated in the bars. *p < 0.05 compared 
to age-matched controls. 
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Supplemental Figure II. Myocardial alterations 20-60 weeks after irradiation (mean ± SEM with 
numbers of mice per group indicated). *p < 0.05 compared to age-matched controls. (A) LV wall 
thickness. (B) Mean myocardial cell area. 
 
 
 
Supplemental Figure III. Non-invasive imaging for measurement of cardiac function in 
unirradiated and age-matched irradiated groups at 20 weeks after treatment, including 16 Gy 
treated mice that suddenly died between 30-40 weeks. (A) SPECT/CT, using 99mTc-HSA 
measurements of mean cardiac blood volume (% total) ± SEM. (B) Gated SPECT/CT 
measurements with 99mTc-Myoview. Values represent mean ± SEM, numbers of mice indicated 
in the bars. *p< 0.05 compared to age-matched controls, (all) representing total number of mice 
of group 0 Gy and 16 Gy, (completed) representing number of mice that completed 40 weeks 
follow up, (not completed) representing number of mice that died before 40 weeks. 
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Abstract 
 
Background and purpose: Radiotherapy of thoracic and chest-wall tumors 
increases the long-term risk of radiation-induced heart disease, such as a 
myocardial infarction. Cancer patients commonly have additional risk factors 
for cardiovascular disease, such as hypercholesterolemia. The goal of this study 
is to define the interaction of irradiation with such cardiovascular risk factors in 
radiation-induced damage to the heart and coronary arteries. 
Material and methods: Hypercholesterolemic and atherosclerosis-prone   
ApoE-/- mice received local heart irradiation with a single dose of 0, 2, 8 or 16 
Gy. Histopathological changes, microvascular damage and functional 
alterations were assessed after 20 and 40 weeks. 
Results: Inflammatory cells were significantly increased in the left ventricular 
myocardium at 20 and 40 weeks after 8 and 16 Gy. Microvascular density 
decreased at both follow-up time-points after 8 and 16 Gy. Remaining vessels 
had decreased alkaline phosphatase activity (2-16 Gy) and increased von 
Willebrand Factor expression (16 Gy), indicative of endothelial cell damage. 
The endocardium was extensively damaged after 16 Gy, with foam cell 
accumulations at 20 weeks, and fibrosis and protein leakage at 40 weeks. 
Despite an accelerated coronary atherosclerotic lesion development at 20 
weeks after 16 Gy, gated SPECT and ultrasound measurements showed only 
minor changes in functional cardiac parameters at 20 weeks. 
Conclusions: The combination of hypercholesterolemia and local cardiac 
irradiation induced an inflammatory response, microvascular and endocardial 
damage, and accelerated the development of coronary atherosclerosis. 
Despite these pronounced effects, cardiac function of ApoE-/- mice was 
maintained. 
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Introduction 
 
Improvements in cancer therapy and earlier detection and diagnosis have lead 
to increasing numbers of cancer survivors. Unfortunately, this also means that 
more patients are at risk of developing treatment-related late tissue damage 
and mortality. Thoracic radiotherapy, given to Hodgkin’s lymphoma and breast 
cancer patients, is widely recognized as an independent long-term risk factor 
for developing heart diseases.1-4 The pathological consequences of radiation-
induced heart disease following therapeutic irradiation are pericarditis, 
myocardial fibrosis, coronary artery disease, valvular disorders and conduction 
abnormalities.5-7 
In a previous study8, the dose and time dependence of structural and 
functional cardiovascular damage after thoracic irradiation were investigated 
in C57BL/6j mice. Inflammation, especially in the epicardium, and micro-
vascular endothelial damage leading to vascular leakage progressed with dose 
(2-16 Gy) and time (20-60 weeks follow-up). However, only modest and non-
progressive changes in cardiac function, detected by gated SPECT, were 
observed in mice surviving cardiac irradiation of 2 and 8 Gy. These data 
indicated that the heart was able to compensate for the structural damage. 
Nevertheless, 16 Gy irradiation led to excessive protein leakage in the 
myocardium and 38% of mice failed to maintain cardiac function at 40 weeks 
follow-up.  
C57BL/6j mice have extremely low plasma levels of cholesterol, 
especially low-density lipoproteins, and they are resistant to the development 
of atherosclerosis.9 Cardiac damage identified after irradiation in such models 
therefore does not include any component of macrovascular damage as a 
result of accelerated atherosclerosis. 
The effect of irradiation on the development of atherosclerosis has been 
studied in apolipoproteinE-/- (ApoE-/-) mice, which have elevated cholesterol 
levels and do develop age-related atherosclerosis. After local carotid artery 
irradiation with a single dose of 14 Gy or fractionated doses (20 x 2 Gy), an 
accelerated development of inflammatory atherosclerotic plaques was 
observed.9, 10 Hu et al.11 described the distribution of atherosclerotic lesions in 
the coronary arteries of 60 week old ApoE-/- mice and found relatively few 
lesions (approximately 4 lesions per heart) after the second level of branching 
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of the coronary arteries, that developed independently from valvular lesions. 
However, the effect of irradiation on this coronary lesion development is not 
known. 
The aim of this study is to investigate the effect of local thoracic 
irradiation of hypercholesterolemic ApoE-/- mice on cardiac structure and 
function, and to compare this with previous results of irradiated wild-type 
C57BL/6j mice in the absence of atherosclerosis8. This should allow us to 
evaluate the contribution of macrovascular (atherosclerosis) and microvascular 
changes in the pathology of radiation-induced cardiac damage. 
 
 
Material and methods 
 
Mice and irradiation procedure 
Male ApoE-/- mice (C57BL/6j background), aged 10-12 weeks (bred at The 
Netherlands Cancer Institute), were housed in a temperature-controlled room 
with 12 h light-dark cycle and received standardized mouse chow (3.7% fat, 
RMI (E) SQC, SDS, London, UK) and water ad libitum. 
Irradiation procedure was performed as described previously8. Mice 
were randomly allocated to receive single doses of 2, 8 or 16 Gy locally to the 
heart (irradiation field of 10.6 x 15.0 mm, including 30% lung volume) at a dose 
rate of 0.94 Gy/min using 250 kV X-rays, operating at 12 mA and filtered with 
0.6 mm of copper, or sham-treatment (0 Gy) as a control. Mice were sacrificed 
20 or 40 weeks after irradiation, and hearts and lungs were collected. 
Experiments were in agreement with the Dutch law on animal 
experiments and welfare, and in line with the international Guide for the Care 
and Use of Laboratory Animals (eighth edition). 
 
Tissue preparation and histology 
The heart was perfused via the aortic arch (retro-grade) with phosphate-
buffered saline (PBS) (frozen sections) or PBS followed by 1% 
paraformaldehyde (paraffin sections), under lethal sodium pentobarbital 
anesthesia (18 mg i.p. per mouse). Immediately after perfusion, the heart was 
excised, divided into three parts (base, mid and apex) and frozen on dry ice or 
immersed in 1% paraformaldehyde. Cross-sections were cut at the level of the 
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mid-horizontal plane of the heart from fixed paraffin-embedded tissues (3 µm) 
or frozen tissues (7 µm). 
 
Paraffin sections 
Sections were immuno-labeled with anti-CD45 antibody (1:5000, 
Becton&Dickinson, Franklin lakes, USA) or anti-CD3 antibody (1:200, Dako, 
Carpinteria, USA) to determine the extent of leukocyte and T-cell infiltration, 
respectively. The absolute number of CD45-positive leukocytes per section was 
counted in the left ventricular (LV) myocardium. The number of CD3-positive T 
cells was counted per LV myocardial area (8 random 40x photographs). 
Interstitial collagen was quantified in 5 randomly selected areas of the LV 
myocardium based on a Sirius Red staining and results were expressed as 
percentage tissue positive for Sirius Red, excluding perivascular collagen, 
relative to myocardial area. To determine if there was a pre-mortem bleeding, 
a Perls’ staining was performed to detect iron. Macrophages store iron by 
metabolizing hemoglobin from engulfed red blood cells. An albumin staining 
(1:2500, Abcam, Cambridge, USA) was performed to determine myocardial 
deposition as a measure of vascular leakage and a Congo Red staining was 
used as previously described8 to detect amyloid deposits in the myocardium.  
To investigate coronary atherosclerotic plaque development, transverse 
sections of the complete mid-part of the heart were cut, stained every 57 µm 
with hematoxylin and eosin (H&E) and analyzed for the presence and number 
of coronary lesions. An average of 20 slides per heart was analyzed. Results are 
expressed as number of coronary lesions per mouse and mean values per 
group are shown. Percentage necrotic core of the coronary lesions was 
determined by dividing the necrotic core area by total plaque area. 
 
Frozen sections 
Sections were stained with H&E to measure the myocardial thickness. 
Photographs of the LV wall were taken using a 5x objective and 12 
measurements per heart were performed. To detect alterations in the number 
of macrophages after irradiation, frozen sections were stained with anti-F4/80 
antibody (1:300, AbD Serotec, Dusseldorf, Germany) and counted per LV 
myocardial area (8 random 40x photographs).  
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An anti-CD31 antibody (1:50, Becton&Dickinson, Franklin lakes, USA) was 
used to visualize cardiac vasculature of the mid part of the heart and to 
quantify microvascular density (MVD). Five random areas (40x photographs) 
from transverse sections of the subendocardium were photographed with a 
CCD 2 - Color Microscope system, including a Zeiss AxioCam color camera 
(Axiocam HRc, Zeiss, Göttingen, Germany). Vessels beneath a size of 1.5 or 
above 200 µm2 were automatically excluded from the measurements, to 
ensure that only microvasculature was counted. To determine functional 
changes in the microvasculature, a histochemical staining with Naphtol AS 
MX/DMF and fast Blue BB salt was performed to detect endothelial cell 
alkaline phosphatase (ALP) activity. Sections were also stained with an 
antibody against von Willebrand Factor (vWF) (1:4000, Abcam, Cambridge, 
USA) as a thrombotic marker. Photographs of whole sections stained for ALP 
and vWF were taken with an Aperio scanner (Scanscope-XT, Aperio 
technologies, Vista, USA) using a 40x objective. Analyses of the percentage 
myocardium positive for each marker were performed in 23 and 30 mice at 20 
and 40 weeks FU respectively. 
Morphometric parameters were analyzed using a computerized 
morphometry system (Leica Qwin V3, Leica, Rijswijk, The Netherlands). 
 
Gene expression profiling and pathway analysis 
Total RNA was isolated from frozen sections (30 slides of 30 µm) of the mid 
part of the heart of 17 mice at 20 weeks FU (5, 4 and 8 for respectively 0, 2 and 
16 Gy) and 21 mice at 40 weeks FU (6, 7 and 8 for respectively 0, 2 and 16 Gy) 
using Trizol® Reagent (Invitrogen Corporation, Carlsbad, USA) according to the 
manufacturer’s protocol. The quantity of total RNA was measured using a 
spectrophotometer (NanoDrop, Thermo scientific, Wilmington, USA) followed 
by a quality check measured by Agilent 2100 Bioanalyzer with the RNA 
Integrity Number (RIN) (Agilent technologies, Santa Clara, USA). Samples with a 
RIN above 7 were used for DNAse treatment and amplified (350 ng per sample) 
using Illumina Totalprep RNA Amplification kit (Ambion, Grand Island, USA). 
Hybridization of aRNA to Illumina Expression Bead Chips Mouse Whole 
Genome (WG-6 vs. 2.0) and subsequent washing, blocking and detecting were 
performed according to the manufacturer’s protocol (Illumina, San Diego, 
USA). Samples were scanned on the IlluminaR BeadArray™ 500GX Reader using 
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IlluminaR Bead-Scan image data acquisition software (version 2.3.0.13). 
MouseWG-6 vs. 2.0 BeadChip contains the full set of MouseRef-8 BeadChip 
probes with additional 11.603 probes from RIKEN FANTOM2, NCBI REfSeq as 
well from the MEEBO database. 
Before analyzing, the database was normalized using the robust spline 
normalization method within the microarray facility of The Netherlands Cancer 
Institute.12 Log2 ratio between expression of genes from control mice and 
expression of genes from irradiated mice was calculated using Excel version 
2003, as well as the sum of the expression of genes from both, control and 
irradiated mice. According to the sum of both expressions, genes with sums 
below 6 were discarded. The threshold for standard deviation (SD) was set to 3 
and mean ± nSD was calculated to identify genes that are above expression 6 
and above threshold 3 of SD. These gene numbers were further analyzed in 
Ingenuity Pathway Analysis (IPA) version September 2011 core analysis. IPA 
calculates a significant score for each associated network. This score indicates 
the likelihood that the assembly of a set of focus genes in a network could be 
explained by random chance alone. A score of 2 indicates a 1 in 100 chance 
that the focus genes are together in a network due to random chance. 
Therefore, networks with scores of 2 or higher have at least a 99% confidence 
of not being generated by random chance alone. 
 
Gated single photon emission computed tomography (gSPECT) 
The tracer tetrofosmin (Myoview, GE-healthcare, Hoevelaken, The 
Netherlands) was labeled with 99mTc-pertechnetate according to the 
manufacturer’s protocol and injected i.v. (150 µl) with a total activity of 70 
MBq per mouse. Three lead electrodes (3M red Dot 2282E, 3M, St. Paul, USA) 
were attached to both hind paws and right front paw of the mouse and 
connected to the integrated electrocardiography (ECG) monitor to measure 
heart rate (HR). Acquisitions were started 1 h after injection of the tracer as 
described previously8. HiSPECT NG software (InVivoScope, Bioscan) was used 
to perform iterative reconstruction into 3D datasets. Quantitative analysis of 
the reconstructed datasets was performed on a clinical e.soft (syngo-based) 
workstation (Siemens Medical Solutions, Siemens AG, Erlangen, Germany), 
using algorithms to automatically reconstruct a count based 3D model of the 
dimensions of the LV end diastolic and systolic volumes (EDV, ESV). The 
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ejection fraction (EF) was calculated based on the difference between EDV and 
ESV divided by EDV. 
 
2D-Ultrasound 
Mice were sedated with 2% isoflurane (Forane, Abbott, Hoofddorp, The 
Netherlands). Echocardiography images were acquired using a Vevo 770 
system (VisualSonics, Toronto, USA) using a 30 MHz transducer with a focal 
depth range of 13 mm. Acquisitions were made in B-mode long-axis, as well as 
short-axis view, at the papillary muscle level as described previously8. 
Calculations were based on the measurement of LV length and surface area 
during diastole and systole and the EF was calculated as described above. 
 
Statistics 
Except where otherwise stated, data are expressed as mean ± SEM. Irradiated 
and control groups were compared using nonparametric Mann-Whitney U-
test. Statistical analysis on data presented in tables was performed using 
Fisher’s exact test. Group differences were considered statistically significant 
at P < 0.05. 
 
 
Results 
 
Mouse weight 
Local heart irradiation with 16 Gy induced a significant increase in heart, lung 
and heart/body weight at 40 weeks follow-up (FU), compared to age-matched 
controls (Supplemental Table I on page 161). No significant differences were 
observed after lower doses or at 20 weeks after 16 Gy. Histological 
examination of lung tissue did not reveal any abnormalities after irradiation. 
Premature deaths were 7% and 20% of total mice (killed before the planned 20 
and 40 weeks sacrifice time respectively). This was due to non-radiation 
induced causes such as elephant teeth, fighting or a tumor that developed 
spontaneously outside the irradiation field. 
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Increased inflammation after 8 and 16 Gy irradiation 
There were no significant differences in LV wall thickness, as measured from 
histological sections, at 20 or 40 weeks after irradiation (data not shown). The 
number of CD45-positive leukocytes was not increased at 20 weeks after 
irradiation, but at 40 weeks after 8 and 16 Gy there was a significant increased 
influx of leukocytes in the myocardium (Figure 1A). The number of CD3-
positive T cells in the myocardium of ApoE-/- mice was significantly increased at 
both 20 and 40 weeks after 8 and 16 Gy, compared to unirradiated mice 
(Figure 1B), while F4/80-positive macrophages showed no differences between 
irradiated hearts and controls (data not shown). The amount of interstitial 
collagen increased significantly at 20 and 40 weeks after 8 and 16 Gy, although 
not more than 2% of tissue area was affected (Figure 2). 
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Figure 1. Inflammatory changes in the LV myocardium at 20 and 40 weeks after irradiation. (A) 
Number of CD45-positive leukocytes in the myocardium per section. (B) Quantification of CD3-
positive T cells per myocardial area (40x objective). Bars represent mean ± SEM with numbers of 
mice indicated per group (the total number of mice analyzed per irradiation and FU group can 
differ between different stainings due to bad quality of the tissue during staining procedure). 
Analysis of CD3-positive T cells at 20 weeks after 2 Gy was only possible on 2 mice, therefore 
values are presented in the bar. *P < 0.05 compared to age-matched controls. 
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Figure 2. Fibrotic changes in the LV myocardium at 20 and 40 weeks after irradiation. 
Percentage interstitial collagen per tissue area. Bars represent mean ± SEM with numbers of 
mice indicated per group. Collagen measurements at 20 weeks after 2 Gy were only possible on 
2 mice, therefore values are presented in the bars. *P < 0.05 compared to age-matched controls. 
 
Endothelial damage of microvasculature after irradiation 
At 20 and 40 weeks after 8 and 16 Gy, there was a significant decrease in MVD 
compared to control mice (Figure 3A). In addition to the loss of capillaries, the 
remaining vessels had signs of endothelial damage, as indicated by a significant 
decrease in ALP activity at 20 and 40 weeks (2-16 Gy) (Figure 3B) and increased 
expression of the thrombotic marker vWF after 16 Gy (Figure 3C). 
Perls’ staining was performed to analyze the presence of iron in the 
myocardium, which is an indication of a previous hemorrhage. Iron-containing 
macrophages were observed in the myocardium of almost all 8 and 16 Gy 
irradiated hearts at 20 and 40 weeks (Table 1). 
Analysis of myocardial albumin deposition, as an indication of vascular 
leakage, showed the presence of albumin in almost all hearts irradiated with 8 
or 16 Gy at 40 weeks FU, but not at 20 weeks (Table 1), while amyloid deposits 
were not detected. 
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Figure 3. Microvascular alterations at 20 and 40 weeks after irradiation. (A) MVD per area 
expressed as percentage of 0 Gy values. (B) ALP-positive and (C) vWF-positive tissue per 
myocardial area expressed as percentage of age-matched controls. Number of mice included for 
analysis was 6, 5, 4 and 8, and 8, 7, 8 and 7 at respectively 20 and 40 weeks after 0, 2, 8 and 16 
Gy. Values represent mean ± SEM. *P < 0.05 compared to age-matched controls. 
 
 
Table 1. Incidence of mice showing iron (Fe)-containing macrophages (Perl’s staining) and 
albumin protein deposition in the myocardium at 20 and 40 weeks after irradiation. 
 
*P < 0.05 compared to age-matched controls. 
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Irradiation increased the number of coronary lesions and caused endocardial 
damage 
Irradiation with 16 Gy significantly increased the number of coronary 
atherosclerotic lesions in the mid part of the heart at 20 weeks FU (Figure 4A 
and B). There was also a trend for increased numbers of lesions at 40 weeks 
after 8 or 16 Gy, but this difference was no longer significant due to an 
increased number of age-related coronary lesions in unirradiated mice. 
Analysis of the necrotic core of the coronary plaques at 20 and 40 weeks FU 
revealed an increased level of necrosis after irradiation (an average of 33.7% 
and 39.7% of plaque area was necrotic at respectively 20 and 40 weeks after 
16 Gy, compared to 0% and 1.8% after 0 Gy). 
The endocardium of the 16 Gy irradiated mice showed the appearance 
of foam cell accumulations, as well as erythrocyte accumulations, at 20 weeks 
FU (Figure 4C), which was not observed after 0, 2 or 8 Gy (Table 2). At 40 
weeks after 8 and 16 Gy increased endocardial collagen deposition (Table 2, 
Figure 4D) and fibrin deposits (confirmed by Martius Scarlet Blue staining), 
suggesting endocardial protein leakage (Table 2, Figure 4E and F), were 
observed. 
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Figure 4. (A) Number of coronary atherosclerotic lesions examined in the mid-part of the heart 
at 20 and 40 weeks after irradiation. Bars represent mean ± SEM with numbers of mice indicated 
per group. *P < 0.05 compared to age-matched controls. (B) Representative H&E photograph of 
a coronary atherosclerotic lesion, showing necrosis (arrows) after 16 Gy. (C) Representative H&E 
of subendocardial foam cell (arrows) and erythrocyte (arrowheads) accumulation observed at 20 
weeks after 16 Gy. (D) Sirius Red photograph showing endocardial fibrosis (arrow) at 40 weeks 
after 16 Gy irradiation. (E) shows endocardial fibrin deposition on H&E-stained section (arrow), 
confirmed by Martius Scarlet Blue staining (F). Photographs are taken with 20x objective. 
 
 
Table 2. Incidence of hearts showing endocardial damage with foam cell accumulation at 20 
weeks, and protein leakage and collagen deposition at 40 weeks after irradiation. 
*P < 0.05 compared to age-matched controls.
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Low-dose irradiation induced survival pathways, while high dose induced 
fibrotic pathways 
In order to identify genes and pathways potentially involved in the cardiac 
response to irradiation, microarray and pathway analyses were performed 
using the software program IPA (a full list of gene expression levels after 
cardiac irradiation of ApoE-/- mice can be found at http://www. 
ebi.ac.uk/arrayexpress). Radiation significantly regulated 111 (2 Gy) and 169 
(16 Gy) genes at 20 weeks, and 116 (2 Gy) and 158 (16 Gy) genes at 40 weeks. 
Supplemental Figures I-IV show gene interaction networks of these radiation-
regulated genes. Known ingenuity functional and/or canonical pathway 
analysis (Supplemental Table II on page 161) was used to identify 
overrepresentation of radiation-correlated genes within known functional 
assignments (such as inflammatory response) and to generate hypotheses. 
The most significant pathway for 2 Gy at 20 weeks (Supplemental Figure 
I on p 162) was involved in cellular growth and proliferation. Matrix 
metalloproteinase 2 (MMP2) was identified as a central molecule. 
Furthermore, genes within this pathway were also involved in the first 
canonical pathway ‘circadian rhythm’ (nervous system) and in maintenance of 
blood pressure and heart beat (aryl hydrocarbon receptor nuclear translocator 
like, ARNTL). Irradiation with 16 Gy at 20 weeks (Supplemental Figure II on 
page 163) resulted in a significant regulation in cell-to-cell signaling and 
interaction pathway, with tissue inhibitor of metalloproteinase 1 (TIMP1) and 
heme oxygenase 1 (HMOX1) as central genes; both genes were significantly 
upregulated. Moreover, the classical and alternative pathway of the 
complement system was negatively regulated after 16 Gy. This operates within 
the cell-to-cell signaling and interaction pathway and was the first canonical 
pathway. Inflammatory response and inflammatory disease were also among 
the top biological functions altered after high-dose irradiation, including 
significant upregulation of Angiopoietin 2 (ANGPT2). 
At 40 weeks after 2 Gy (Supplemental Figure III on page 164), cellular 
development associated network was significantly regulated. This includes 
cyclin dependent kinase inhibitor 1A (CDKN1A) and a number of heat shock 
genes, with heat shock protein 70 (Hsp70) as central molecule. P13K/Akt 
signaling was the prominent canonical pathway. Irradiation with 16 Gy 
(Supplemental Figure IV on page 165) resulted in significant regulation in cell 
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movement pathway at 40 weeks. The most pronounced molecules within this 
pathway are fibronectin-1 and collagen, indicating tissue injury. Moreover, 
fibrosis was the most upregulated canonical pathway including, connective 
tissue growth factor (CTGF), endothelin 1 (EDN1), fibronectin 1 (FN1) and 
platelet-derived growth factor (PDGF). Once again, inflammatory response and 
inflammatory disease were also among the top biological functions altered at 
40 weeks after high-dose irradiation.  
 
Modest changes in cardiac function after irradiation 
Ultrasound measurements showed significant decreases in EDV and ESV, and 
an increase in EF at 20 weeks after 16 Gy (Supplemental Figure V on page 
166). Gated-SPECT (99mTc-Myoview) showed similar radiation-induced 
decreases in EDV and ESV. However, these parameters are all within normal 
ranges and are not indicative of severe cardiac dysfunction. 
 
 
Discussion 
 
In this study the effect of local cardiac irradiation on heart structure and 
function, and the development of coronary atherosclerotic lesions, was 
investigated in hypercholesterolemic ApoE-/- mice. Compared to previously 
examined C57BL/6j mice8, which do not develop atherosclerosis, radiation-
induced inflammatory changes in the myocardium of ApoE-/- mice were similar, 
although the baseline level of inflammation in ApoE-/- mice was higher, as 
expected13. Pathway analyses also indicated a stimulated inflammatory 
response at 20 and 40 weeks after 16 Gy. This included upregulation of 
ANGPT2, which is increased in endothelial cells after tissue injury and 
stimulates an aggressive fibrotic response.14 Furthermore, 16 Gy regulated cell-
to-cell signaling and interaction pathway of which TIMP1 is a central gene. 
TIMP1 levels are correlated with myocardial hypertrophy, fibrosis and diastolic 
dysfunction.15 Moreover, the complement system pathway was negatively 
regulated after 16 Gy, whereas activation of the pathway results in beneficial 
effects in immune defense.16 In contrast, 2 Gy triggered a survival response, 
presumably in an attempt to stimulate recovery, by regulating the pathway of 
cellular growth and proliferation (20 weeks) and cellular development (40 
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weeks). Hsp and MMP2 are known to be involved in these pathways and play a 
crucial role in cardiomyocyte protection.17, 18 Hsp70 can protect from stress-
induced injury by inhibiting Fas-mediated apoptosis. Another central molecule 
of the cellular development pathway is CDKN1A, which is known to play a role 
in stress response and repair of DNA damage.19  
On the other hand, high-dose irradiation induced fibrotic pathways. 
Diffuse interstitial fibrosis is one of the morphological hallmarks of radiation-
induced myocardial injury.20, 21 An increase in interstitial collagen content with 
dose was found in the myocardium of ApoE-/- mice at 20 and 40 weeks after 
irradiation, which was not observed until 40 weeks after irradiation of 
C57BL/6j mice8. Microarray pathway analysis also showed highly upregulated 
collagen pathway in ApoE-/- mice after 16 Gy, which was not observed in 
C57BL/6j mice (data shown at http://www.ebi.ac.uk/arrayexpress). This could 
eventually lead to a more serious increase in cardiac fibrosis at later time-
points. 
In previous studies9, 10, we investigated the effect of local irradiation on 
the progression of atherosclerosis in the carotid arteries of ApoE-/- mice and 
observed an accelerated development of inflammatory plaques. In addition, 
the present study shows an accelerated development, independently from 
valvular lesions, of atherosclerotic lesions in the coronary arteries after 
radiotherapy. High-dose irradiation significantly increased the number of 
coronary lesions at 20 weeks FU (in mice aged 30 weeks), while age-related 
atherosclerosis in these coronary arteries is mostly observed at 60 weeks of 
age in ApoE-/- mice.11 In addition, the coronary lesions in irradiated hearts 
contained much larger necrotic cores, indicative of a more advanced 
phenotype. 
Radiation has been shown to increase the permeability of endothelial 
cells by induction of inflammatory and thrombotic pathways22, 23, including 
increased production and release of vWF. The increase in vWF deposition in 
the irradiated heart observed in this study is also indicative of thrombotic 
endothelial cell damage.21 This could increase vascular permeability and, 
combined with hypercholesterolemia, lead to lipid accumulation, thus 
stimulating atherogenesis. Furthermore, at 20 weeks 16 Gy irradiation 
regulated genes that are associated with severe and persistent endothelial 
damage, but prevent intravascular thrombosis (e.g. HMOX124). Irradiated  
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ApoE-/- hearts also showed microvascular damage, indicated by a loss of 
microvessels and a decreased activity of endothelial ALP in the remaining 
vessels. Decreased ALP activity was already observed at 20 weeks after 2 Gy in 
ApoE-/- mice, whereas there was no decrease in MVD after this dose. Decreases 
in ALP were only found after higher doses in C57BL/6j mice8, suggesting that 
hypercholesterolemia accelerated the response. An increase in the presence of 
iron-containing macrophages, as a sign of vascular damage and bleeding, was 
found in the myocardium of irradiated mice and was associated with an 
increased deposition of albumin at 40 weeks after high-dose irradiation. These 
results indicate that ApoE-/- mice are susceptible to both macrovascular and 
microvascular damage. In addition, high-dose irradiation caused an increased 
permeability of the endocardium, leading to leakage of fibrin at 40 weeks. 
Irradiation of ApoE-/- mice modestly affected cardiac function at 20 
weeks FU, similar to C57BL/6j mice8. However, 16 Gy lead to sudden death of 
C57BL/6j mice before 40 weeks FU, while ApoE-/- mice survived until 40 weeks 
after local high-dose irradiation. The high mortality rate observed in C57BL/6j 
mice was probably due to the prominent deposition of amyloid in the 
myocardium caused by vascular leakage, leading to the inability to compensate 
for the structural damage and to maintain cardiac function. Since ApoE itself is 
one of the components of amyloid25, irradiated ApoE-/- mice showed no signs 
of cardiac amyloidosis, although there was evidence of vascular leakage. The 
fact that we did not observe a decreased survival in the irradiated ApoE-/- mice, 
despite more pronounced microvascular damage and a similar reduction in 
cardiac function, suggests that the amyloid deposits played a detrimental role 
in cardiac integrity and led to the high mortality rate of the irradiated C57BL/6j 
mice. 
In C57BL/6j mice, inflammatory changes were mainly observed in the 
epicardium8, while ApoE-/- mice showed endocardial damage with foam cell 
accumulations at 20 weeks after 16 Gy and collagen deposits at 40 weeks. 
Endocardial foam cell accumulation was previously described in diabetes, 
hyperlipidemic diseases and congenital diseases, whereby the endocardium is 
subjected to atherosclerotic events similar to those in lesion-prone sites such 
as aortic valves and bifurcations of large arteries.26, 27 It is possible that, 20 
weeks after irradiation, the underlying damaged inflammatory myocardium 
CH6 ApoE heart paper.pdf   17 18-11-2013   14:17:18
chapter six 
 
160 
attracted macrophages to the endocardium, which transform into foam cells in 
the presence of hyperlipidemia. 
In conclusion, the combination of irradiation and hypercholesterolemia 
led to an early and pronounced inflammatory response and microvascular 
leakage in the hearts of ApoE-/- mice. In addition, the progression of 
atherosclerosis in the coronary arteries was clearly accelerated after high-dose 
local irradiation of the heart, combined with foam cell deposits in the 
endocardium. Despite these pronounced effects on cardiac structure and 
increased development of coronary atherosclerosis, the mice were able to 
maintain cardiac function up to 40 weeks after irradiation. 
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Supplemental data 
 
Supplemental Table I. Body and organ weights of mice at sacrifice.  
Treatment Body weight (g) Heart weight (g) Lung weight (g) Heart/body weight %
20 weeks FU
0 Gy 32.3 ± 0.6 0.21 ± 0.006 0.17 ± 0.003 6.7 ± 0.2
2 Gy 32.5 ± 0.3 0.20 ± 0.005 0.17 ± 0.003 6.0 ± 0.1
8 Gy 32.1 ± 0.9 0.22 ± 0.013 0.17 ± 0.006 6.7 ± 0.4
16 Gy 30.9 ± 0.5 0.21 ± 0.007 0.17 ± 0.002 6.7 ± 0.2
40 weeks FU
0 Gy 33.2 ± 0.8 0.20 ± 0.006 0.17 ± 0.004 6.0 ± 0.1
2 Gy 32.5 ± 1.0 0.21 ± 0.009 0.17 ± 0.004 6.3 ± 0.3
8 Gy 34.5 ± 1.1 0.21 ± 0.005 0.18 ± 0.004 6.1 ± 0.2
16 Gy 34.1 ± 0.8 0.23 ± 0.006* 0.21 ± 0.011* 6.9 ± 0.2*  
Values represent mean ± SEM. * P<0.05 compared to age-matched controls. 
 
 
Supplemental Table II. Top first pathway and significant canonical pathways (limited to three) 
analyzed in Ingenuity Pathway Analysis (IPA) at 20 and 40 weeks after 2 and 16 Gy. IPA score 
represents the likelihood (decreases with a score >2) that the set of focus genes in a pathway 
could be explained by random chance alone.  
Pathway IPA score Canonical pathway
20 weeks FU
2 Gy Cellular growth and 49 1. Circadian rhythm signaling
proliferation
16 Gy Cell-To-Cell signaling 45 1. Complement system
and interaction 2. Fibrosis
3. Acute phase response signaling
40 weeks FU
2 Gy Cellular development 46 ND
16 Gy Cellular movement 35 1. Fibrosis  
ND means not detected. 
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Supplemental Figure I. Gene interaction network of 2 Gy irradiation-correlated genes at 
20 weeks, generated using IPA. Genes are represented as nodes. Solid lines represent a direct 
relationship and dashed lines represent an indirect relationship. Node color represents the 
correlation of expression level with irradiation and color intensity indicates the degree of 
correlation (red means a positive correlation, while green means a negative correlation).  
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Supplemental Figure II. Gene interaction network of 16 Gy irradiation-correlated genes at 
20 weeks, generated using IPA. Genes are represented as nodes. Solid lines represent a direct 
relationship and dashed lines represent an indirect relationship. Node color represents the 
correlation of expression level with irradiation and color intensity indicates the degree of 
correlation (red means a positive correlation, while green means a negative correlation). 
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Supplemental Figure III. Gene interaction network of 2 Gy irradiation-correlated genes at 
40 weeks, generated using IPA. Genes are represented as nodes. Solid lines represent a direct 
relationship and dashed lines represent an indirect relationship. Node color represents the 
correlation of expression level with irradiation and color intensity indicates the degree of 
correlation (red means a positive correlation, while green means a negative correlation). 
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Supplemental Figure IV. Gene interaction network of 16 Gy irradiation-correlated genes at 
40 weeks, generated using IPA. Genes are represented as nodes. Solid lines represent a direct 
relationship and dashed lines represent an indirect relationship. Node color represents the 
correlation of expression level with irradiation and color intensity indicates the degree of 
correlation (red means a positive correlation, while green means a negative correlation). 
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Supplemental Figure V. Ultrasound and myoview (gated SPECT/CT) measurements of (A) EDV, 
(B) ESV and (C) EF for control and 16 Gy irradiated mice at 20 weeks FU. Bars represent mean ± 
SEM. * P<0.05 compared to age-matched controls. 
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The hypotheses underlying this thesis were that the dosage of calcineurin-
NFAT-dependent immunosuppression is critical in protecting against 
inflammation-driven atherosclerosis, and that radiotherapy increases the risk 
for late cardiovascular diseases (CVD) via stimulating inflammation-induced 
vascular and cardiac damage. Therefore, we aimed to unravel dose-dependent 
mechanisms of the immunosuppressive drug FK506 on atherosclerosis 
(chapter 2), to investigate the therapeutic potential of blocking NFATC2, a 
target of FK506, in atherosclerosis (chapter 3), to determine the effect of 
irradiation on existing plaque progression and inflammatory responses 
(chapter 4), and to evaluate the dose and time dependence of structural and 
functional cardiovascular damage after heart irradiation in wild-type (chapter 
5) and hypercholesterolemic (chapter 6) mice. 
 
Immunosuppressive therapy in atherosclerosis 
Transcription factors of the nuclear factor of activated T-cell (NFAT) family 
have crucial roles in the development and function of the immune system and 
are tightly regulated by calcineurin and NFAT kinases. NFAT has been 
considered as a target for therapeutic approaches that are aimed at regulating 
immune responses, like in the treatment of graft transplant rejection. We 
explored the therapeutic potential of immunsuppressive FK506 (tacrolimus), a 
calcineurin-NFAT signaling inhibitor, in protecting against atherosclerosis. We 
clearly indicated FK506 dosage as a determinant of the effect of FK506 on 
murine atherosclerosis and risk for developing severe complications.  
FK506 is a widely used immunosuppressive drug that inhibits the 
calcineurin-NFAT signaling pathway, responsible for amongst others activation 
of T-cell immune responses. Nevertheless, high-dose, long-term use of FK506 
in transplant recipients is associated with severe inflammatory complications, 
such as CVD, due to hyperlipidemia and hypertension.1 This was confirmed by 
experimental studies reporting that high-dose FK506 treatment exacerbated 
atherosclerosis2, whereas we have previously shown that low-dose FK506 
treatment attenuated the progression of atherosclerosis and improved plaque 
stability in apolipoprotein E-knockout (ApoE-/-) mice without affecting plasma 
lipid levels or systemic parameters3. In chapter 2, we were able to address this 
paradox, showing a dose-dependent effect of FK506 on macrophage 
polarization and cholesterol levels. Low-dose FK506 treatment protected 
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against atherosclerosis by favoring anti-inflammatory M2 macrophage 
polarization, whereas high-dose FK506 did not result in atheroprotection due 
to absent M2 skewing and increased cholesterol levels.  
The dose-dependent effect of FK506 on macrophage inflammatory 
status can be explained by the fact that NFAT family members NFAT1(C2), 
NFAT2(C1), NFAT4(C3) (activated by intracellular Ca2+ signaling) and NFAT5 
(activated in response to osmotic stress) are co-expressed in diverse cell types 
of the immune system4. NFATC1, C2 and C3 isoforms are identified as major 
transcriptional regulators in naïve T-cells and differentiated effector T-cells, as 
well as in T-cell anergy and regulatory T-cells (Treg), and high-dose FK506 has 
been shown to induce a shift towards Th2-immune responses. Recently, it has 
become apparent that NFAT transcription factors also play a role in various 
other cells of the haematopoietic system, such as macrophages (NFAT5 
regulates expression of Toll-like receptor (TLR)-induced genes and macrophage 
migration)5, 6, dendritic cells (NFATC2 regulates life cycle and dectin-1 activated 
gene expression)7, 8, mast cells (NFATC1 and C2 regulate hypoxia-inducible 
factor 1α (HIF1α), interleukin (IL)-13, tumor necrosis factor α (TNFα) and 
prosurvival protein A1 gene transcription)9-11 and B-cells (NFATC1 regulates 
CD5 expression)12-15. In addition, we identified a possible role of NFAT proteins 
in macrophage polarization, as low-dose FK506 treatment induced a M2 
macrophage polarization (chapter 2).  
In an attempt to pinpoint the target of FK506 atherogenic activity, we 
further investigated the impact of deficiency of one candidate target of FK506, 
NFATC2, on atherosclerosis (chapter 3). NFATC2 is known to induce Th1-
immune responses, but surprisingly NFATC2 deficiency aggravated rather than 
protected against atherosclerotic plaque formation despite Th2 skewing. The 
increased atherosclerosis was due to an augmented proliferative activity and 
effector/memory phenotype of T-cells, more prone to migrate to the 
atherosclerotic lesion. Cell-specific differences in the expression of NFAT 
proteins or the ability to differentially interact with lineage-specific co-
activators and interact with a given promoter domain during T-cell activation 
or differentiation might explain why opposite T-cell responses and functions 
were found in mice deficient in specific NFAT isoforms (Table 1).16-29 In contrast 
to NFATC2 deficiency, T-cells deficient in NFATC1 had impaired production of 
Th2-related cytokines and NFATC3 deficiency resulted in a mild hyperactivation 
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of peripheral T-cells. Interestingly, NFATC2 has been shown to bind to both 
interferon-γ (IFN-γ) and IL-4 promoters in activated Th1- and Th2-cells 
respectively30, thus both NFATC1 and C2 are positive regulators of IL-4 gene 
transcription.24, 31 This indicates that NFAT proteins not only are functionally 
redundant in orchestrating Th2-responses, but also can modulate both 
branches of T-cell differentiation. Furthermore, Ranger et al. showed that the 
absence of NFATC2 and NFATC3 led to the continuous import of NFATC1 into 
the nucleus upon T-cell activation to induce IL-4 expression, resulting in an 
enhanced Th2-immune response.28 Thus, selective inhibition of NFAT isoforms 
can induce compensatory activation of other NFAT-family members forming 
nuclear homo- or heterodimers, responsible for unexpected immune 
responses. The balance between NFAT-family members and co-stimulatory 
transcription factors is therefore decisive in the coordinated transcriptional 
regulation of immune responses. 
 
Table 1. NFAT-deficient mice. Adapted from Macian 4. 
NFAT protein Phenotype in the immune system References 
NFAT1(C2) Moderate hyperproliferation with splenomegaly. 16-21 
Moderately enhanced B- and T-cell responses, with 
bias towards Th2-cell responses. Prolonged IL-4 
expression and decreased IFN-γ production in 
response to TCR ligation. Increased Th17 response 
with NFAT1 hyperactivation. 
NFAT2(C1) In the RAG2-deficient complementation system, 22-24 
  reduced proliferative responses by T-cells. Impaired   
  repopulation of the thymus and lymphoid organs.   
  Impaired Th2-cell responses and IL-4 production.   
NFAT1(C2) and In fetal liver chimeras, grossly impaired T-cell  25 
NFAT2(C1) effector functions, with profound defects in cytokine 
production and cytolytic activity. B-cell hyperactivity. 
NFAT4(C3) Impaired development of CD4 and CD8 single-positive 26 
  cells, with increased apoptosis of double-positive   
  thymocytes. Mild hyperactivation of peripheral T-cells. 
NFAT1(C2) and TCR hyper-reactivity, with profound lymphopro- 27, 28 
NFAT4(C3) liferative disorder. Notable increase in Th2-cell  
responses. Allergic blepharitis and interstitial  
pneumonitis. 
NFAT5 Impaired T-cell function under hyperosmotic  29 
  conditions. Decreased cellularity of the thymus and    
  spleen.   
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Although Th2-responses were originally deemed atheroprotective32, 
NFATC2 deficiency induced a splenic Th2-differentiation of T-cell responses and 
decreased Th1-cytokine IFN-γ production concomitant with enhanced 
atherosclerosis. This is in line with other experimental studies that showed a 
marked decrease in plaque development when the Th2-cytokine IL-4 was 
depleted. Davenport and Tipping found a significant reduction in plaque area 
in the root (at 30 weeks of age) and arch (at 45 weeks of age) of the aorta of IL-
4-/-//ApoE-/- mice compared to ApoE-/- mice.33  Chimeric low-density lipoprotein 
receptor (LDLr)-/- mice with IL-4-deficient bone marrow also showed reduced 
atherosclerosis in the arch and thoracic regions of the aorta, but not in the 
aortic root.34  Further support for a pro-atherogenic effect of IL-4 is provided 
by a study of George et al. using a model of accelerated fatty streak 
formation.35  IL-4-/- mice had significantly reduced fatty streak formation 
compared with wild-type C57BL/6J mice. On the other hand, exogenous 
administration of IL-4 had no effect on atherogenesis in ApoE-/- mice fed a 
normal chow or high-fat diet.36 These data indicate that the role of the Th2-
cytokine IL-4 in atherosclerosis development depends on the vascular site, 
disease stage and experimental model. In contrast, other Th2-cytokines (IL-5, 
IL-13 and IL-10) have been shown to exhibit overt and consistent anti-
atherogenic properties.37-39 Both high-dose FK506 treatment and NFATC2 
deficiency induced Th2-immune responses, indicating that the pro-atherogenic 
effect of FK506 treatment could in part be determined by inhibition of NFATC2. 
Blocking NFATC2 transcriptional activity, and thereby inducing possible 
dominant IL-4-mediated pro-atherogenic responses, would therefore not be an 
ideal therapeutic option for atherosclerosis. Interestingly, in patients with 
psoriasis, a prototypic Th1-associated autoimmune disease, daily IL-4 
treatment induced a pronounced skewing of intralesional cytokines towards a 
Th2 pattern and increased IL-4-producing T-cells in blood, resulting in markedly 
reduced symptoms of psoriasis.40  
An alternative approach for NFAT inactivation can be achieved by 
targeting specific docking of calcineurin on NFAT proteins rather than blocking 
calcineurin phosphatase activity. Already in 1999, a small peptide was 
discovered by Aramburu et al.41, which was able to selectively inhibit 
calcineurin-NFAT interaction and subsequent cytokine expression without 
affecting other calcineurin-signaling pathways, thereby reducing unwanted 
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side-effects.42-44 This small peptide, VIVIT, has been successfully used to 
prolong graft survival after pancreatic islet cell transplantation in mice44 and 
effectively targets inflammatory and smooth muscle cell (SMC) hyperplastic 
responses that underlie restenosis.45 It is therefore expected that VIVIT has a 
protective effect on atherosclerosis, but this has not yet been investigated. 
However, VIVIT has a low potency (i.e. low cellular uptake), limiting its direct 
clinical application, and displays a preference for NFATC2. It is therefore likely 
that less selective but more potent antagonists of the calcineurin-NFAT 
interaction are needed to coordinate inhibition of cytokine secretion and other 
immune cell functions regulated by NFAT (such as macrophage inflammatory 
status). Nevertheless, VIVIT is less toxic than FK506 (or cyclosporin A) and can 
lead to the development of novel immunomodulatory strategies for the 
treatment of atherosclerosis. In this respect, MCV1 was recently designed, 
which targets two separate calcineurin docking sites and selectively prevented 
NFAT dephosphorylation at a potency of almost 1000-fold higher than that of 
the parental peptide VIVIT, without blocking calcineurin-phosphatase activity 
(Figure 1).46 Another beneficial effect of MCV1 may be that MCV analogues are 
rather lipophilic, favoring cellular uptake, in contrast to highly hydrophilic 
VIVIT. Thus MCV1 is not only more potent than VIVIT, but also more selective 
than FK506 in inhibiting NFAT. Interestingly, whereas the effect on 
atherosclerosis is still unknown, neointima formation in a mouse model of 
restenosis was reduced by MCV1.46  
Overall, a better characterization of the roles of individual NFAT proteins 
in regulating T-cells and other cells of the immune system, and their extent of 
overlap in function, is necessary for selecting the optimal target for developing 
NFAT-mediated immunosuppressive therapeutic approaches in athero-
sclerosis. Currently, partial inhibition of calcineurin-NFAT signaling by low-dose 
FK506 has been shown atheroprotective. However, selective prevention of 
calcineurin-NFAT interactions will circumvent possible unfavorable side-effects 
and is expected to be even more effective in the treatment of atherosclerosis.   
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Figure 1. Presumed mode of action of cyclosporin A (CsA)/FK506 and VIVIT/MCV1 interference 
with NFAT activity. MCV1 selectively inhibits calcineurin-NFAT interactions, whereas CsA or 
FK506 disrupts the calcineurin phosphatase activity by binding to immunophilin CyP or FK506 
binding protein (FKBP). Adapted from Yu et al.46 
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Radiation-induced cardiovascular damage 
There is clear epidemiological evidence that thoracic radiotherapy increases 
the long-term risk for cardiovascular morbidity and mortality. However the 
pathogenesis of radiation-induced cardiotoxicity has not been studied in detail. 
In chapters 5 and 6, we reported dose-dependent progressive damage to the 
microvasculature after cardiac irradiation, indicated by a loss of microvessels, 
decreased endothelial alkaline phosphatase (ALP) activity as well as thrombotic 
endothelial cell (EC) damage (release of von Willebrand Factor (vWF)) in 
remaining microvessels, and vascular leakage. This could eventually lead to 
focal ischemia, myocardial cell death, inflammation, interstitial fibrosis, 
arrhythmias and heart failure.47-50 Permanent loss of ALP was evident after 
irradiation doses ≥2 Gray (Gy), making this a particular sensitive marker of 
radiation-induced EC damage. Furthermore, we showed a transient increase in 
microvascular density at 20 weeks after irradiation of the heart of C57BL/6J 
mice with 2 and 8 Gy. This was most probably due to stimulated proliferation 
in response to damage, a compensatory mechanism that was lost after higher 
irradiation dose (16 Gy) or at later times after lower doses. In keeping with 
these results, ECs isolated from irradiated murine hearts were recently 
reported to have an impaired angiogenic response.51 Moreover, after 
preoperative radiotherapy in the head and neck region, vascularization of the 
graft bed decreased as a function of the total dose and time after 
radiotherapy52, and free flap necrosis, due to loss of blood supply to the 
transferred tissue, occurred53.  
In addition, we showed in chapter 6 that high-dose irradiation, in 
combination with hypercholesterolemia, accelerated atherosclerosis 
development with increased intraplaque necrosis in coronary arteries. 
Furthermore, radiation exposure to the neck region, including both carotid 
arteries and the aortic arch, of young54 mice as well as of old 
hypercholesterolemic mice with pre-existing atherosclerotic lesions (chapter 4) 
accelerated atherosclerosis and predisposed to the formation of highly 
inflammatory, macrophage-rich, thrombotic plaques. In these studies, a high 
single dose of radiation was used. Although fractionated doses would closer 
resemble clinical radiotherapy, a previous study by our group demonstrated 
that fractionation (20 x 2 Gy) resulted in a similar plaque phenotype compared 
to a single-dose treatment (14 Gy).55 In line with our findings after single-dose 
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irradiation, Yu et al. recently showed that local radiation exposure of ApoE-/- 
mice resulted in accelerated progression of advanced aortic root lesions, 
characterized by larger necrotic cores associated with increased numbers of 
apoptotic macrophages and reduced collagen content compared to sham-
treated mice.56 Pakala et al. found atherosclerotic lesions in irradiated iliac 
arteries of hypercholesterolemic rabbits predominantly composed of 
macrophages expressing matrix metalloproteinases (MMPs).57 Interestingly, 
Virmani et al. reported severe luminal narrowing of pig coronary arteries at 6 
months after radioactive stent placement.58  
There is also epidemiological evidence of vascular damage among cancer 
survivors that received radiotherapy to the thorax or neck. In a recently 
published population-based case-control study of Darby et al., including 2168 
women who underwent radiotherapy for breast cancer between 1958 and 
2001, the mean cardiac dose was 4.9 Gy. The risk of a major coronary event, 
defined as myocardial infarction, coronary revascularization or death from 
ischemic heart disease, increased linearly with the mean dose to the heart 
(7.4%/Gy), and started to increase within the first 5 years after treatment to 
continue to be elevated for at least 20 years.59 Interestingly, the percentage 
increase in risk per Gy was higher when breast cancer was diagnosed at an age 
of 40 to 74 and patients were more likely suffering from subclinical age-related 
atherosclerosis (6.3-9.7% increase/Gy), compared to an age of 20-39 years       
(-1.5% increase/Gy). Moreover, the absolute increase in risk for a given cardiac 
dose was larger for women with pre-existing cardiac risk factors (e.g. history of 
ischemic heart disease or chronic obstructive pulmonary disease and smoking). 
Hancock et al. described coronary artery disease (CAD) among Hodgkin’s 
lymphoma survivors treated with mediastinal radiation therapy. The relative 
risk of death from a myocardial infarction was 3.1 (95% confidence interval 
(CI), 2.4-3.7), which progressively increased with time from treatment.60, 61 
Dorresteijn et al. showed an increased intima-media thickness (IMT) in carotid 
arteries of head and neck cancer patients treated with radiotherapy.62 Also an 
elevated risk for cerebrovascular diseases (stroke or transient ischemic attack) 
has been reported in survivors of head and neck cancer63-65 or Hodgkin’s 
lymphoma, compared with the general population, and was related to large-
artery atherosclerosis and cardio-embolisms.66, 67 Additional recent studies 
among cancer survivors confirming radiotherapy as a risk factor for vascular 
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injury and subsequent cardiac and cerebrovascular diseases are summarized in 
Table 2.68-78  
 
Table 2. Selection of reported vascular studies among cancer survivors. Adapted from Mulrooney 
et al.79 
Study type Major vascular findings Reference
Case series Acute carotid (common, internal, and external) 68
artery hemorrhage following radiotherapy,
fatal in 4 of 10
Cross-sectional Total coronary artery calcium volume score higher 69
in survivors of Hodgkin's lymphoma with verified
coronary disease compared with those without
(439 vs. 68, p=0.022). 
Cross-sectional Carotid plaque present in 18% of pediatric cancer 70
survivors treated with neck irradiation vs 2% 
controls (p<0.001). Intima-media thickness (IMT) 
0.46 mm±0.12 in survivors vs. 0.41 mm±0.06 
in controls (p<0.001)
Retrospective cohort 7.4% of Hodgkin's lymphoma survivors developed 71
carotid and/or subclavian artery disease at a median 
of 17 years from treatment.
Observed-to-expected ratio for coronary bypass
surgery or percutaneous intervention 1.6 (95%
CI, 0.98–2.3)
Cross-sectional Significantly impaired endothelium-dependent 72
vasodilatation compared with contralateral,
non-irradiated arteries (−0.4±0.4 vs. 3.2±0.8%) 
in breast cancer survivors and compared with
healthy controls (-0.4±0.4 vs. 2.5±0.6%), p<0.001
Cross-sectional Impaired endothelium-dependent relaxation 73
to acetylcholine (33±6% vs. 100±4%,
p<0.001) and A23187 (65±8% vs. 98±4%,
p<0.01) in human irradiated cervical arteries
compared with non-irradiated arteries.
No expression of endothelial nitric oxide
synthase on irradiated arteries
Cross-sectional Increased IMT in irradiated carotid vessels compared 74
with non-irradiated controls
Cross-sectional Intimal thickness was significantly increased in 75
irradiated vessels compared to unirradiated 
arteries in head and neck cancer patients
(0.173 ± 0.113 vs. 0.118 ± 0.065, p= 0.018)  
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Table 2. Continued. 
Study type Major vascular findings Reference
Cross-sectional Larger IMT of the common carotid artery in post- 76
radiotherapy patients with head and neck malignancy 
compared with matched healthy controls
(0.74mm vs. 0.46mm, p<0.001)
Cross-sectional Irradiated stenotic carotid arteries showing greater 77
IMT (0.96mm vs. 0.80mm, p=0.008)
and a narrower lumen (5.5mm vs 6.6mm, p<0.001)
Cross-sectional Mean carotid IMT of patients treated with head and 78
neck irradiation was statistically greater than controls
(2.2 ± 1.5mm vs. 0.7 ± 0.15mm, p<0.05)  
 
Potential mechanisms of radiation-induced atherosclerosis initiation 
The underlying mechanisms of radiation-induced atherosclerosis and cardiac 
damage, progressing subclinically over many years, are unknown and studies 
investigating the underlying pathogenesis of radiation-induced atherosclerosis 
in humans and mice are scarce. Since ECs are regarded as highly radiosensitive 
cells80, one possible mechanism is radiation-induced chronic endothelial 
damage or dysfunction. This may be explained by cumulative radiation-
induced DNA injury or chronic oxidative stress by overproduction of reactive 
oxygen species (ROS) contributing to atherosclerosis.81 Endothelial damage 
following radiation has been observed by electron microscopy with swelling of 
the cytoplasm, formation of pseudopodia leading to luminal narrowing and 
detachment of ECs from the basal lamina82, 83, which could lead to a reduction 
in the microvascular network and atherosclerotic plaque development in large 
arteries. This is supported by Halle et al. showing that genes in the nuclear 
factor kappa B (NFκB) pathway were expressed in arterial biopsies from 
irradiated vessels compared to unirradiated vessels in the same patients from 
4 weeks to 9 years after treatment, suggesting chronic activation of pro-
inflammatory pathways following radiation exposure.84  In addition, doses of 
more than 2 Gy increased endothelial inflammation and adhesiveness, 
triggering pro-atherogenic subendothelial accumulation of leukocytes.47, 80, 85, 86 
Further support for a vascular response to radiotherapy was provided by 
Sugihara et al. indicating, ex vivo, that nitric oxide (NO)-mediated endothelial-
dependent relaxation is impaired in human cervical arteries 4-6 weeks after 
radiotherapy.73  
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Our group recently evaluated the in vivo expression of well-known 
endothelial adhesion (vascular (VCAM-1) and intercellular adhesion molecule-1 
(ICAM-1)) and thrombotic molecules (thrombomodulin (TM) and tissue factor), 
pivotal in the initiation of atherosclerosis, short-term after a high local 
radiotherapeutic dose on the carotid arteries of ApoE-/- and C57BL/6J mice.87 
As early as 4 weeks after 14 Gy, a significant increase in the number of fatty 
streaks was observed compared to non-irradiated ApoE-/- mice, while none of 
the C57BL/6J mice developed atherosclerotic lesions. Although prothrombotic 
pathways (governed by TM and tissue factor) were induced in irradiated 
carotid arteries of ApoE-/- mice only, early changes in expression of endothelial 
adhesion molecules (atheroprotective decrease in VCAM-1, no difference in 
ICAM-1) did not correlate with the increased fatty streak formation. Recently, 
Khaled et al. reported that irradiation can indeed change the adhesiveness of 
inflamed vascular endothelium via a chemokine-dependent activation of 
leukocyte integrins, establishing firm adhesion, even in the absence of 
increased expression of adhesion molecules.88 This highlights the need for 
further identification of the chemokines that are responsible for radiation-
induced increased endothelial adhesiveness. On the other hand, irradiation of 
microvascular or tumor ECs enhanced expression of EC adhesion molecules 
(such as ICAM-1, VCAM-1, platelet endothelial cell adhesion molecule-1 
(PECAM-1) and P-selectin) and decreased endothelial thrombo-resistance by 
loss of TM and increased expression of tissue factor.89-96 Jelonek et al. recently 
isolated mouse primary cardiac ECs and found an upregulated expression of 
VCAM-1 and E-selectin after in vitro and local heart irradiation.97 These data 
suggest that ECs lining large arteries respond differently to irradiation than ECs 
in small vessels and that genetic and site-specific differences in response to 
radiotherapy should be taken into account. Depending on the site of 
irradiation, radiotherapy may therefore result in different clinical 
manifestations making it more challenging to develop specific interventions.   
In our studies, radiation-induced atherosclerosis was present in both 
larger elastic (carotid, aortic arch) and coronary arteries. In hyper-
cholesterolemic mice, we found evidence of additional cardiac damage, i.e. 
lipid-laden macrophages (foam cells) and erythrocyte accumulation in the 
subendocardial layer (chapter 6), as well as in vessel-like structures with thin 
walls and absent elastic laminae (Figure 2). It remains to be determined 
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whether these thin-walled vessels are cardiac venules, lymph vessels or 
telangiectatic capillaries, i.e. abnormal, dilated vessels prone to rupture, 
although the latter has not been described in the heart. Of note, Hoving et al. 
recently observed a decrease in pericyte coverage after murine cardiac 
irradiation with 16 Gy, contributing to blood vessel instability.98 In breast 
cancer patients, the incidence of telangiectasia progressively increased in 
irradiated skin from 1 to 10 years after radiotherapy.99, 100 These signs are 
suggestive of broader radiation-induced endothelial damage. 
 
 A                                         B                                         C 
 
 
 
 
 
Figure 2. Representative H&E of foam cell (arrows) and erythrocyte (arrowheads) accumulation 
in (A) the subendocardial layer and (B, C) thin-walled vessels at 20 weeks after 16 Gy cardiac 
irradiation of ApoE-/- mice.  
 
 In contrast to high doses generally employed in radiotherapy, low 
radiation doses, as may be delivered by medical, environmental or 
occupational exposures, are suggested to be anti-inflammatory and 
atheroprotective. Doses below 1 Gy reduced leukocyte adhesion to ECs in vitro 
and in vivo due to elevated expression of the anti-inflammatory cytokine 
transforming growth factor β (TGFβ) 1101, 102, decreased expression of adhesion 
molecules such as E-selectin103 and diminished chemokine CCL20 expression104. 
Interestingly, low-dose radiation exposure (≤1 Gy) of murine macrophages 
before skewing towards a pro-inflammatory M1 phenotype decreased 
inducible nitric oxide synthase (iNOS)105 and TNFα106 production, as well as 
reduced the oxidative burst107. In a recent study using activated human 
monocyte cell line-derived macrophages, a significant decrease in IL-1β 
secretion after 0.5 and 0.7 Gy was observed.108 The effect of whole body low-
dose (≤0.5 Gy) radiation on splenocytes has recently been investigated in 
C57BL/6J mice. Low doses decreased expression of Th1- and Th2-related 
cytokines, whereas a higher dose of 2 Gy induced an increased immune 
response.109 In line with these findings, Mitchel et al. found that a total body 
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exposure of less than 0.5 Gy decreased the number and size of atherosclerotic 
lesions in ApoE-/- mice.110 In addition, intracoronary low-dose irradiation 
prevented neointima formation after coronary injury in pig.111 Other preclinical 
models of inflammatory disorders confirming low-dose radiation-induced anti-
inflammatory properties are reviewed by Rödel et al.112 Furthermore, evidence 
from atomic-bomb survivors indicated that heart diseases significantly 
associated with low-dose radiation were related to capillary perfusion defects, 
inflammation and fibrosis (congestive heart failure and rheumatic heart 
disease), but not to coronary atherosclerosis, and analysis restricted to doses 
lower than 0.5 Gy showed no significant risk increments for heart diseases.113-
115 The degree of risk for heart diseases at doses below 0.5 Gy therefore 
remains unclear. Further elucidation of the existence of a threshold dose 
below which there is no increased risk of CVD is extremely relevant for 
therapeutic measures and the development of better treatment guidelines. 
 
Potential mechanisms of radiation-induced atherosclerosis progression 
 
DNA damage 
Another mechanism by which radiotherapy can increase the risk for CVD 
presenting years after the initial exposure is accelerating the progression of a 
stable towards an unstable atherosclerotic plaque. Ionizing radiation of an 
existing plaque can directly or indirectly (through the production of hydroxyl 
radicals resulting from the ionization of water or by exposing to free radicals) 
cause DNA double strand breaks of cells in situ, activating DNA damage 
checkpoints.116 Bennett et al. recently showed that cumulative DNA damage of 
intimal macrophages and vascular SMCs (vSMCs) in the plaque led to 
premature senescence (i.e. irreversible growth arrest) and cell death.117, 118 
Subsequent secondary necrosis (i.e. loss of cell membrane integrity causing 
leakage of toxic intracellular material) of macrophages will promote 
inflammation and necrotic core expansion, rendering the plaque more 
unstable.119 vSMC death results in multiple features of plaque instability, like a 
marked thinning of the fibrous cap, loss of collagen, larger necrotic core and 
intimal hyperinflammation.120-123 Moreover, radiation can also directly trigger 
cell senescence after telomere damage.124 There is extensive evidence in 
human and mouse models that plaque macrophages and vSMCs express 
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markers of (oxidative) DNA damage, senescence and apoptosis, which 
increased with disease progression.125, 126 Shortened telomeres have also been 
reported in circulating leukocytes of patients with CAD.127 On the other hand, 
telomerase was activated in macrophages during experimental atherosclerotic 
formation128 and telomere shortening impaired proliferation of both 
lymphocytes and macrophages resulting in reduced atherosclerosis in ApoE-/- 
mice.129  
Although it has to be further elucidated which lesional cell types are the 
most sensitive for radiation-induced senescence or apoptosis, either oxidative 
stress or DNA damage could be major targets for controlling radiation-
associated atherosclerosis progression. In this respect, Tribble et al. have 
shown that oxidative damage and inflammation in radiation-induced 
atherosclerosis could be inhibited by overexpression of the antioxidant 
superoxide dismutase.130 In addition, anti-oxidant diet has been shown to 
inhibit atherosclerosis and reduce lesional macrophage and oxidized (ox) LDL 
content in balloon-injured arteries of irradiated hypercholesterolemic 
rabbits.131  
In conclusion, radiation-induced oxidative damage and cell death could 
lead to chronic inflammation and transform the phenotype of an existing 
stable plaque to an unstable phenotype.  
 
Macrophage polarization 
A macrophage-rich, in particular pro-inflammatory M1 macrophages, 
thrombotic phenotype and increased number of lesional apoptotic cells long-
term after plaque irradiation has been shown in chapter 4. The atherosclerotic 
plaque contains a wide range of local factors, such as cytokines (e.g. IFN- γ, IL-
4, IL13 and IL10), chemokines (e.g. chemokine (C-X-C motif) ligand (CXCL) 4132 
and chemokine (C-C motif) ligand (CCL) 2133), growth factors (macrophage 
colony-stimulating factor (M-CSF) and granulocyte (G)M-SCF134) and lipid 
mediators135. These factors exert essential roles in monocyte differentiation 
into heterogeneous macrophage populations exhibiting a broader spectrum of 
phenotypes than the extremes identified in vitro. Macrophages maintain 
phenotypic plasticity, meaning that alteration of micro-environmental signals 
can shift their differentiated phenotype and subsequent function back and 
forth from pro- M1 to anti-inflammatory M2.136 Khallou-Laschet et al. reported 
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that bone-marrow derived macrophages, polarized to an M1 or M2 phenotype, 
were able to reverse their phenotype when the culture conditions were 
switched.137 This was supported by in vivo studies showing that M2 
macrophages predominated in initial lesions that were enriched in M-CSF and 
the Th2-cytokine IL-4, as well as in regressing plaques, but switched to a M1 
phenotype producing pro-inflammatory cytokines when the plaque progressed 
in size and complexity and contained high levels of pro-atherogenic Th1-
cytokine IFN-γ.137-139 Similarly, M1 macrophages characterized by a high pro-
inflammatory cytokine expression profile were associated with symptomatic 
carotid atherosclerotic disease in humans.140 Taken together, changes in 
plaque micro-environmental signals, also those induced by irradiation, can 
induce a phenotypic conversion of plaque macrophages, rendering the plaque 
more inflammatory. Most likely also a direct effect of irradiation on the 
inflammatory status of macrophages (as demonstrated in our in vitro studies in 
chapter 4) and newly recruited monocytes from the circulation play a 
significant role. There is also data that emphasize the need for investigating 
the effect of irradiation on vSMCs. Impaired phagocytosis leading to secondary 
necrosis of apoptotic vSMCs in atherosclerosis releases IL-1α. IL-1α 
subsequently stimulates surrounding viable vSMCs to release IL-6 and 
monocyte chemotactic protein (MCP)-1, thereby attracting more 
macrophages.120, 123 
Interestingly, as stated above, we have shown that M1 macrophages 
outnumber M2 macrophages in irradiated murine atherosclerotic lesions 
containing increased numbers of apoptotic cells. As in vitro studies showed 
that M1 macrophages secrete MMPs and strongly phagocytose oxLDL rather 
than apoptotic cells, they are suggested to play a prominent role in promoting 
plaque inflammation. In contrast, M2 macrophages are less prone to form 
foam cells, but are highly effective in clearing apoptotic cells, thereby 
preventing secondary necrosis and triggering anti-inflammatory responses.141 
Therefore, they are suggested to be protective in atherosclerosis.142, 143 Indeed, 
shifting the balance towards M2 macrophages reduced circulating cholesterol 
levels144, 145 and plaque size146-148 in hypercholesterolemic mice. Moreover, a 
recent study investigated the spatial distribution of polarized M1 and M2 
macrophages in advanced human atherosclerosis. It was shown that pro-
atherogenic M1 macrophages preferentially locate in rupture-prone shoulder 
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regions of plaques, while M2 macrophages were more prominent in the 
vascular adventitia, implying that inflammation is the driving force for fibrous 
cap rupture and subsequent cardiovascular events.149 Indeed, in vitro co-
culture experiments indicated that macrophages could trigger apoptosis in 
SMCs by activating their Fas apoptotic pathway and by secreting pro-apoptotic 
TNFα and NO, which could lead to decreased synthesis of collagen and fibrous 
cap weakening.150 The radiation-induced imbalance in the ratio of lesional M1 
and M2 macrophages therefore may cause impaired resolution of 
inflammation, ultimately leading to necrotic core expansion and enhanced 
plaque instability.  
 
Radiation-induced cardiac dysfunction 
The heart continues to be an organ at risk in cancer survivors that received 
thoracic radiotherapy, even despite improved radiotherapy techniques, such 
as tangential radiotherapy.151 Harris et al. observed an increased incidence of 
myocardial infarction after a median follow-up of 12 years in women irradiated 
for left-sided versus right-sided breast cancer between 1977 and 1994.152 The 
cardiac risk associated with modern treatment regimens cannot yet be 
assessed, as the increased risk of cardiac mortality will only become evident 
after a follow-up of minimum 10 years. Currently available retrospective and 
prospective studies have shown early regional myocardial perfusion defects 
(within 6 months to a few years after treatment) in asymptomatic breast 
cancer patients using functional imaging.153 Perfusion defects were 
substantially more observed in left-side treated patients compared to right-
side treated patients.154, 155 Marks et al. showed that the incidence of perfusion 
defects was related to the volume of the heart in the irradiation field.156 
Furthermore, it was reported that the appearance of new perfusion defects 
continued up to 6 years after radiotherapy.157 These persistent radiation-
induced perfusion defects are expected to contribute to the long-term 
increased risk for heart diseases, although the association in humans could not 
be proven yet. Longer follow-up of prospective studies will enable evaluation 
of the contribution of early radiation-induced micro- and macrovascular 
damage to the late development of symptomatic heart diseases and increased 
risk for cardiac mortality. Furthermore, retrospective analysis of clinical data 
and cardiac dosimetry of past regimens would enable to develop reliable dose-
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response relationships and to estimate the future risk of thoracic radiotherapy 
techniques used today, although comorbidity factors most likely influence final 
outcome. Modern radiotherapy techniques have considerably reduced the 
average dose exposure to the heart to <2 Gy, yet techniques such as IMRT 
(intensity modulated radiotherapy) can be associated with total body 
exposures of 2-3 Gy, again increasing the risk of cardiovascular damage. In 
addition, part of the heart, including the left anterior descending coronary 
artery (LADCA), still receives more than 20 Gy in about 50% of breast cancer 
patients treated with left-tangential radiotherapy.158, 159 This dose was seen to 
result in left-ventricular perfusion defects in the first months and LADCA 
stenosis years after treatment, suggesting both micro- and macrovascular 
damage.160 Previous dosimetry studies showed that both recent breast cancer 
radiotherapy techniques and those used in the past tended to deliver the 
highest doses to the anterior part of the heart, including the LADCA, which is a 
common site of myocardial infarction.161-164  
Next to the aforementioned substantial evidence of micro- and 
macrovascular injury in mice, radiation was also seen to result in pronounced 
structural myocardial (interstitial fibrosis) and epicardial damage (epicarditis). 
Nevertheless, murine cardiac function was maintained for up to 60 weeks after 
low (2 Gy) and intermediate (8 Gy) doses, whereas high-dose irradiation (16 
Gy) led to sudden death in C57BL/6J mice (chapter 5). Moreover, we found 
that genes involved in survival pathways (heat shock proteins (Hsp), MMP2 
and cyclin dependent kinase inhibitor 1A (CDKN1A)), regulating cellular 
development, growth and proliferation, were activated after low doses in 
parallel with inflammatory pathways, presumably in an attempt to stimulate 
recovery, while the expression profile switched to fibrotic pathways after high-
dose (chapter 6). The radiation-induced myocardial fibrosis and increased 
infiltration of inflammatory cells in the epicardium could not be circumvented 
by anti-inflammatory and -fibrotic thalidomide treatment, as recently 
investigated by Hoving et al.98 Although thalidomide has been proven 
protective in several diseases involving inflammation and fibrosis165-168, other 
strategies reducing radiation-induced heart damage have to be tested.  
The increased mortality after high-dose irradiation was most likely due 
to extensive microvascular leakage resulting in extracellular deposition of 
amyloid fibrils, i.e. autologous protein in an abnormal insoluble β-pleated 
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sheet fibrillary conformation.169, 170 Recently it was proposed that radiation-
induced oxidative stress in the heart of C57BL/6J mice deactivated peroxisome 
proliferator-activated receptor (PPAR)α, a key regulator of cardiac lipid 
metabolism and anti-inflammatory and -fibrotic responses, leading to a low 
level of myocardial lipid metabolism, mitochondrial dysfunction, increased ROS 
production, enhanced inflammation and cardiac amyloidosis.171-173 Cardiac 
amyloid deposition can cause progressive diastolic and subsequently systolic 
biventricular dysfunction and arrhythmia, associated with higher mortality.174 
In general, cardiac amyloidosis has a poor prognosis, depending on the type of 
protein, degree of heart damage and response to therapy (recently reviewed 
by Banypersad et al.175). Amyloid deposits contain non-fibrillary constituents, 
such as ApoE, and ApoE-/- mice were protected from amyloidosis and 
subsequent cardiac dysfunction, but not from the development of coronary 
atherosclerosis after high-dose irradiation (chapter 6). ApoE is therefore 
essential in the development of cardiac amyloidosis.  
It remains unclear which part of the heart is most radiosensitive and 
determines the long-term risk of CVD seen in epidemiological studies. In an 
ongoing project using ApoE-/- mice, we are investigating whether irradiation of 
the major branching points of the coronary arteries affects atherosclerosis 
development in mid-size vessels towards the apex, or whether radiation has a 
direct effect on smaller vessels even when major branching points are outside 
the irradiation field. For these ongoing experiments we made use of a cone 
beam irradiator to irradiate whole and partial volumes of the heart (basal or 
apical irradiation), as nowadays occurs in the clinical treatment of cancer 
patients. 
 
Possible targets and strategies for intervention of radiation-induced 
cardiovascular damage 
Cardiac microvascular endothelial damage was evident after 2 Gy, most likely 
resulting in perfusion defects, diffuse ischemia and myocardial fibrosis, 
ultimately leading to congestive heart failure. In combination with elevated 
cholesterol levels, radiation doses of 8-16 Gy accelerated atherosclerosis 
development in coronary arteries and predisposed to a macrophage-rich, 
unstable plaque phenotype with thrombotic features in larger arteries. Specific 
interventions in thrombotic or inflammatory pathways are therefore suggested 
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to be potential therapeutic approaches to prevent radiation-induced 
atherosclerosis. However, we recently demonstrated that chronic (NO-
donating) aspirin treatment was effective in reducing age-related 
atherosclerosis in larger arteries of ApoE-/- mice, but had no effect on 
radiation-induced atherosclerotic plaque development176, suggesting that 
other pathways are involved after irradiation. Thus, there is a high need for 
detailed knowledge about underlying molecular mechanisms of radiation to 
identify new leads for intervention and to design tailored therapies. Possible 
strategies to prevent radiation-associated cardiovascular injury are reducing 
DNA damage and immune therapy.  
 
DNA damage  
Pathways protecting lesional cells from oxidative DNA damage and its 
consequences are unclear. Sirtuin 1 deacetylase has been shown to promote 
DNA damage repair and to suppress apoptosis by targeting among others p53, 
increasing resistance to DNA damage.177, 178 ApoE-/- mice with sirtuin 1-deficient 
vSMCs exhibit elevated DNA damage markers and vSMC apoptosis, identifying 
sirtuin 1 as a potential protective protein in atherosclerosis.179 P53, the main 
sensor of DNA damage and transcriptional regulator of genes involved in 
cellular growth arrest and apoptosis, is activated following radiation-induced 
DNA damage, and could therefore serve as a potential target in preventing 
cell-specific apoptosis in atherosclerosis and subsequent accelerated plaque 
progression after radiotherapy. Although the role of p53 in the induction of 
proliferation and apoptosis in atherosclerosis is controversial, it has been 
shown by Mercer et al. that endogenous p53 limited atherosclerosis 
development in ApoE-/- mice by protecting vSMCs from apoptosis, in part by 
inhibiting DNA damage response enzymes, while promoting macrophage 
apoptosis.180 Macrophage p53 deficiency decreased apoptosis and enhanced 
plaque macrophage content, thereby aggravating atherosclerosis.181, 182 On the 
other hand, adenovirus expression of p53 induced apoptosis and plaque 
rupture in a collar-model of atherosclerosis in ApoE-/- mice.183 The adverse 
consequences of macrophage apoptosis may be explained by difference in 
plaque stage; in early atherosclerosis it can reduce plaque progression, while in 
advanced atherosclerosis it will contribute to necrotic core expansion and 
enhanced plaque instability.184 Furthermore, it was recently demonstrated that 
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suppression of p53 reduced functional defects in endothelial progenitor cells 
after radiation exposure, which could prevent the onset of vascular disease.185 
In addition, ApoE-/- mice with reduced p53 functionality were exposed to low-
dose irradiation at late stage atherosclerosis and showed increased lesion 
growth, while at early stage the atheroprotective effect of low dose (discussed 
on pages 183-184) was not affected.186 These studies indicate that the possible 
protective role of p53 in atherosclerosis depends on the cell type involved and 
plaque stage, influencing its use as a therapeutic target for regulating plaque 
stability.  
 
Immune therapy 
Another potential immunoregulatory mechanism protecting against radiation-
induced accelerated inflammatory atherosclerosis is adiponectin treatment, 
favoring human and murine M2 macrophage polarization.187, 188 Indeed, 
adiponectin has been shown effective, reducing age-related atherosclerosis in 
ApoE-/- mice189 and increasing cholesterol efflux from human macrophages by 
the activation of liver X receptor (LXR)α and PPARγ.190 Similarly, as shown in 
this thesis, low-dose immunosuppressive FK506 treatment induced a M2 
skewing and prevented atherosclerosis development in ApoE-/- mice, while 
clinically a high-dose FK506 treatment is applied which increases the risk for 
CVD1. It is worth noting that pharmacological PPARγ activation was seen to 
upregulate anti-oxidant enzymes and concomitantly induced anti-
inflammatory M2 pathways191-194, interfering in two major pathways in 
radiation injury. PPARγ agonists (e.g. tesaglitazar) or ligands (e.g. pioglitazone) 
may therefore represent potential therapeutic agents and indeed have 
previously been shown to block both cholesterol-mediated and radiation-
induced atherosclerosis.195, 196  
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Concluding remarks and future perspectives 
Taken together, our data showed that radiation-induced cardiovascular defects 
are primarily caused by diffuse damage to the microvasculature after 
moderate and therapeutic doses, leading to cardiac amyloidosis, and by 
accelerated inflammatory atherosclerosis in the presence of hyper-
cholesterolemia. We propose that specifically selecting cancer patients with a 
high-risk profile, based on biomarkers representing (asymptomatic) 
cardiovascular damage, before and after radiotherapy may enable early 
prognostic stratification and preventive individualized measures for CVD 
during clinical follow-up. Developing guidelines for cancer treatment that take 
cardiovascular profile into account is pivotal to improve care and long-term 
survival of cancer patients receiving thoracic radiotherapy. 
Based on results from this thesis, and recent literature, we propose that 
radiation-induced oxidative damage is a major causal factor in both 
accelerated atherosclerosis initiation and progression, by increasing 
endothelial damage and by inducing apoptosis and pro-inflammatory 
responses. Preventing or counteracting these adverse effects of radiotherapy 
and reducing conventional risk factors for CVD (e.g. hyperlipidemia and 
hypertension) will significantly improve care and long-term survival of cancer 
patients treated with thoracic radiotherapy. However, specific preventive 
measures for radiation-induced CVD in humans are not yet available. Potential 
therapeutic options of particular interest are stabilizing endothelial function, 
enhancing natural anti-oxidant pathways, reducing DNA damage and targeted 
(limiting general effects on the immune system) stimulation of anti-
inflammatory immune responses, before radiotherapy as well as during long-
term follow-up. We showed a protective effect of low-dose immune-
suppressive FK506 (nuclear factor of activated T-cells (NFAT) inhibitor) 
treatment in age-related atherosclerosis and suggested future therapeutic 
potential in selectively blocking calcineurin-NFAT interactions. Nevertheless, 
our group has shown that anti-inflammatory and -thrombotic intervention 
strategies were not efficient in reducing radiation-induced atherosclerosis in 
young mice. Currently, protective effects have only been reported for anti-
oxidant strategies and PPARγ activation in animal models of atherosclerosis. 
This indicates that radiation-induced oxidative damage should be a main target 
for therapy.  
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Future research should address a range of critical open questions, all of 
which may have an impact on the choice of radiation treatment and course of 
follow-up. Some of these open questions include: 
1. What are the underlying mechanisms of radiation-induced 
micro- and macrovascular damage and subsequent CVD? 
2. Which biomarkers represent cardiovascular damage prior and 
after radiotherapy and are associated with an increased long-
term risk for CVD? 
3. Which are potential targets for preventive therapy? 
4. Which medication should be given to cancer patients with a 
higher-risk profile and when?  
Most importantly, further studies should be directed to map the 
molecular pathways involved in early radiation-induced micro- and 
macrovascular damage to provide important entries for diagnosis and/or 
prevention of radiotherapy-associated CVD. This will enable the design of 
potential tailored mechanism-based therapies and will improve treatment 
guidelines. 
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Cardiovascular disease (CVD) and cancer are two leading life-threatening 
diseases in developed countries. The main underlying pathological cause of 
most CVDs is atherosclerosis, characterized by a chronic inflammatory 
response in the arterial wall. In the first part of this thesis, we focused on two 
immunosuppressive strategies to protect against inflammation-driven 
atherosclerosis. In chapter 2, we explored the potential therapeutic use of 
immunosuppressive drug FK506 (tacrolimus), targeting the calcineurin-nuclear 
factor of activated T-cells (NFAT) signaling pathway, in atherosclerosis. 
Transcription factors of the NFAT family have crucial roles in the development 
and function of the immune system and are tightly regulated by calcineurin, a 
calmodulin-dependent calcium-activated phosphatase, and NFAT kinases. 
NFAT has been considered as a target for therapeutic approaches that are 
aimed at regulating T-cell-mediated immune responses, like in the treatment 
of graft transplant rejection and autoimmune diseases. Low-dose (0.05 
mg/kg/day) FK506 treatment markedly reduced atherosclerotic plaque 
initiation and progression in apolipoprotein E-knockout (ApoE-/-) mice, most 
likely by favoring anti-inflammatory M2-macrophage polarization, whereas this 
protective effect was not observed after high-dose treatment (1 mg/kg/day). 
Moreover, high-dose FK506 treatment was associated with hyper-
cholesterolemia, an adverse side-effect that has also been reported after the 
long-term use of calcineurin inhibitors in transplant recipients. These data 
show that FK506 dosage is critical for its therapeutic application in 
atherosclerosis. 
To circumvent the regulation of undesired targets when blocking 
calcineurin, we additionally investigated the role of a specific isoform of NFAT 
signaling in T-cells, NFATC2, in atherosclerosis (chapter 3). As NFAT activation 
is indispensable for regulatory T-cell function and NFATC2 selectively promotes 
T-helper (Th)1-cell differentiation, we hypothesized that NFATC2 would be an 
excellent target for anti-atherogenic therapy. Although we observed a 
pronounced compensatory shift towards a Th2-immune response, NFATC2 
deficiency, either specific in whole-body or hematopoietic cell-lineage, 
aggravated rather than protected against atherosclerotic plaque formation. An 
augmented proliferative response and effector/memory phenotype of 
NFATC2-deficient T-cells, more prone to migrate to the atherosclerotic lesion, 
contributed to the aggravated atherogenic response. 
SUMMARY.pdf   2 10-11-2013   11:03:18
summary 
 
211 
In the next chapters, we focused on a unique interface between CVD and 
radiotherapy. There is a strong correlation between radiotherapy treatment 
and an increased long-term risk for developing CVD in breast cancer, Hodgkin’s 
lymphoma and head and neck cancer patients. In previous experimental 
studies, we have shown that local radiation exposure to the carotid arteries of 
young hypercholesterolemic ApoE-/- mice accelerated the progression of 
atherosclerotic plaques and predisposed to an inflammatory, thrombotic 
plaque phenotype. In chapter 4, we demonstrate that irradiation of pre-
existing atherosclerotic lesions in the aortic arch of aged ApoE-/- mice resulted 
in a macrophage-rich plaque phenotype, more specifically pro-inflammatory 
M1 macrophages, with increased presence of intraplaque hemorrhage and 
apoptotic cells. These highly-inflamed plaques can augment the risk for 
cardiovascular complications. As the majority of cancer patients involve the 
elderly suffering subclinical cardiovascular damage, stratification of patients 
with a higher risk for CVD to enable tailored therapeutic approaches and early 
preventive measures should be a major future concern in our progressively 
aging society.  
Breast cancer is one of the most common cancers among women. Each 
month almost 1000 women are diagnosed in the Netherlands (Netherlands 
Cancer Registry). There is abundant epidemiological evidence that breast 
cancer patients treated with radiotherapy have an increased risk of cardiac 
mortality, which is higher for left-side-treated than right-side-treated patients. 
In chapters 5 and 6 we addressed radiation-induced cardiac damage in wild-
type C57BL/6J and hypercholesterolemic ApoE-/- mice. Whereas mice were 
able to maintain cardiac function to a certain extent, progressive cardiac 
microvascular damage with increasing radiation dose and follow-up time, 
indicated by a loss of microvessels and endothelial cell injury in remaining 
vessels, was found. Consequently, cardiac irradiation caused vascular leakage, 
which was extensively observed after radiotherapy with 16 Gy as evidenced by 
diffuse myocardial albumin and amyloid deposition, and lead to sudden death. 
Although ApoE-/- mice were protected from developing radiation-induced 
cardiac amyloidosis, as ApoE itself is one of the components of amyloid, 
hypercholesterolemia in combination with 16 Gy irradiation enhanced 
microvascular damage and accelerated coronary atherosclerosis development.  
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In chapter 7 the major findings of this thesis and future directions are 
given. Potential underlying mechanisms of radiation-induced cardiovascular 
damage and possible targets for intervention, as well as the therapeutic 
potential of inhibiting calcineurin-NFAT interactions in atherosclerosis, are 
discussed. In conclusion, future research characterizing the roles of individual 
NFAT proteins in regulating immune cells, and their extent of overlap in 
function, is necessary for selecting the optimal target for developing NFAT-
mediated immunosuppressive anti-atherogenic approaches. Novel immuno-
suppressive agents selectively targeting calcineurin-docking sites on NFAT can 
prevent unwanted side effects, thereby enhancing their therapeutic potential 
in the treatment of atherosclerosis. Our data further provide new insights into 
the pathogenesis of radiation-induced CVD, emphasizing the need to assess 
individual cardiovascular risk profile and to develop clinical preventive 
measures.  
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Hart- en vaatziekten en kanker zijn de twee meest voorkomende 
doodsoorzaken in de Westerse landen. Atherosclerose (of ‘aderverkalking’) is 
de voornaamste onderliggende oorzaak van hart- en vaatziekten en wordt 
gekenmerkt door een chronische ontstekingsreactie in de arteriële vaatwand. 
In het eerste deel van mijn proefschrift hebben we twee strategieën 
onderzocht die beschermen tegen de ontsteking in atherosclerose.  
 Als eerste hebben we in hoofdstuk 2 gekeken naar de behandeling met 
FK506 (tacrolimus), een medicijn dat het immuunsysteem onderdrukt door 
remming van calcineurine. Calcineurine controleert de werking van bepaalde 
transcriptiefactoren, genaamd NFAT’s, die cruciaal zijn voor de activatie van 
een subset van belangrijke ontstekingscellen, de T-cellen. Medicijnen, zoals 
FK506, worden ook in andere ziekten waarbij het immuunsysteem geblokkeerd 
moet worden, zoals auto-immuun ziekten en bij orgaantransplantaties, 
gebruikt. Uit eerder onderzoek in ons laboratorium bleek dat behandeling met 
een lage dosis FK506 de start en verdere ontwikkeling van atherosclerose in 
een muismodel voor atherosclerose (ApoE-/- muis) verminderde. In dit 
proefschrift is dit verder onderzocht. Daaruit bleek dat de lage dosis FK506 een 
effect had op de macrofagen en dat leidde tot een verhoogde aanwezigheid 
van anti-inflammatoire (M2) macrofagen. Dit beschermend effect werd niet 
geobserveerd na een hoge dosis FK506, sterker nog, de hoge dosis resulteerde 
in verhoogde cholesterol waarden in het bloed. Een hoge cholesterol-
concentratie in het bloed is ook aangetoond na lang gebruik van calcineurine 
remmende medicatie door patiënten met een orgaantransplantatie. Deze 
resultaten geven aan dat de dosering een kritische factor is bij de effecten van 
FK506-behandeling van atherosclerose.  
Om de neveneffecten van calcineurineremming te vermijden, hebben we 
vervolgens de rol van een specifiek subtype van de NFAT transcriptiefactoren, 
namelijk NFATC2, in atherosclerose onderzocht (hoofdstuk 3). Aangezien 
NFAT-activatie onmisbaar is voor het normaal functioneren van 
ontstekingsremmende T-helper (Th)2-cellen en NFATC2 selectief de werking 
van ontstekingsbevorderende Th1-cellen stimuleert, veronderstelden we dat 
blokkering van NFATC2 bescherming zou bieden tegen atherosclerose. Hoewel 
de afwezigheid van NFATC2 in atherosclerotische muizen wel de 
ontstekingsremmende Th2 immuun respons veroorzaakte, werd een 
verergering van de atherosclerose geobserveerd. Dit was te verklaren door een 
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verhoogde aanwezigheid van een ander type T-cellen, de ‘effector/memory’ T-
cellen, die een hogere reactiviteit vertoonden en meer geneigd waren zich 
naar de plek van atherosclerose te verplaatsen om daar de ontstekingsreactie 
te versterken. 
In de volgende hoofdstukken van mijn proefschrift hebben we een 
unieke interactie tussen het ontstaan van hart- en vaatziekten en de 
behandeling van kanker bestudeerd. Er is een sterke correlatie tussen 
radiotherapiebehandeling en een verhoogd risico op hart- en vaatziekten op 
lange termijn bij borstkanker, Hodgkinlymfoom en hoofd/hals kanker-
patiënten. Uit vorige experimentele studies van onze groep is gebleken dat 
lokale bestraling van de halsslagaders van jonge ApoE-/- muizen de 
ontwikkeling van atherosclerose versnelt en verergert. In hoofdstuk 4 tonen 
we aan dat bestraling van reeds bestaande atherosclerotische plaques in de 
aortaboog van oude ApoE-/- muizen leidde tot macrofaag-rijke plaques, met 
name meer pro-inflammatoire (M1) macrofagen, met meer intraplaque 
bloedingen en meer dode cellen. Deze plaques zijn gevaarlijk, aangezien ze 
kunnen scheuren en er een bloedstolsel kan ontstaan. Sinds de meeste 
kankerpatiënten van oudere leeftijd zijn en daardoor al atherosclerose 
ontwikkeld hebben, ligt het risico op complicaties, namelijk een hart- of 
herseninfarct, bij oudere kankerpatiënten behandeld met radiotherapie 
mogelijk dan ook hoger. Het is daarom - in onze verouderende samenleving - 
van groot belang patiënten met kanker en een hoger risico op hart- en 
vaatziekten te selecteren om zo de kankertherapie individueel aan te passen 
en preventieve maatregelen te treffen.  
Borstkanker is één van de meest voorkomende kankers bij vrouwen. Elke 
maand krijgen bijna 1000 vrouwen in Nederland de diagnose (Netherlands 
Cancer Registry). Er is sterk epidemiologisch bewijs dat vrouwen met 
borstkanker, die behandeld zijn met radiotherapie, een verhoogd risico hebben 
op sterfte door een hartaandoening, waarbij het risico hoger ligt bij 
behandeling van de linkerborst dan bij behandeling van de rechterborst. In 
hoofdstukken 5 en 6 hebben we radiotherapie geïnduceerde hartschade 
onderzocht in normale en atherosclerotische ApoE-/- muizen. Hoewel de 
hartfunctie van deze muizen redelijk goed behouden bleef, werd 
voortschrijdende schade aan de kleine weerstandsvaatjes in het hart gezien. 
Deze schade was erger na een hogere stralingsdosis en naarmate meer tijd 
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verliep na de behandeling. De kleine vaatjes bleken ook niet meer goed te 
functioneren en lekten bloedbestanddelen (o.a. albumine) in het hart. Dit was 
waarschijnlijk de oorzaak van een verhoogde aanwezigheid van amyloid 
(abnormaal afgezette eiwitvezels) en de ontwikkeling van hartfalen. Hoewel 
we bij de ApoE-/- muizen geen amyloid zagen (omdat ApoE zelf een component 
is van amyloid), zorgden de hoge cholesterolconcentraties in het bloed van 
deze muizen in combinatie met 16 Gy bestraling voor meer schade aan de 
kleine vaatjes en een versnelde ontwikkeling van atherosclerose in de 
kransslagaders.  
In hoofdstuk 7 worden de belangrijkste bevindingen uit dit proefschrift 
en verdere onderzoeksmogelijkheden aangegeven. Onderliggende mecha-
nismen van straling geïnduceerde hart- en vaatschade en mogelijke opties voor 
interventie, alsook de remming van calcineurine-NFAT interacties als immuun 
onderdrukkende therapie voor atherosclerose worden bediscussieerd. 
Concluderend kan gesteld worden dat de rol van individuele NFAT-eiwitten in 
de ontstekingsreactie, en hun overlap in functie, verder onderzocht moet 
worden om het ideale eiwit te selecteren in de behandeling van 
atherosclerose. Nieuwe medicijnen, die selectief de binding plaatsen van 
calcineurine op NFAT blokkeren en als gevolg mogelijk neveneffecten kunnen 
voorkomen, moeten verder ontwikkeld en getest worden. Op deze manier kan 
hun klinisch gebruik in de behandeling van atherosclerose verbeterd worden. 
Ons onderzoek heeft ook nieuwe inzichten in de pathogenese van straling 
geïnduceerde hart- en vaatziekten opgeleverd, die de noodzaak voor het 
vaststellen van individuele risicoprofielen en de ontwikkeling van klinisch 
preventieve maatregelen bij patiënten behandeld met radiotherapie 
benadrukken.  
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7KC  7-ketocholesterol 
 
ALP  alkaline phosphatase 
ANGPT2 angiopoietin 2 
AP1  activator protein 1 
APC  antigen-presenting cell 
ApoE  apolipoprotein E 
Arg1  arginase 1 
 
BMDM  bone marrow-derived macrophages 
BMT  bone-marrow transplanted 
BSA  bovine serum albumin 
 
CAD  coronary artery disease  
CCL  chemokine (C-C motif) ligand 
CCR  CC-chemokine receptor 
CDKN1A cyclin dependent kinase inhibitor 1A 
CI  confidence interval 
CRP  C-reactive protein 
CsA  cyclosporin A 
CTGF  connective tissue growth factor 
CVD  cardiovascular disease 
CXCL  chemokine (C-X-C motif) ligand 
 
DAB  diaminobenzidine 
DCIR  dendritic cell immuno receptor 
DKO  double knockout 
 
EC  endothelial cell 
ECG  electrocardiography 
ECM  extracellular matrix  
EDN1  endothelin 1 
EDV  end diastolic volume 
EF  ejection fraction 
Eff/Mem effector/memory 
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EPC  endothelial progenitor cell 
ER  endoplasmic reticulum 
ESV  end systolic volume 
 
FACS  fluorescence-activated cell sorting 
FCS  fetal calf serum 
Fe  iron 
FKBP  FK506 binding protein 
FN1  fibronectin 1 
FOV  field of view 
Foxp3  forkhead box p3 
FU  follow-up 
 
GATA3  GATA-binding protein 3 
Gy  Gray 
GM-CSF granulocyte macrophage-colony stimulating factor 
gSPECT  gated single photon emission computed tomography 
 
H&E  hematoxylin and eosin 
HIF1α  hypoxia-inducible factor 1α 
HMOX1 heme oxygenase 1 
HR  heart rate 
HRP  horse radish peroxidase 
HSA  human serum albumin 
Hsp  heat shock protein 
 
ICAM-1  intercellular adhesion molecule-1 
IFN-γ  interferon-γ 
IGF1  insulin-like growth factor 1  
IL  interleukin 
IMT  intima-media thickening 
iNOS  inducible nitric oxide synthase 
i.p.  intraperitoneal 
IPA  ingenuity pathway analysis 
i.v.  intravenously 
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LADCA  left anterior descending coronary artery  
LDLr  low-density lipoprotein receptor 
LN  lymph nodes 
LPS  lipopolysaccharides 
LRP-1  lipoprotein receptor-related protein 1 
LV  left ventricular 
LXR  liver X receptor 
 
MCP-1  monocyte chemoattractant protein-1 
M-CSF  macrophage-colony stimulating factor 
MDA  malondialdehyde 
MFI  mean fluorescent intensity 
MHC  major histocompatibility complexes 
MMF  mycophenolate mofetil 
MMP  matrix metalloproteinase 
MR/MaRc mannose receptor 
MVD  microvascular density 
 
NFAT  nuclear factor of activated T-cells 
NFκB  nuclear factor κB 
NO  nitric oxide 
Nos2  nitric oxide synthase 2 
 
oxLDL  oxidized low-density lipoprotein 
 
PAMP  pathogen associated molecular pattern 
PBS  phosphate-buffered saline 
PECAM-1 platelet endothelial cell adhesion molecule-1 
PCR  polymerase chain reaction 
PDGF  platelet-derived growth factor 
PMA  phorbol 12-myristate 13-acetate 
PPAR  peroxisome proliferator-activated receptor 
 
qPCR  quantitative polymerase chain reaction 
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RIHD  radiation-induced heart disease 
RIN  RNA integrity number 
RorγT  retinoid-related orphan receptor γT 
ROS  reactive oxygen species 
RR  relative risk 
RT-PCR  reverse transcriptase polymerase chain reaction 
 
SD  standard deviation 
SEM  standard error of the mean 
SERCA  sarcoplasmic reticulum Ca2+ ATPase 
SMC  smooth muscle cell 
SPECT/CT single photon emission computed tomography 
STAT  signal transducer and activator of transcription 
 
T-bet  T-box transcription factor TBX21 
TCR  T-cell receptor 
TGFβ  transforming growth factor β 
Th  T-helper cell 
TIMP1  tissue inhibitor of metalloproteinase 1 
TLR  Toll-like receptor 
TM  thrombomodulin 
TNFα  tumor necrosis factor α 
Treg  regulatory T-cell 
TXA2  thromboxane 
 
VCAM-1 vascular cell adhesion molecule 1 
vSMC  vascular smooth muscle cell 
vWF  von Willebrand factor 
 
WT  wild-type 
 
YM1  chitinase-like lectin 
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Tot slot nog een woordje van dank. Hoewel dit waarschijnlijk het makkelijkste 
en meest gelezen deel van mijn thesis is, vind ik het toch moeilijk om in enkele 
pagina’s iedereen op gepaste wijze te bedanken. Alleen had ik dit namelijk 
nooit kunnen bereiken en daar ben ik iedereen oprecht héél erg dankbaar 
voor! 
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Biessen bedanken. Beste Mat, ik ben je enorm dankbaar voor je vertrouwen en 
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Beste Erik, ik heb ontzettend veel bewondering voor je enorme weten-
schappelijke kennis. Hoewel ik na onze meetings vaak even nodig had om al je 
creatieve ideeën op een rijtje te zetten, vergrootte dat vooral ook mijn 
motivatie en passie voor het onderzoek. Bedankt voor je steun alsook je 
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vereerd dat jij mijn co-promotor bent! Ik kan je niet genoeg bedanken voor je 
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stralingsstudies! Ik hoop dan ook dat jullie op 20 december dit mee kunnen 
vieren. Ik wens jullie het allerbeste toe, zowel privé als in jullie carrière! 
Jeffrey, ondanks de eindeloos frustrerende uren achter de microtoom 
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het is zo tof dat we niet alleen op het werk, maar ook thuis zo dicht bij elkaar 
zitten en altijd bij elkaar terecht kunnen. 
De vriendinnen thuis, Julie en Anneleen, door alle drukte zien we elkaar 
heel wat minder dan we eigenlijk zouden willen. Nu kunnen jullie dan ook 
eindelijk eens zien waar ik zo veel tijd in gestoken heb . We zijn al zo lang 
vriendinnen en dat zullen we zeker en vast voor altijd blijven. 
Lieve Caroline, jouw zorgzaamheid en meeleven maken je een 
fantastische vriendin! Dankjewel dat ik bij jou met alles terecht kan! Als we 
weer even niet kunnen gaan zwemmen, mis ik onze babbels en gezelligheid 
(met chocomelk ) heel hard.  
 Niet alleen mijn familie, maar ook mijn schoonfamilie, wil ik heel erg 
bedanken voor alle steun, interesse en lekkere etentjes in de Hoogstraat! 
Kim, we hebben elkaar nooit echt goed begrepen en we verschillen op 
zo veel vlakken, maar één ding hebben we zeker gemeen: de liefde voor Louize 
en Emma. Ik beloof dat ik hierna eindelijk wat meer tijd vrij zal maken voor 
Emma en dat ik er altijd voor haar zal zijn! 
Mama en papa, ik kan met geen woorden beschrijven hoeveel jullie voor 
mij betekenen. De afgelopen jaren van mijn doctoraat hebben mij enorm veel 
geleerd en besef ik eens te meer hoe bijzonder het is dat jullie altijd klaar staan 
als ik iets nodig heb. Zelfs al werkten jullie dag en nacht! Jullie hebben mij altijd 
mijn eigen gang laten gaan en ik wil jullie bedanken voor het vertrouwen! 
Hopelijk hebben jullie met dit boekje en mijn verdediging op 20 december een 
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beter beeld van waar ik het de afgelopen jaren zo druk mee heb gehad. Ik kan 
jullie niet genoeg bedanken voor de hulp en steun die jullie mij altijd gegeven 
hebben! 
 Wim, m’n alles, onvoorwaardelijk heb je mij gesteund in deze stressvolle 
jaren! Ik vind het geweldig hoe je kan uitleggen waar mijn onderzoek over gaat 
 en het is zalig hoe je samen met mij toeleeft naar 20 december. Dit wordt 
ONZE dag! Ik apprecieer enorm alles dat je voor mij doet! Elke dag geniet ik 
van het samenwonen en kijk ik er naar uit om na een lange dag werken thuis te 
komen in ons liefdevol nestje. Ik koester het geluk dat we samen hebben en 
kan niet wachten om te zien wat de toekomst voor ons in petto heeft! Zie je 
hemelsgraag! 
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